| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Tonix Pharmaceuticals Holding Corp.$12.53
-0.5 (-3.84%)
C 45Pipeline Score Fair Value Pharma · Commercial
Market Cap
203.56 M
EPS
-14.35
P/E Ratio
-
Value Trade
4.19 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
6.88 M
R&D Expenses
18.21 M
Operating CF
-42.32 M
Total Assets
257.91 M
Total Liabilities
30.77 M
Equity
227.14 M
D/E Ratio
12,345
-6.86 %
Week
-6.52 %
1 Month
-15.71 %
3 Month
-18.56 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
185.47 M
Monthly Burn
14.11 M
Runway
11.1 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
505.97 K
52 Week Range
11.60 - 69.97
% held by Insiders
0.31 %
% held by Institutions
39.25 %
Enterprise Value
19.38 M
Total Shares
15.94 M
Short %
22.93 %
Float Shares
15.62 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tonix Pharmaceuticals Holding Corp.
1644Total events
11Upcoming
369Tier-1 (high impact)
2014 – 2029Coverage
Upcoming catalysts 11
2027
T3Manufacturing Milestone
Expect GMP investigational product available for clinical testing in early 2027
Event history 1633
Q3 2026
◆Type C MeetingTNX-4800FDA Meeting
Type C meeting with FDA scheduled early Q3 2026 to discuss adaptive Phase 2 field study design
Prevention of Lyme Diseasesource ↗
Jun 29, 2026
▲First Patient DosedTNX-102 SLApprovedTrial
First patient enrolled in Phase 2 HORIZON study of TNX-102 SL for MDD
major depressive disordersource ↗
Jun 16, 2026
◆R&D DayPresentation
Tonix management to participate in 1x1 meetings at BTIG Infectious Disease Day 2026
Jun 1, 2026
▲Product LaunchTNX-102 SLApprovedPost-Market
TONMYA commercial launch with GPO coverage expansion
fibromyalgiasource ↗
Jun 2026
◆Trial InitiationTNX-102 SLApprovedTrial
Expected to initiate enrollment in HORIZON Phase 2 study
major depressive disordersource ↗
May 28, 2026
●Poster PresentationTNX-102 SLApprovedPresentation
Poster presentation of retrospective claims analysis of opioid use in fibromyalgia at ASCP 2026
Fibromyalgiasource ↗
May 27, 2026
▲Full ResultsTNX-1500Clinical Data
Publication of Phase 1 clinical data of TNX-1500 in Journal of Clinical Immunology
prevention of kidney transplant rejectionsource ↗
May 20, 2026
May 20, 2026
◆Poster PresentationPresentation
Poster presentation at ISPOR 2026: Characterizing Patients with Fibromyalgia: A U.S. Real-World Claims Analysis
Fibromyalgiasource ↗
May 19, 2026
◆Oral PresentationPresentation
RBC Capital Markets Global Healthcare Conference Fireside Chat
May 17, 2026
●Poster PresentationTNX-102 SLApprovedPresentation
Poster presentation of real-world claims analysis characterizing fibromyalgia patients at ISPOR 2026
Fibromyalgiasource ↗
May 1, 2026
▲Product LaunchTNX-102 SLApprovedPost-Market
First commercial coverage agreement for TONMYA
fibromyalgiasource ↗
Drug Pipeline Intelligence
C45
Pipeline Score $351M
Pipeline ValueFair Value
Valuation Signal10
Drugs Scored1.7x
rNPV / MCap Top 65%
Micro Cap (rank 320 of 912)
Percentile RankTonix Pharmaceuticals Holding Corp. carries a moderate pipeline score (45/100), with $2.9B risk-adjusted pipeline value, led by TNX-1500 in Kidney Transplant (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNX-1500 Small molecule | Kidney Transplant | Phase 2 | NCT07204080 | 31% | $1.6B | NOT YET_RECRUITING | 5 | - | - | Jun 30, 2029 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TNX-1500 | prevention of kidney transplant rejection | Phase 1 | 2026-05-27 | blocked the primary T cell–dependent antibody response to KLH at all doses; blocked the secondary response at the 10 and 30 mg/kg doses; reduced peak secondary response to KLH by ~70% relative to placebo at the 3 mg/kg dose Read More | Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology Read More | |
TNX-1500 | prevention of kidney transplant rejection | Phase 1 | 2026-05-27 | blocked the primary T cell–dependent antibody response to KLH at all doses; blocked the secondary response at the 10 and 30 mg/kg doses; reduced peak secondary response to KLH by ~70% relative to placebo at the 3 mg/kg dose Read More | Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology Read More | |
TNX-1500 | prevention of kidney transplant rejection | Phase 1 | 2026-05-27 | blocked the primary T cell–dependent antibody response to KLH at all doses; blocked the secondary response at the 10 and 30 mg/kg doses; reduced peak secondary response to KLH by ~70% relative to placebo at the 3 mg/kg dose Read More | Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TNXP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TNXP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TNXPTonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
Tonix Pharmaceuticals has announced the enrollment of the first patient in the Phase 2 HORIZON study, which evaluates TNX-102 SL as a treatment for major depressive disorder (MDD). The study aims to assess the drug's efficacy in improving depressive symptoms and sleep quality. TNX-102 SL has previously shown positive signals in related conditions, suggesting its potential effectiveness for MDD.
Read more →TNXPTonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
Tonix Pharmaceuticals will participate in BTIG's Infectious Disease Day 2026, scheduled for June 16, 2026. CEO Seth Lederman will represent the company in virtual 1x1 meetings. Tonix is focused on CNS and immunology treatments, with several products in development, including TONMYA for fibromyalgia and others targeting Lyme disease and kidney transplant rejection.
Read more →TNXP▲ +5.8%on this newsshared move
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA , Expanding Total Commercial Coverage to ~52 Million U.S. Lives
Tonix Pharmaceuticals has announced a new commercial payer agreement for its fibromyalgia treatment, TONMYA, effective from June 1, 2026. This agreement adds approximately 17 million U.S. commercial lives to its coverage, bringing the total to around 52 million lives, or 29% of the total commercial lives in the U.S. The company's CEO has emphasized the importance of this coverage in expanding patient access to TONMYA, which is notably the first new fibromyalgia treatment approved by the FDA in over 15 years. Additional initiatives and ongoing discussions are underway to further enhance access through Medicare and Medicaid channels.
Read more →TNXPTonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA , Expanding Total Commercial Coverage to ~52 Million U.S. Lives Agreement with second leading group purchasing organization (GPO), effective
Tonix Pharmaceuticals has announced a new agreement with a group purchasing organization, effective June 1, 2026, that expands coverage for its fibromyalgia treatment TONMYA to an additional 17 million U.S. commercial lives. This brings the total commercial coverage to approximately 52 million lives, amounting to about 29% of the total commercial lives in the U.S. The medication, which received FDA approval in August 2025, is notable for being the first new option for fibromyalgia in over 15 years. This expansion of coverage aims to enhance patient access as the company progresses with the commercial launch of TONMYA.
Read more →TNXPTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Tonix Pharmaceuticals presented a retrospective analysis at the 2026 ASCP Annual Meeting, revealing high opioid prescription rates among fibromyalgia patients, despite guidelines discouraging their use. The analysis included over 261,000 patients and highlighted the health burden of opioid use. Tonix also launched TONMYA, a new non-opioid treatment for fibromyalgia, emphasizing the need for better education on available therapies.
Read more →TNXPTonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
Tonix Pharmaceuticals has published Phase 1 clinical data for TNX-1500, an Fc-modified anti-CD40L monoclonal antibody, in the Journal of Clinical Immunology. The study demonstrated TNX-1500's safety and tolerability, with promising results in suppressing T cell-dependent antibody responses. A Phase 2 study is anticipated to begin in late 2026, pending FDA approval.
Read more →TNXPTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
Tonix Pharmaceuticals presented findings at ISPOR 2026 from a real-world claims analysis of U.S. adults with fibromyalgia, utilizing over three years of closed claims data. The study revealed a high prevalence of comorbidities and extensive healthcare resource utilization among this patient demographic. Notably, Tonix launched TONMYA, the first new fibromyalgia treatment in more than 15 years. The data reinforce the complexities of managing fibromyalgia and the need for comprehensive approaches to improve patient outcomes.
Read more →TNXP▲ +11.7%on this news
Tonix Pharmaceuticals Holding Corp. TNX - 4800: A Long - Acting, Bactericidal, Human Monoclonal Antibody to Prevent Lyme Disease in the U.S. Zeil Rosenberg MD, MPH Executive Vice President, Medical Tonix Pharmaceutical s
Tonix Pharmaceuticals Holding Corp. is presenting TNX-4800, a long-acting human monoclonal antibody aimed at preventing Lyme disease. This investigational biologic, which provides passive immunity, is designed to potentially block the transmission of Lyme disease from infected ticks. TNX-4800 is currently undergoing development, and its approval is contingent on successful clinical trials and compliance with regulatory standards. The company highlights the importance of addressing market competition and financial needs as they advance this innovative treatment.
Read more →TNXPTonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026, focusing on a retrospective analysis of fibromyalgia patients using U.S. claims data. The study aims to characterize the patient population and enhance understanding of the condition. TONMYA, a recently approved treatment for fibromyalgia, represents a significant advancement in therapy options. The presentation will take place on May 20, 2026, in Philadelphia.
Read more →TNXPTonix Pharmaceuticals to Participate in Two Investor Conferences in May 2026
Tonix Pharmaceuticals announced participation in two investor conferences in May 2026. CEO Seth Lederman will present at the RBC Capital Markets Global Healthcare Conference and A.G.P.'s Annual Virtual Healthcare Conference. The company continues to focus on CNS and immunology treatments, with several products in development and ongoing clinical trials.
Read more →TNXP▼ -5.9%on this newsshared move
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
Tonix Pharmaceuticals reported strong initial performance for its fibromyalgia treatment, TONMYA, with over 3,500 patients initiating treatment since its launch. The company signed a partnership to enhance access for millions of U.S. lives and plans to initiate a Phase 2 study for Lyme disease prevention. Despite a significant net loss this quarter, Tonix remains focused on advancing its clinical pipeline.
Read more →TNXP▼ -5.9%on this newsshared move
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
Tonix Pharmaceuticals announced its participation in two investor conferences in May 2026. CEO Seth Lederman will present at the RBC Capital Markets Global Healthcare Conference and A.G.P.'s Annual Virtual Healthcare Conference. The company is focused on CNS and immunology treatments, with ongoing clinical trials for several investigational drugs.
Read more →TNXP▲ +8.8%on this news
Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
Tonix Pharmaceuticals has secured an agreement with a leading group purchasing organization, providing coverage for its fibromyalgia treatment, TONMYA, to approximately 35 million U.S. commercial lives. This marks a significant milestone in expanding patient access to the first new FDA-approved treatment for fibromyalgia in over 15 years. The company is also pursuing additional coverage options and has established a patient support program.
Read more →TNXPTonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University
Tonix Pharmaceuticals announced plans for an adaptive Phase 2 field study of TNX-4800, a monoclonal antibody aimed at preventing Lyme disease. The study is set to begin in the first half of 2027, pending FDA agreement, and will evaluate a two-dose regimen. Phase 1 data indicates TNX-4800 could provide rapid protection against Lyme disease.
Read more →TNXPTonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated g
Tonix Pharmaceuticals presented updates on their preclinical immuno-oncology programs during the AACR Annual Meeting 2026. The data highlighted the efficacy of TNX-1700 in reversing aging-associated gastric inflammation and its potential in treating gastric and colorectal cancers. Additionally, TNX-4700 exhibited strong binding characteristics as a monoclonal antibody designed for various cancer treatments. Both programs indicate promising developments in Tonix's cancer therapy pipeline.
Read more →TNXP▲ +7.4%on this news
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
Tonix Pharmaceuticals announced the publication of a pharmacokinetic study in a peer-reviewed journal, detailing the effectiveness of its newly FDA-approved treatment, TONMYA (cyclobenzaprine HCl sublingual tablets), for fibromyalgia. The study demonstrates the tablet’s suitability for long-term daily dosing and potential benefits for patients suffering from nonrestorative sleep associated with the condition. Notable findings included faster absorption and lower plasma exposure compared to oral extended-release formulations, indicating a favorable profile for the management of fibromyalgia symptoms. The publication is seen as supportive of TONMYA's existing approval and anticipated commercialization in the U.S.
Read more →TNXP▲ +14.3%on this news
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026
Tonix Pharmaceuticals presented Phase 1 data for TNX-4800 at the World Vaccine Congress Washington 2026, showing promising results for preventing Lyme disease. The company plans to initiate an adaptive Phase 2 field study in 2027, pending FDA clearance. TNX-4800 is a monoclonal antibody designed to provide protection against Lyme disease with a single dose.
Read more →TNXP▼ -8.3%on this newsshared move
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
Tonix Pharmaceuticals has initiated a Phase 1 study for TNX-1900, an intranasal formulation of oxytocin aimed at treating migraine and craniofacial pain. The study will assess the drug's effects on trigeminal nerve-mediated vasodilation in healthy volunteers. This innovative approach could address unmet needs in migraine treatment by targeting a different pathway than existing therapies.
Read more →TNXPTonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
Tonix Pharmaceuticals announced its participation in the World Vaccine Congress Washington 2026, where it will present Phase 1 data on TNX-4800, a monoclonal antibody for Lyme disease prevention. Additionally, the company will showcase TNX-801, a horsepox vaccine candidate for smallpox and mpox. The presentations will feature key researchers discussing advancements in vaccine technology.
Read more →TNXP▼ -5.1%on this news
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
Tonix Pharmaceuticals announced its participation in the AACR Annual Meeting 2026, where it will present an oral presentation and two posters on its preclinical immuno-oncology portfolio. The oral presentation will focus on TFF2 deficiency and its role in gastric tumor progression, while the posters will cover anti-BTLA monoclonal antibodies and pharmacokinetics of TNX-1700. These presentations highlight Tonix's commitment to advancing cancer treatment research.
Read more →TNXP▼ -5.1%on this newsshared move
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
Tonix Pharmaceuticals announced that CEO Seth Lederman will present at BIO-Europe Spring 2026 in Lisbon, Portugal, on March 24. The company is known for its focus on central nervous system and immunology treatments, including TONMYA, the first new fibromyalgia treatment in over 15 years. Tonix is also advancing several investigational drugs in various clinical stages.
Read more →TNXPTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Tonix Pharmaceuticals reported strong financial results for Q4 and full year 2025, highlighted by the successful launch of TONMYA, the first new fibromyalgia treatment in over 15 years. The company has seen positive prescription trends and has a solid cash position of $207.6 million. Looking ahead, Tonix plans to advance its clinical pipeline, including TNX-4800 for Lyme disease prevention and TNX-102 SL for major depressive disorder.
Read more →TNXPTonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYA TM at the 8th International Congress on Controversies in Fibromyalgia Company launched TONMYA, approved by the FDA as a treatment for fibromyalg
Tonix Pharmaceuticals presented promising post hoc analyses of its Phase 3 data on TONMYA, a treatment for fibromyalgia, at the 8th International Congress on Controversies in Fibromyalgia. The analyses revealed that TONMYA can provide rapid pain relief, with significant improvements noted as early as Day 2 of treatment. Furthermore, the pooled analysis indicated that the treatment has a favorable benefit-risk profile, making it a potentially effective option for the millions suffering from fibromyalgia. This presentation underscores TONMYA's credentials as a differentiated and generally well-tolerated medication.
Read more →TNXPTonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
Tonix Pharmaceuticals presented data on TONMYA at the 2026 AAPM PainConnect Annual Meeting, demonstrating its effectiveness in treating fibromyalgia. The Phase 3 RESILIENT trial showed significant pain reduction and an increase in patients reporting a clinically meaningful response. TONMYA, launched in November 2025, is the first new prescription therapy for fibromyalgia approved in over 15 years, providing a non-opioid alternative for patients. The drug's sublingual formulation allows for improved absorption and reduced side effects compared to traditional treatments.
Read more →TNXPTonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
Tonix Pharmaceuticals has announced the publication of clinical pharmacokinetic studies for TONMYA, its sublingual formulation of cyclobenzaprine approved for fibromyalgia treatment. The studies demonstrate that TONMYA achieves rapid absorption and decreased production of an active metabolite, potentially improving treatment durability. Published in the journal Clinical Pharmacology in Drug Development, the studies were based on trials involving healthy volunteers and underscored the favorable pharmacokinetics of the drug, which is now on the market in the U.S. as of August 2025.
Read more →TNXPTonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting
Tonix Pharmaceuticals announced that it will present a poster on Tonmya™ at the 2026 AAPM PainConnect Annual Meeting. The presentation will highlight the clinically meaningful improvements in patient-centered outcomes for fibromyalgia. The event will take place from March 5-8, 2026, in Salt Lake City, Utah, with Dr. Errol Gould as the presenter.
Read more →TNXPTonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market
Tonix Pharmaceuticals has announced its uplisting from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective March 3, 2026. This transition signifies compliance with higher financial and corporate governance standards, potentially enhancing the company's visibility and liquidity. CEO Seth Lederman expressed optimism about leveraging this platform for future growth and value creation.
Read more →TNXPTonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. announced its uplisting from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective March 3, 2026. This transition reflects compliance with higher financial and corporate governance standards, which may enhance visibility and liquidity. CEO Seth Lederman highlighted the uplisting as a significant milestone that could drive growth and increase value for shareholders. The company anticipates better recognition among investors and customers as a result of this change.
Read more →TNXPTonix Pharmaceuticals to Participate in Two Investor Conferences in March
Tonix Pharmaceuticals announced its participation in two investor conferences in March 2026. CEO Seth Lederman will present at the TD Cowen Healthcare Conference, while the management team will be available for one-on-one meetings at the Barclays Healthcare Conference. The company continues to focus on its CNS and immunology treatments, including its recently approved drug for fibromyalgia.
Read more →TNXP▼ -5.4%on this news
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
Tonix Pharmaceuticals presented positive Phase 3 RESILIENT study data for TONMYA, a sublingual formulation of cyclobenzaprine, at the 2026 Non-Opioid Pain Therapeutics Summit. The study demonstrated significant pain reduction in fibromyalgia patients compared to placebo, with favorable tolerability. TONMYA is the first new FDA-approved treatment for fibromyalgia in over 15 years.
Read more →TNXPTonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
Tonix Pharmaceuticals Holdings Corp. announced its participation in two investor conferences in January 2026. Seth Lederman, M.D., the company's CEO, will present at both the Sachs Associates 9th Annual Neuroscience Innovation Forum and the Biotech Showcase 2026 in San Francisco. The presentations will focus on the company's advancements in neuropsychiatric drug development and its range of marketed and pipeline products targeting various health conditions. Interested investors are encouraged to arrange meetings with management during these events.
Read more →TNXPTonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
Tonix Pharmaceuticals has announced a registered direct offering of $20 million, selling 615,025 shares at $16.26 each. The proceeds will be used for commercialization of products and development of its pipeline. The offering is expected to close on December 30, 2025, pending customary conditions. TD Cowen is the sole placement agent for this transaction.
Read more →TNXPTonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Tonix Pharmaceuticals has announced updates on TNX-4800, a long-acting monoclonal antibody aimed at preventing Lyme disease. The company plans to explore Phase 2/3 development options, including a controlled human infection model, and expects to have the investigational product ready for clinical trials by early 2027. TNX-4800 could potentially benefit millions in endemic areas by providing immediate immunity against Lyme disease.
Read more →TNXPTonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
Tonix Pharmaceuticals has licensed TNX-4900, a selective Sigma-1 receptor antagonist, from Rutgers University. This compound has shown efficacy in treating chronic neuropathic pain in animal models and possesses a favorable safety profile. Tonix plans to advance TNX-4900 through further studies to support its development as a non-opioid analgesic.
Read more →TNXPTonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University Non-opioid analgesic shows efficacy
Tonix Pharmaceuticals has licensed exclusive worldwide rights to TNX-4900, a selective Sigma-1 receptor antagonist designed for treating chronic neuropathic pain. Preclinical studies indicate that TNX-4900 is effective in reducing pain behaviors in animal models without causing tolerance or motor impairment. The compound's promising safety profile and pharmacokinetic properties support further development towards clinical application. Tonix plans to conduct additional studies to support investigational new drug (IND) approval for TNX-4900.
Read more →TNXPTonix Pharmaceuticals Appoints Irina Ishak as General Counsel
Tonix Pharmaceuticals has appointed Irina Ishak as General Counsel, effective December 8, 2025. Ishak brings extensive experience in corporate law and has advised Tonix since 2017. Her appointment comes at a pivotal time as the company has recently launched the first FDA-approved treatment for fibromyalgia in over 15 years, signaling a period of growth and opportunity for Tonix.
Read more →TNXP▼ -11.3%on this news
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
Tonix Pharmaceuticals has received FDA clearance for its IND application to develop TNX-102 SL for treating major depressive disorder. The upcoming Phase 2 HORIZON study aims to evaluate the drug's efficacy in approximately 360 adults experiencing moderate to severe depression. The study will focus on its effects on depressive symptoms and sleep disturbances, with enrollment expected to begin in mid-2026.
Read more →TNXP▲ +5.7%on this news
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
Tonix Pharmaceuticals has announced the U.S. commercial availability of TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years. This non-opioid, once-daily sublingual tablet has shown significant efficacy in reducing pain associated with fibromyalgia. The approval follows positive results from Phase 3 clinical trials, providing new hope for millions of patients suffering from this chronic condition.
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
Tonix Pharmaceuticals reported its third quarter 2025 financial results, highlighting the upcoming launch of Tonmya™, the first new FDA-approved treatment for fibromyalgia in over 15 years. The company has a strong cash position of $190.1 million, expected to fund operations into early 2027. Additionally, Tonix is advancing its pipeline with new collaborations and product candidates.
Read more →TNXPTonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference
Tonix Pharmaceuticals will be represented by CEO Seth Lederman at the Stifel 2025 Healthcare Conference on November 13, 2025. Investors can schedule meetings with management during the event, and a webcast of the presentation will be available. Tonix has a robust pipeline, including FDA-approved products and investigational therapies for various conditions.
Read more →TNXP▼ -6.5%on this newsshared move
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
Tonix Pharmaceuticals has announced a collaboration with Massachusetts General Hospital to advance a Phase 2 clinical trial for TNX-1500, a monoclonal antibody aimed at preventing kidney transplant rejection. The study will evaluate the safety and efficacy of TNX-1500 while minimizing the use of conventional immunosuppressive drugs. The trial is expected to begin in the first half of 2026, pending necessary approvals.
Read more →TNXPTonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
Tonix Pharmaceuticals announced that CEO Seth Lederman will present at BIO-Europe 2025 in Vienna, Austria, on November 4. The presentation will cover the company's strategy and pipeline, including recent FDA approval for TonmyaTM, a new treatment for fibromyalgia. Tonix's diverse portfolio includes candidates for CNS disorders, immunology, and infectious diseases.
Read more →TNXPTonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence
Tonix Pharmaceuticals presented positive data on Tonmya™ at the 2025 ACR Convergence, showing significant pain reduction in fibromyalgia patients compared to placebo. The Phase 3 RESILIENT study indicated Tonmya was well-tolerated with minimal side effects. This approval marks a significant advancement in non-opioid treatments for fibromyalgia, a condition affecting millions.
Read more →TNXPTonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital
Tonix Pharmaceuticals has announced the dosing of the first patient in the FOCUS study, which evaluates intranasal potentiated oxytocin products for treating Arginine-Vasopressin Deficiency (AVP-D). This randomized, double-blind, placebo-controlled pilot study aims to gather preliminary data to inform future clinical trials. The study is being conducted at Massachusetts General Hospital and may lead to better treatment options for patients suffering from this rare endocrine disorder.
Read more →TNXPTonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
Tonix Pharmaceuticals announced that Dr. Gregory Sullivan will present a poster on Tonmya™ at the 2025 American College of Rheumatology Convergence. The poster will highlight the drug's effectiveness in reducing pain and its favorable tolerability in fibromyalgia patients. This presentation marks a significant milestone for Tonix, as Tonmya™ is the first new fibromyalgia treatment approved in over 15 years.
Read more →TNXPTonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025
Tonix Pharmaceuticals presented promising data on TNX-801, a live virus vaccine candidate for mpox and smallpox, at the World Vaccine Congress–Europe 2025. The vaccine demonstrated favorable safety and long-term immune protection in preclinical studies. The findings support its advancement towards clinical trials, with potential applications in global pandemic preparedness.
Read more →TNXPTonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
Tonix Pharmaceuticals presented an update on TNX-1500 at the Japan Society for Transplantation. The CEO highlighted positive Phase 1 study results supporting TNX-1500's development for preventing organ rejection. The presentation also emphasized the significance of T-regulatory cells in immune response, coinciding with recent Nobel Prize recognition in this area. Next steps toward Phase 2 studies were outlined.
Read more →TNXPTonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025
Tonix Pharmaceuticals announced its participation at the World Vaccine Congress in Europe 2025. Dr. Sina Bavari will present on the TNX-801 Mpox vaccine, while Dr. Zeil Rosenberg will moderate a panel discussion on enhancing vaccine effectiveness. The conference will take place from October 14-16, 2025, in Amsterdam.
Read more →TNXP▼ -5%on this newsshared move
TONIX PHARMACEUTICALS HOLDING CORP.
Tonix Pharmaceuticals Holding Corp. has announced the FDA approval of its drug, TONMYA, which is the first approved treatment for fibromyalgia in over 15 years. This novel sublingual formulation of Cyclobenzaprine HCl is expected to be available by Q4 2025 and aims to address the significant dissatisfaction among fibromyalgia patients with current therapies. The company has laid out its strategic plans for future products while acknowledging the risks associated with regulatory approvals and market competition.
Read more →TNXPTonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations ex
Tonix Pharmaceuticals has appointed Ganesh Kamath as the new Head of Market Access. Kamath, who has over 25 years of experience in market access and commercial operations, will play a crucial role in the upcoming launch of Tonmya, an FDA-approved treatment for fibromyalgia. The launch is anticipated in the fourth quarter of 2025. Tonix aims to leverage Kamath's expertise to ensure patient access to their therapies while pushing for growth within the company. However, the company faces various commercialization risks despite this positive development.
Read more →TNXPTonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026 Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in
Tonix Pharmaceuticals has announced plans to initiate a Phase 2 clinical trial for TNX-2900, an intranasal formulation aimed at treating Prader-Willi syndrome. This trial is set to begin in 2026 and will evaluate the drug's safety, tolerability, and efficacy in children and adolescents. TNX-2900 has received Orphan Drug and Rare Pediatric Disease Designations from the FDA, which may facilitate expedited review and approval. The company aims to address significant challenges related to hyperphagia and obesity associated with this rare genetic disorder.
Read more →TNXPTonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a p
Tonix Pharmaceuticals reported a successful Pre-IND meeting with the FDA regarding TNX-102 SL for major depressive disorder. The company received positive feedback and aims to file a supplemental new drug application in the fourth quarter of 2025. TNX-102 SL is designed to improve sleep quality in patients with depression, potentially impacting their depressive symptoms. The drug is already FDA-approved for treating fibromyalgia, and its development highlights the company's commitment to addressing underserved conditions in psychiatric care.
Read more →TNXPTonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800) Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic
Tonix Pharmaceuticals has announced the in-licensing of TNX-4800, a monoclonal antibody aimed at preventing Lyme disease. The drug, developed by UMass Chan Medical School, showed positive results in a Phase 1 study regarding safety and tolerability. TNX-4800 offers a unique single-dose administration that is expected to provide immunity quickly, potentially addressing the unmet medical need as there are currently no approved vaccines for Lyme disease. The company plans to advance TNX-4800 through further trials toward a Biologics Licensing Application.
Read more →TNXPTonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025
Tonix Pharmaceuticals has received FDA approval for Tonmya™, a new treatment for fibromyalgia, marking the first approval for this condition in over 15 years. The approval follows the successful results of two pivotal Phase 3 studies that demonstrated Tonmya's efficacy in significantly reducing fibromyalgia pain. Additionally, the drug displayed consistent improvements across key symptoms, including sleep disturbance and fatigue, and was well tolerated in patients. Tonmya is anticipated to be commercially available by the end of this year.
Read more →TNXPTonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025
Tonix Pharmaceuticals Holding Corp. is set to participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on September 4, 2025. CEO Seth Lederman will represent the company, which recently achieved FDA approval for TONMYA, a new non-opioid analgesic for fibromyalgia treatment. This marks a major milestone as it is the first FDA approval for a new prescription medication for fibromyalgia in over 15 years. The company also has a diverse pipeline focused on various therapeutic areas.
Read more →TNXP▼ -22%on this news
Tonix Pharmaceuticals Announces FDA Approval of Tonmya TM (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 y
Tonix Pharmaceuticals has received FDA approval for Tonmya (cyclobenzaprine HCl sublingual tablets), marking it as the first new treatment for fibromyalgia in over 15 years. The approval was based on three Phase 3 clinical trials indicating significant pain reduction in fibromyalgia patients. Tonmya's unique sublingual formulation allows rapid absorption, potentially improving the quality of life for millions affected by chronic pain. The product is expected to be commercially available in the fourth quarter of this year.
Read more →TNXP▼ -13.8%on this news· ran to -39% by day 3shared move
Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia
Tonix Pharmaceuticals announced the FDA approval of Tonmya (cyclobenzaprine HCl sublingual tablets) as a new treatment for fibromyalgia, marking the first new approval for this condition in over 15 years. The approval followed positive results from two pivotal Phase 3 trials, which showed significant pain reduction compared to placebo in nearly 1,000 patients. Tonmya is designed for rapid absorption, offering a non-opioid treatment option taken once daily. Despite some common side effects reported, the approval is viewed as a landmark advancement for millions of people affected by fibromyalgia in the U.S.
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights FDA PDUFA goal date of
Tonix Pharmaceuticals reported its financial results for Q2 2025, highlighting a PDUFA goal date of August 15th for TNX-102 SL, aimed at treating fibromyalgia. The company also announced its recent inclusion in the Russell 3000 and 2000 indexes. Notable advancements include the publication of successful Phase 3 trial results, a strong cash position indicating operational funding until the third quarter of 2026, and ongoing trials for other pipeline candidates. Despite the optimistic progress, the company posted a notable net loss for the quarter.
Read more →TNXPTonix Pharmaceuticals Announces the Launch of the "Move Fibro Forward" Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia CHATHAM, N.J.
Tonix Pharmaceuticals has launched the 'Move Fibro Forward' campaign aimed at raising awareness for fibromyalgia, a condition that has seen no new FDA-approved treatments in over 15 years. The initiative reflects the company's commitment to support individuals affected by this chronic pain disorder, which impacts millions in the U.S. The campaign aims to validate the experiences of those living with fibromyalgia and encourage outreach for education and resources. Initiatives like these are vital to shine a light on the experiences of afflicted individuals and address the challenges they face.
Read more →TNXPTonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia
Tonix Pharmaceuticals has launched the 'Move Fibro Forward' campaign to raise awareness and support for individuals affected by fibromyalgia. This condition, which has seen no new FDA-approved treatments in over 15 years, impacts millions, predominantly women. The campaign aims to educate patients and emphasize the importance of acknowledging their struggles. Statements from company leaders reflect a commitment to the fibromyalgia community and promoting their experiences.
Read more →TNXPTonix Pharmaceuticals Holding Corp. Corporate Presentation July 2025 NASDAQ: TNXP PO6091 July 2025 (Doc 1608 ) 2 2025 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements
Tonix Pharmaceuticals Holding Corp. presented its strategic plans and product pipeline in a recent corporate presentation. Noteworthy highlights include the Fast Track designation for TNX-102 SL, a potential breakthrough treatment for Fibromyalgia, aimed at addressing significant patient dissatisfaction with current therapies. The company is focused on various areas including nociplastic pain and immuno-oncology, but it also shared cautionary notes about the risks related to FDA approvals and the challenges of clinical development. Investors are advised to review the associated risks when evaluating the company's forward-looking statements.
Read more →TNXP▲ +10.4%on this news
Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a si
Tonix Pharmaceuticals has announced the presentation of new data on its vaccine candidate TNX-801 at the Vaccine Congress 2025. TNX-801, derived from recombinant horsepox, offers a robust immunogenic response and is significantly less virulent than traditional smallpox vaccines. The data supports subcutaneous administration as an effective method, potentially simplifying the vaccination process. The findings position TNX-801 as a promising candidate for enhancing public health responses to mpox and preparing for potential smallpox threats.
Read more →TNXP▲ +7.9%on this news· ran to +20% by day 3shared move
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine The previously disclosed and now published RESILIENT data
Tonix Pharmaceuticals has announced the online publication of results from its Phase 3 RESILIENT trial of TNX-102 SL for fibromyalgia in the journal Pain Medicine. The trial demonstrated statistically significant pain reduction compared to placebo, confirming previous findings from the RELIEF trial. The FDA has set a PDUFA date of August 15, 2025, for reviewing the drug's New Drug Application, which could lead to its approval as the first new treatment for fibromyalgia in over 15 years. The findings underscore the therapeutic potential of TNX-102 SL and its general tolerability among patients.
Read more →TNXPTonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025
Tonix Pharmaceuticals announced that Dr. Sina Bavari will present data on their vaccine candidate TNX-801 at the Vaccine Congress 2025. TNX-801 is designed to offer durable protection against monkeypox and other orthopoxviruses after a single dose. The preclinical results show that TNX-801 is well tolerated in immunocompromised animals. This development represents a significant step for Tonix in addressing emerging viral diseases.
Read more →TNXP▼ -5.7%on this newsshared move
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models Combination treatment of mTNX-1700 (mTFF2-MSA fusion pr
Tonix Pharmaceuticals announced the publication of preclinical data demonstrating that the combination of mTNX-1700 and anti-PD-1 antibody improved survival and decreased metastases in gastric cancer animal models. The study, conducted in collaboration with Columbia University, highlights the potential of mTNX-1700 to enhance immunotherapy effectiveness against resistant cancers. These findings support further development of TNX-1700 for treating gastric and colorectal cancers.
Read more →TNXPTonix Pharmaceuticals Announces Inclusion in the Russell 3000 and Russell 2000 Indexes
Tonix Pharmaceuticals Holding Corp. has announced its addition to the Russell 3000 and Russell 2000 indexes, effective June 30, 2025. This inclusion reflects the company's growth and is expected to enhance its visibility among investors and institutions. The CEO, Seth Lederman, highlighted the importance of this milestone as Tonix advances towards the potential FDA approval of TNX-102 SL for fibromyalgia, which has a decision date set for August 15, 2025.
Read more →TNXP▲ +15.6%on this news
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 TNX-102 SL is a sublingual formulation of cyclobenzaprine des
Tonix Pharmaceuticals presented data on TNX-102 SL, a sublingual formulation of cyclobenzaprine, at the Annual European Congress of Rheumatology (EULAR) 2025. The Phase 3 studies showed that TNX-102 SL significantly reduced fibromyalgia pain and improved clinical outcomes, with FDA's decision on marketing authorization expected by August 15, 2025. The drug aims to address chronic pain and related sleep disturbances without the risks associated with opioids. If approved, it could offer a novel treatment option for fibromyalgia patients, which has seen no new drugs in the past 15 years.
Read more →TNXP▼ -7.4%on this newsshared move
Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim" Hunter, to Board of Directors Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in th
Tonix Pharmaceuticals announced the appointment of James "Jim" Hunter to its Board of Directors, effective June 12, 2025. Hunter has over 40 years of experience in the biopharmaceutical sector, previously serving as Executive Vice President, Commercial at Tonix. His expertise is expected to strengthen Tonix's commercial strategy as the company prepares for a potential launch of TNX-102 SL for fibromyalgia later this year. This appointment highlights Tonix's commitment to expanding its commercial footprint in the migraine market and beyond.
Read more →TNXPTonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention
Tonix Pharmaceuticals announced that CEO Seth Lederman will present at the 2025 BIO International Convention in Boston. The presentation is scheduled for June 16, 2025. The company is actively advancing its pipeline, particularly focusing on TNX-102 SL for fibromyalgia, which has recently been submitted for marketing authorization. They also have innovative projects in development addressing various medical challenges, including vaccines and treatments for central nervous system disorders.
Read more →TNXPTonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025
Tonix Pharmaceuticals Holding Corp. announced a poster presentation for their innovative treatment of fibromyalgia, TNX-102 SL, at the Annual European Congress of Rheumatology (EULAR) 2025. The presentation will detail the medication's ability to target non-restorative sleep and provide sustained pain reduction. Tonix has submitted a New Drug Application (NDA) for TNX-102 SL, based on significant Phase 3 study results, and has received Fast Track designation from the FDA. This event marks a significant step in the company’s ongoing development efforts in pain management.
Read more →TNXP▼ -6.8%on this news· ran to +33% by day 3
Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase
Tonix Pharmaceuticals Holding Corp. has announced that CEO Seth Lederman participated in a fireside chat at the A.G.P. Annual Healthcare Company Showcase. The company emphasized its commitment to developing therapies for pain management, particularly with its lead product TNX-102 SL for fibromyalgia. They aim for a marketing authorization decision by the FDA by August 15, 2025, after submitting an NDA based on successful Phase 3 studies. Tonix is also active in immunology and infectious diseases, demonstrating a broad approach to addressing public health challenges.
Read more →TNXP▼ -5.3%on this news· ran to +24% by day 3shared move
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction Investigator-initiated Phase 2 trial to evaluate TNX-102 SL's potential to reduce severity o
Tonix Pharmaceuticals has initiated the Phase 2 OASIS trial, which aims to evaluate TNX-102 SL for reducing acute stress reactions and preventing acute stress disorder among trauma patients. The trial, sponsored by the University of North Carolina and funded by a $3 million grant from the U.S. Department of Defense, has successfully dosed its first patient. Results from the trial are expected in the second half of 2026. TNX-102 SL is also highlighted for its previously observed efficacy in improving sleep quality related to PTSD.
Read more →TNXP▲ +9.4%on this news· ran to +32% by day 3
Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations Mr. Hand brings more than 20 years of strategic legal and business leadership experience acr
Tonix Pharmaceuticals has appointed Joseph Hand, Esq. as their new General Counsel and Executive Vice President of Operations, effective immediately. With over 20 years of experience in strategic legal and business leadership, including significant roles at Celgene, Mr. Hand is seen as a valuable addition to the Tonix team. This appointment comes at a crucial time as the company prepares for the potential approval of its product candidate TNX-102 SL for the management of fibromyalgia, which has a PDUFA goal date set for August 15, 2025.
Read more →TNXPTonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights FDA PDUFA goal date of
Tonix Pharmaceuticals announced its financial results for the first quarter of 2025, highlighting significant operational achievements. The company is preparing for a pivotal FDA decision on TNX-102 SL for fibromyalgia, with a goal date of August 15, 2025. Positive results from a Phase 1 study of TNX-1500 were also reported, which is aimed at preventing kidney transplant rejection. However, the company's net loss increased year-over-year, drawing attention to its financial performance amidst ongoing development efforts.
Read more →TNXPTonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting Combination treatment of TFF2 with anti-PD1 antibody was associated wit
Tonix Pharmaceuticals presented promising preclinical data on its gastric cancer treatment, TNX-1700, at the AACR 2025 Annual Meeting. The data indicated that combining TFF2 with an anti-PD1 antibody activated CD8+ T cells and mitigated immune evasion by tumor cells in murine models. This strategy may enhance the effectiveness of immunotherapies against gastric and colorectal cancers. The findings support further exploration of TNX-1700, positioned as a lead candidate in Tonix's immuno-oncology pipeline.
Read more →TNXPTonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 pr
Tonix Pharmaceuticals presented data on its potential mpox vaccine, TNX-801, during the World Vaccine Congress Washington 2025. The vaccine, which is a single-dose live virus formulation, has shown efficacy in protecting animals against both mpox and rabbitpox while demonstrating tolerability in immunocompromised species. The findings suggest durable immune protection for up to six months, adding to the calls for more vaccine options amid ongoing mpox epidemics. TNX-801 aligns with WHO guidelines for effective vaccine development, aiming to address public health emergency concerns.
Read more →TNXP▼ -6.7%on this news
Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025
Tonix Pharmaceuticals announced their participation in the World Vaccine Congress Washington 2025, set for April 22-24, where they will deliver an oral presentation and lead a panel discussion. The presentations will focus on topics like mpox and smallpox vaccine development. Key personnel, including Farooq Nasar, PhD, will lead discussions on their innovative vaccine strategies. The company continues to advance its pipeline aimed at addressing CNS disorders and vaccine development for public health challenges.
Read more →TNXP▼ -9.6%on this news
Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation
Tonix Pharmaceuticals and Makana Therapeutics have entered a collaboration to combine Tonix's anti-CD40L monoclonal antibody, TNX-1500, with Makana's genetically engineered organs for xenotransplantation studies. The partnership aims to utilize TNX-1500 in preclinical and clinical studies to support regulatory filings for organ transplantation in human recipients. This collaboration could advance the clinical application of xenotransplantation, as it leverages innovations in organ compatibility and immunomodulation.
Read more →TNXP▲ +13.8%on this news· ran to +27% by day 1shared move
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
Tonix Pharmaceuticals presented optimistic data on TNX-102 SL, a sublingual formulation of cyclobenzaprine for treating fibromyalgia, at the AAPM 2025 Annual Meeting. The results from two pivotal Phase 3 studies showed significant improvement in reducing fibromyalgia pain, meeting its primary endpoint. If approved by the FDA by the PDUFA goal date of August 15, 2025, TNX-102 SL would be the first member of a new class of non-opioid analgesics for fibromyalgia. The formulation aims to address chronic pain issues and enhance sleep quality among patients.
Read more →TNXPTonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference
Tonix Pharmaceuticals Holding Corp. has announced that CEO Seth Lederman will present at the 2025 Jones Trading Healthcare and Innovation Conference on April 9, 2025. The company is focused on advancing its product candidates, including TNX-102 SL for fibromyalgia, which is currently under FDA review with a PDUFA date of August 15, 2025. Investors have the opportunity to request meetings with management during the conference. Tonix continues to expand its pipeline in CNS disorders and other therapeutic areas.
Read more →TNXPTonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition
Tonix Pharmaceuticals has launched TONIX ONE, a fully-integrated digital platform aimed at aiding patients in managing their migraine conditions. The platform simplifies the patient journey through partnerships with UpScript Telemedicine, ProModRx, and Blink Health, facilitating access to education, telehealth services, and prescription fulfillment. By enhancing the management of migraines and addressing treatment barriers, Tonix aims to solidify its leadership in innovation within the biopharma space.
Read more →TNXPTonix Pharmaceuticals Launches TONIX ONE TM , a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition Tonix expands its all-in-one platform, partnering with the
Tonix Pharmaceuticals has launched TONIX ONE, a fully-integrated digital platform aimed at better managing migraine conditions for patients. This platform offers educational resources, telehealth services, and an intuitive interface that connects patients to migraine specialists and prescription services. Partnerships with UpScript Health, ProModRx, and Blink Health enhance accessibility and streamline the journey for individuals with migraines. The initiative signifies Tonix’s commitment to removing barriers in migraine care and improving patient outcomes.
Read more →TNXP▼ -7.3%on this news· ran to -39% by day 3shared move
Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
Tonix Pharmaceuticals Holding Corp. announced that CEO Seth Lederman will present a poster at the AAPM 2025 Annual Meeting in Austin, Texas, on April 5, 2025. The company is focused on developing therapies for pain management, particularly for fibromyalgia, with an NDA in progress for its candidate TNX-102 SL. The FDA has granted Fast Track designation for this candidate. Additionally, Tonix is working on various other CNS and infectious disease therapies, supported by substantial research funding.
Read more →TNXP▲ +32.5%on this newsshared move
Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia On track for
Tonix Pharmaceuticals announced that the FDA will not require an Advisory Committee meeting for its New Drug Application for TNX-102 SL, a non-opioid analgesic for managing fibromyalgia. This marks a positive step toward a potential approval, which, if granted, would make TNX-102 SL the first new drug for fibromyalgia in over 15 years. The company is preparing for a product launch in the fourth quarter of 2025, contingent on FDA approval. The drug has been granted Fast Track designation, highlighting its importance in addressing the needs of fibromyalgia patients.
Read more →TNXP▲ +26.1%on this news· ran to +41% by day 3
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Tonix Pharmaceuticals has reported its financial results for the fourth quarter and full year ended December 31, 2024. The company announced a PDUFA goal date of August 15, 2025, for its candidate TNX-102 SL, aimed at fibromyalgia treatment, which could represent a significant therapeutic advancement. Financially, Tonix reported a net loss of $22.1 million for Q4 2024, although it retains a healthy cash position of $98.8 million. The company also revealed positive early results from TNX-1500, indicating progress in their pipeline.
Read more →TNXPTonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025
Tonix Pharmaceuticals announced that its CEO, Seth Lederman, will present at the BIO-Europe Spring 2025 Convention regarding TNX-102 SL for fibromyalgia. The FDA has set an August 15, 2025, PDUFA goal date for marketing authorization, representing a significant potential advancement in treatment options. The company is focused on addressing unmet needs in the fibromyalgia space, with the possibility of becoming the first new treatment approved in 15 years. This presentation is part of Tonix's broader engagement strategy at industry conferences.
Read more →TNXPTonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th
Tonix Pharmaceuticals Holding Corp. announced that its CEO, Seth Lederman M.D., will present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025. The event will allow investors to ask questions in real-time, enhancing interactive engagement. Tonix continues to focus on advancing its product candidates, particularly in the CNS disorder space, including their management of fibromyalgia. The company's development initiatives and pipeline offerings reflect its commitment to addressing significant health challenges.
Read more →TNXPTonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company's Single-Dose Mpox and Smallpox Vaccine Candidate The World Health Organization (WHO) recently reaff
Tonix Pharmaceuticals has announced that it has received a grant from the Medical CBRN Defense Consortium (MCDC) to support the development of TNX-801, a single-dose vaccine candidate for mpox and smallpox. This grant will facilitate comprehensive market analyses and planning for commercialization of the vaccine. The World Health Organization has reaffirmed mpox as a public health emergency, highlighting the ongoing need for effective vaccines like TNX-801, which has demonstrated promising tolerability and immune protection in preclinical models.
Read more →TNXP▲ +40.5%on this news· ran to +88% by day 1shared move
Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit
Tonix Pharmaceuticals Holding Corp. will present at the 2025 Virtual Investor Summit on March 11, 2025. Jessica Morris, the COO, will detail the firm's advancements, including the development of TNX-102 SL for fibromyalgia and other CNS disorders. The presentation aims to engage investors and emphasize the company’s extensive pipeline, which includes various therapies and collaborations with U.S. government entities. The company faces inherent challenges in obtaining regulatory approvals and successfully marketing its products.
Read more →TNXP▲ +5.7%on this news· ran to +76% by day 3shared move
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia TNX-102 SL is a sublingual formulation of cyclobenzaprine d
Tonix Pharmaceuticals has presented promising data on TNX-102 SL, a sublingual formulation of cyclobenzaprine, at the 7th International Congress on Controversies in Fibromyalgia. In two Phase 3 studies, TNX-102 SL achieved significant reductions in fibromyalgia pain, indicating its potential as a new treatment option. If approved, it would mark the first advancement in fibromyalgia medications in over 15 years, with a PDUFA goal date from the FDA set for August 15, 2025.
Read more →TNXP▲ +10.2%on this news
Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash Company had $98.8 million in cash as of
Tonix Pharmaceuticals Holding Corp. recently announced preliminary operating results for the year ending December 31, 2024, highlighting a cash position of $98.8 million which is expected to fund planned operations into the first quarter of 2026. The company is debt-free, having repaid its mortgage, and anticipates gross proceeds of approximately $30.4 million from sales under its at-the-market facility. A PDUFA goal date of August 15, 2025, has been assigned by the FDA for TNX-102 SL, targeting fibromyalgia management. However, the financial results are preliminary and may change upon completion of financial closing procedures.
Read more →TNXP▼ -25%on this newsshared move
Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases Resu
Tonix Pharmaceuticals announced positive topline results from its Phase 1 trial of TNX-1500, a next-generation anti-CD40L monoclonal antibody. The trial demonstrated that TNX-1500 effectively blocked antibody responses at specified doses and showed a favorable safety profile, supporting further development. The company plans to advance to a Phase 2 trial aimed at kidney transplant recipients and expects to discuss these results with the FDA. TNX-1500 has potential indications beyond transplantation, including treatment for autoimmune diseases.
Read more →TNXPTonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference
Tonix Pharmaceuticals announced that its CEO, Dr. Seth Lederman, will present at the BIO CEO & Investor Conference on February 10, 2025. The company is focused on advancing its product candidate TNX-102 SL for fibromyalgia management, having submitted an NDA based on positive Phase 3 study results. Additionally, Tonix's development pipeline includes treatments for central nervous system disorders and infectious diseases, supported by significant funding from the Department of Defense.
Read more →TNXP▼ -22%on this news· ran to -36% by day 3shared move
Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development Tonix is Preparing for Potential Launch
Tonix Pharmaceuticals has promoted Siobhan Fogarty to Chief Technical Officer, effective immediately. Fogarty, who joined the company in 2016 and has extensive experience in biotech product development, will guide the company as it approaches the FDA's PDUFA goal date of August 15, 2025, for TNX-102 SL, a treatment aimed at managing fibromyalgia. The promotion comes at a significant time for Tonix, which is focusing on expanding its portfolio and advancing its product candidates through clinical development.
Read more →TNXP▼ -54.5%on this news· ran to -74% by day 3shared move
Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split CHATHAM, N.J.
Tonix Pharmaceuticals has announced a 1-for-100 reverse stock split of its common stock, effective February 5, 2025, to address compliance with NASDAQ minimum bid price requirements. The reverse split means that every hundred shares will consolidate into one share, which is intended to increase the per share trading price. The company continues to advance its product candidates, including TNX-102 SL for fibromyalgia, which has a PDUFA goal date set for August 15, 2025, along with other candidates targeting CNS disorders and infectious diseases.
Read more →TNXP▼ -11.1%on this news· ran to -21% by day 3
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access Mr. Ainsworth brings over two decades of industry and market access experience to
Tonix Pharmaceuticals has appointed Gary Ainsworth as Vice President of Market Access, effective immediately. Ainsworth, with over twenty years of experience, is expected to strengthen Tonix's market access strategies, particularly as the company aims for the FDA approval of its fibromyalgia treatment, TNX-102 SL, by August 2025. The appointment reflects Tonix's commitment to enhancing its leadership team in preparation for future product launches. The company continues to focus on managing pain and developing treatments for various conditions.
Read more →TNXP▼ -7.8%on this news· ran to -18% by day 1shared move
Tonix Pharmaceuticals to Present at Two Upcoming January Investor Conferences
Tonix Pharmaceuticals announced its participation in two upcoming investor conferences in January 2025, featuring presentations from CEO Seth Lederman. Key presentations will discuss the company's innovative approaches to neuropsychiatric treatments and its lead product candidate TNX-102 SL for fibromyalgia. The company is focused on transforming therapies for CNS disorders and has multiple product candidates in its pipeline. They are also expanding their presence in other therapeutic areas, such as infectious diseases and immunology.
Read more →TNXP▼ -34.1%on this news· ran to -45% by day 3
Tonix Pharmaceuticals Announces PDUFA Goal Date of
Tonix Pharmaceuticals announced that the FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for a decision on TNX-102 SL's marketing approval for fibromyalgia. TNX-102 SL is a non-opioid analgesic that may represent the first new drug for this condition in over 15 years. The drug has demonstrated significant efficacy in Phase 3 trials and offers a new treatment option for fibromyalgia, which affects over 10 million adults in the U.S. The FDA's Fast Track designation further underscores the potential importance of this treatment in addressing the unmet needs of fibromyalgia patients.
Read more →TNXP▼ -37%on this news
Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether
Tonix Pharmaceuticals announced that the FDA has accepted its New Drug Application (NDA) for TNX-102 SL, an investigational treatment for fibromyalgia. This acceptance indicates the FDA will soon assign a target action date and potentially grant Priority Review. TNX-102 SL is positioned to be the first new drug in over 15 years for this chronic pain condition and aims to fill significant treatment gaps experienced by over 10 million adults in the U.S. The NDA is supported by two successful Phase 3 clinical trials demonstrating its efficacy and safety profile.
Read more →TNXPTonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires Tonix appoints two executives with decades of experience successfully launching and commercializing new CNS products Bradley Raudabaug
Tonix Pharmaceuticals has expanded its leadership team by appointing Bradley Raudabaugh as Vice President of Marketing and Errol Gould as Vice President of Medical Affairs. Both executives bring over 25 years of experience in launching and commercializing products. This move aims to bolster the company's strategy for the upcoming launch of TNX-102 SL, a proposed treatment for fibromyalgia, which is set to be reviewed by the FDA in 2025. The addition of these seasoned professionals is intended to enhance Tonix's market readiness and commercial capabilities as it seeks to deliver innovative treatments for CNS disorders.
Read more →TNXPTonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference
Tonix Pharmaceuticals, represented by COO Jessica Morris, will present at the NobleCon20 Investor Conference on December 3-4, 2024. The company focuses on CNS disorders and has advanced its product candidate TNX-102 SL, currently awaiting FDA review after Fast Track designation. Additionally, Tonix is involved in various other developments, including a contract with the U.S. Department of Defense for antiviral agents. The event aims to boost investor engagement and showcase the company's pipeline and growth potential.
Read more →TNXPTonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual
Tonix Pharmaceuticals Holding Corp. announced that Chief Operating Officer Jessica Morris will present at the Winter 2024 Investor Summit Virtual on November 21, 2024. The company is focused on developing therapies for pain management and CNS disorders, including TNX-102 SL for fibromyalgia, which has received FDA Fast Track designation. Tonix is also advancing other projects, including antiviral agents and treatments for various medical conditions. The company has recently signed a contract with the U.S. DoD to develop antiviral therapies.
Read more →TNXPTonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
Tonix Pharmaceuticals recently presented promising results from the Phase 3 RESILIENT study concerning TNX-102 SL, showing significant pain reduction in fibromyalgia patients. The treatment also met key secondary endpoints related to sleep and overall symptom management. Tonix submitted a New Drug Application (NDA) to the FDA in October 2024, expecting a decision on approval in 2025. If approved, TNX-102 SL would be the first new analgesic class for fibromyalgia in over a decade.
Read more →TNXPTonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
Tonix Pharmaceuticals has announced that CEO Seth Lederman will deliver a poster presentation at the ACR Convergence 2024 Annual Meeting in Washington, D.C. The presentation will focus on the randomized, double-blind, placebo-controlled Phase 3 trial of TNX-102 SL for fibromyalgia. The company is expecting an FDA decision on their NDA submission by December 2024, which could lead to an approval decision in 2025. Tonix continues to advance its product candidates for various CNS disorders and has received Fast Track designation for TNX-102 SL.
Read more →TNXPTonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals The World Hea
Tonix Pharmaceuticals announced the publication of a study in mSphere demonstrating that their single-dose Mpox and smallpox vaccine candidate, TNX-801, is significantly less virulent than traditional vaccines in immune-compromised animals. The findings support further clinical testing and underscore the potential for TNX-801 to provide durable protection against mpox emergencies amid ongoing outbreaks. The publication reinforces the feasibility of TNX-801's distribution and the broader implications for global health amidst rising mpox cases in various regions.
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 stu
Tonix Pharmaceuticals recently reported its third quarter financial results, highlighting the submission of a New Drug Application (NDA) to the FDA for TNX-102 SL aimed at treating fibromyalgia. The drug has received Fast Track designation, enabling expedited review due to the unmet medical need in the fibromyalgia space. The company also provided updates on its mpox vaccine candidate, TNX-801, and reported a net loss of $14.2 million for the quarter. Tonix's cash reserves improved, reaching approximately $28.2 million, supporting ongoing operational activities.
Read more →TNXPTonix Pharmaceuticals Holding Corp. 2024 Tonix Pharmaceuticals Holding Corp. TNX - 1700 Gastric and Colorectal Cancers NASDAQ: TNXP Version PO6019
Tonix Pharmaceuticals is advancing its candidate TNX-1700, a recombinant Trefoil Factor 2 fusion protein, which shows promise in treating gastric and colorectal cancers. Preclinical data indicate that TNX-1700 has the potential to improve the effectiveness of PD-1 therapies by altering the tumor microenvironment. However, TNX-1700 is still in the pre-IND stage, with several regulatory and financial hurdles ahead. The drug targets a substantial unmet need among patients with limited treatment options for these cancers.
Read more →TNXPTonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya Proposed clinical st
Tonix Pharmaceuticals has entered a research agreement with the Kenya Medical Research Institute (KEMRI) to develop a Phase I clinical study for TNX-801, a vaccine designed to prevent mpox. This agreement aims to assess the vaccine's safety, tolerability, and immunogenicity in Kenya. With mpox declared a public health emergency, there is heightened focus on effective vaccines, particularly single-dose options that ensure durable protection and can be stocked easily. TNX-801 has demonstrated efficacy in preclinical studies, positioning it as a potential solution amid increasing global concern over mpox outbreaks.
Read more →TNXPTonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix's atten
Tonix Pharmaceuticals presented promising preclinical data for its potential mpox vaccine, TNX-801, at the World Vaccine Congress-Europe 2024. The data indicate that TNX-801 exhibits strong tolerability and shows no evidence of spreading in blood or tissues, even at elevated doses in immunocompromised animals. The vaccine aligns with WHO guidelines and demonstrates efficacy in protecting against clade I monkeypox challenges. With favorable characteristics and a new manufacturing collaboration, TNX-801 is poised to play a significant role in controlling mpox outbreaks.
Read more →TNXP▼ -6.1%on this news· ran to -22% by day 3shared move
Tonix Pharmaceuticals to Present at BIO-Europe 2024
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that its CEO, Dr. Seth Lederman, will present at BIO-Europe 2024, scheduled for November 4-6, 2024, in Stockholm, Sweden. The company focuses on biopharmaceutical innovations for pain management and CNS disorders, boasting products in various stages of development. Notably, TNX-102 SL has received Fast Track designation from the FDA for fibromyalgia treatment. Additionally, Tonix recently secured funding from the U.S. Department of Defense for developing antiviral agents.
Read more →TNXPTonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Tonix Pharmaceuticals Holding Corp. announced that COO Jessica Morris will present at the ThinkEquity Conference on October 30, 2024, in New York City. The presentation will discuss Tonix's product pipeline, which includes treatments for fibromyalgia and cocaine intoxication, as well as collaborations with the U.S. Department of Defense. The company is focused on addressing various health challenges through innovative therapies, but it acknowledges the inherent risks in drug development and regulatory approval processes.
Read more →TNXPTonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024
Tonix Pharmaceuticals Holding Corp. announced that Dr. Zeil Rosenberg will deliver an oral presentation at the World Vaccine Congress Europe in Barcelona. The presentation will detail a new single-dose vaccine for mpox. The congress will take place from October 28 to 31, 2024. Tonix continues to advance its pipeline of biopharmaceutical products, including the recently designated Fast Track product TNX-102 SL for fibromyalgia.
Read more →TNXP▲ +12.8%on this news
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA) First payment received under
Tonix Pharmaceuticals has received its first payment of $34 million from the U.S. Department of Defense's Defense Threat Reduction Agency (DTRA) for the development of broad-spectrum antiviral agents. This funding, designated for a five-year contract, is aimed at improving medical readiness of military personnel in biological threat environments. The contract validates Tonix's research efforts and will support the acceleration of its antiviral discovery program focused on targeting CD45 to enhance immune response against infections.
Read more →TNXP▲ +12.8%on this news· ran to +35% by day 3shared move
Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) NDA based on two Phase 3 studies of TNX-102 SL in fibromyalgia with
Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for TNX-102 SL, a non-opioid treatment for fibromyalgia. The NDA is based on positive results from two Phase 3 studies that showed statistically significant reductions in chronic pain associated with the condition. If approved, TNX-102 SL would represent the first new drug for fibromyalgia in over 15 years, offering a novel treatment option for a significant patient population. The drug has been granted Fast Track designation by the FDA, which aims to expedite the review process for important new therapies.
Read more →TNXPTonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of sma
Tonix Pharmaceuticals announced a research collaboration with X-Chem to utilize AI and machine learning in the development of broad-spectrum antiviral drugs. The partnership aims to expedite the advancement of Tonix's TNX-4200 program, which targets CD45 phosphatase for antiviral treatment. The initiative is supported by a substantial contract from the U.S. Department of Defense for up to $34 million, intended to enhance medical countermeasures against a variety of viral infections. This collaboration underscores Tonix's focus on innovative solutions within the biopharmaceutical sector.
Read more →TNXPTonix Pharmaceuticals Announces Participation in Endpoints Panel at the Long COVID Workshop and RECOVER TLC Workshop Convened by the Foundation for the National Institutes of Health (FNIH) and the National Institute of Allergy and Infectious Diseases (NIAID)
Tonix Pharmaceuticals announced its participation in the RECOVER TLC workshop focused on developing treatments for Long COVID. CEO Seth Lederman discussed potential clinical trial endpoints to support regulatory approval, highlighting the significance of Patient Global Impression of Change as a primary endpoint. Tonix is progressing with its TNX-102 SL application for fibromyalgia and expects to submit a New Drug Application to the FDA soon. The initiative aims to foster collaboration among various stakeholders to tackle Long COVID effectively.
Read more →TNXP▲ +6.9%on this newsshared move
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace SymTouch to Treat Migraines New patent expected to provide market exclusivity into 2036 Zembrace SymTouc
Tonix Pharmaceuticals has announced the issuance of a new U.S. patent covering the subcutaneous delivery of Zembrace SymTouch, an FDA-approved treatment for migraines. The patent is expected to ensure market exclusivity until 2036, which could strengthen the company's market position. The CEO emphasized the importance of educating patients on non-oral migraine treatments and the advantages they offer over traditional oral medications. Tonix continues to develop and market innovative solutions for migraine management as part of its dual focus on CNS disorders and public health challenges.
Read more →TNXP▼ -8.5%on this news
Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11 th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024) Presentations highlighted the proprietary form
Tonix Pharmaceuticals presented key data on its drug TNX-102 SL for fibromyalgia at the PDDS 2024 conference. The presentations detailed the drug's sublingual formulation, pharmacokinetic properties, and results from the Phase 3 RESILIENT study, which demonstrated significant pain relief and improved sleep quality. The company is poised for an NDA submission to the FDA set for October 2024, with expectations for approval by 2025. Tonix maintains a strong patent portfolio protecting TNX-102 SL’s formulation and has highlighted its potential as a new treatment option for fibromyalgia patients.
Read more →TNXPTonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines New patent expected to expire in 2030 T
Tonix Pharmaceuticals has announced the issuance of a new U.S. patent for the intranasal delivery of Tosymra, an FDA-approved treatment for migraines. The patent is significant as it enhances the intellectual property protection for Tosymra, which is expected to remain valid until 2030. This differentiation in administration may bolster the product's market presence, potentially benefiting millions of migraine sufferers. The company continues to innovate in the biopharmaceutical landscape, focusing on pain management and CNS disorders.
Read more →TNXP▼ -5.9%on this newsshared move
Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency The World Health Organizati
Tonix Pharmaceuticals announced that its single-dose mpox vaccine candidate, TNX-801, aligns with the World Health Organization's newly issued preferred target product profile, which highlights its potential for effective public health response. TNX-801 is positioned for rapid deployment due to its stability at ambient temperatures and suitability for immunocompromised individuals. Studies indicate that it provides effective protection against the lethal Clade I strain of mpox. Furthermore, a collaboration with Bilthoven Biologics aims to boost the manufacturing processes for TNX-801 in response to a declared public health emergency by WHO.
Read more →TNXP▼ -6.1%on this news
Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations Thomas brings more than 20 years of commercial and operations experience in the biopharmaceutical industr
Tonix Pharmaceuticals has appointed Thomas Englese as Executive Vice President of Commercial Operations, effective immediately. Englese is expected to leverage his extensive experience in the biopharmaceutical sector to enhance the company’s strategic growth and commercialization efforts. Furthermore, Tonix is on track to submit a New Drug Application for its fibromyalgia treatment, TNX-102 SL, by October 2024, marking a significant milestone for the company. Englese succeeds Jim Hunter, who is retiring, and aims to bring innovative therapies to patients in need.
Read more →TNXP▲ +15.9%on this newsshared move
Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in "Using Synthetic Biology to Battle Mpox" Talk at Immunology Symposium at the University of Alberta TNX-801 vaccination demonstrated efficacy i
Tonix Pharmaceuticals presented promising data on its mpox vaccine, TNX-801, during a recent symposium at the University of Alberta. The vaccine demonstrated efficacy in protecting animals and improved tolerability compared to traditional vaccines, specifically in immunocompromised subjects. TNX-801, derived from horsepox, aims to provide a single-dose solution with reduced storage requirements, aligning with current public health guidelines amid rising mpox cases. The vaccine is currently part of NIH’s Project NextGen for further clinical testing.
Read more →TNXP▼ -10.3%on this newsshared move
Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek
Tonix Pharmaceuticals has launched a national awareness campaign at PAINWeek to educate patients and healthcare providers about the impact of gastroparesis on the effectiveness of oral migraine medications. The campaign highlights the benefits of non-oral treatment options, such as nasal sprays and injectables, which can provide faster relief by bypassing the digestive system. Additionally, the company is introducing a dedicated website and hosting a webinar to further disseminate important information regarding gastroparesis and migraine management. This initiative aims to empower patients in optimizing their migraine treatment plans.
Read more →TNXP▼ -14.8%on this news· ran to -45% by day 3
Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MH
Tonix Pharmaceuticals presented notable data at the 2024 Military Health System Research Symposium, focusing on TNX-102 SL's efficacy in reducing acute stress reaction and preventing PTSD. The anticipated Phase 2 trial is set to commence in the third quarter of 2024, aiming to fill the existing treatment gap for patients suffering from trauma. Additionally, the company showcased preclinical advancements in automated wound healing assays, potentially leading to innovative therapeutic approaches in this field.
Read more →TNXP▼ -17.4%on this news· ran to -54% by day 3shared move
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium (MHSRS)
Tonix Pharmaceuticals presented data on TNX-102 SL, a treatment for fibromyalgia, during the 2024 Military Health System Research Symposium. The Phase 3 RESILIENT study results showed statistically significant reductions in nociplastic pain, enhanced sleep quality, and improvements across several secondary endpoints. The company is set to submit a New Drug Application (NDA) to the FDA by late 2024, with anticipated approval in 2025. Additionally, TNX-102 SL has been granted Fast Track designation by the FDA.
Read more →TNXP▲ +10%on this newsshared move
Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix's Mpox Vaccine, TNX-801 World Health Organization declared spread of mpox in multiple African countries a public health eme
Tonix Pharmaceuticals is collaborating with Bilthoven Biologicals to advance the development of TBX-801, a vaccine candidate for mpox. This partnership comes in light of a World Health Organization declaration that mpox has become a public health emergency in several African countries due to a new strain with significant mortality risks. Preclinical studies indicate TNX-801 offers strong immune protection, and its single-dose regimen could facilitate broader vaccination efforts. The collaboration seeks to address the urgent global health needs and enhance pandemic preparedness through effective vaccine manufacturing strategies.
Read more →TNXP▼ -5.3%on this newsshared move
Tonix Pharmaceuticals Announces Oral Presentation and Three Poster Presentations at the 2024 Military Health System Research Symposium (MHSRS)
Tonix Pharmaceuticals Holding Corp. announced its participation in the 2024 Military Health System Research Symposium, showcasing an oral presentation and three posters. The oral presentation emphasizes TNX-102 SL’s efficacy in managing fibromyalgia pain, based on results from the Phase 3 RESILIENT trial. Additionally, poster presentations will cover other applications of TNX-102 SL as well as innovative techniques in assessing wound healing. The event highlights Tonix's commitment to developing therapeutics for military-related health issues.
Read more →TNXP▼ -14.6%on this newsshared move
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in pat
Tonix Pharmaceuticals has initiated the Phase 2 CATALYST study for TNX-1300, aimed at treating acute cocaine intoxication. This is a single-blind, placebo-controlled trial involving patients in emergency settings, highlighting the urgent need for effective treatments given the rising number of cocaine overdose deaths in the U.S. TNX-1300 has previously shown promising results in laboratory settings and has been granted Breakthrough Therapy designation by the FDA. With an estimated 505,000 emergency room visits annually related to cocaine use, this study could significantly impact treatment approaches in emergency medicine.
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights On track to submit NDA in second half 2024 for TNX-102 SL for fibromyalgia; completed successful pre-NDA meetings with FDA in
Tonix Pharmaceuticals announced its second quarter 2024 financial results, indicating significant advancements toward submitting a New Drug Application (NDA) for TNX-102 SL for fibromyalgia, expected in the latter half of 2024. The FDA's Fast Track designation for TNX-102 SL is set to expedite the drug's review process. Additionally, the company secured funding from the U.S. Department of Defense to develop a broad-spectrum antiviral. Despite progress, financial results showed a substantial net loss and significant impairments.
Read more →TNXPTonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency
Tonix Pharmaceuticals has announced progress in the development of TNX-801, a live attenuated virus vaccine candidate for mpox, in light of the WHO's declaration of a public health emergency due to the outbreak. The vaccine is designed to provide effective immunity against mpox with just a single dose, distinguishing it from traditional vaccines requiring multiple doses. Recent findings indicate TNX-801's ability to prevent lethal monkeypox disease in animal models. The urgency of this development is underscored by the rising cases of mpox both domestically and internationally.
Read more →TNXPTonix Pharmaceuticals to Present at the Summer 2024 Virtual Investor Summit
Tonix Pharmaceuticals announced that its CEO, Seth Lederman, will present at the Summer 2024 Virtual Investor Summit on August 20, 2024. The company is focused on developing treatments for human diseases, especially CNS disorders, and aims to submit a New Drug Application for TNX-102 SL for fibromyalgia management by the end of 2024. The product has already achieved Fast Track designation from the FDA, reflecting its potential benefit. Tonix's diverse product pipeline also includes treatments for acute stress reaction and cocaine intoxication.
Read more →TNXP▲ +7%on this newsshared move
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain Bedtime TNX-102 SL (sublingual cycloben
Tonix Pharmaceuticals presented data from the Phase 3 RESILIENT study at the IASP 2024 World Congress on Pain, showcasing that TNX-102 SL significantly reduced daily pain for fibromyalgia patients. The treatment also demonstrated statistically significant improvements in sleep quality and other related symptoms. TNX-102 SL has received Fast Track designation from the FDA, with a New Drug Application submission expected in the second half of 2024. Overall, the study results indicate promising potential for TNX-102 SL as a treatment option for fibromyalgia patients.
Read more →TNXPTonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company’s Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens
Tonix Pharmaceuticals announced the publication of a research paper in the journal Microorganisms, which focuses on their high-throughput imaging technology to identify neutralizing antibodies against SARS-CoV-2 and other pathogens. This development underscores the company's commitment to enhancing its R&D capabilities in infectious diseases, particularly in light of rising COVID-19 rates. Additionally, Tonix is advancing various antiviral programs, including TNX-4200, supported by a significant contract from the U.S. Department of Defense. Their involvement in the federal Project NextGen further solidifies their role in the development of next-generation vaccines and therapeutics for COVID-19.
Read more →TNXP▼ -12.2%on this news
Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya™
Tonix Pharmaceuticals announced that the new definition of Long COVID by the U.S. National Academies recognizes fibromyalgia as a diagnosable condition in affected patients. This recognition is expected to expand the addressable market for Tonmya, an investigational treatment for fibromyalgia, as the company aims for a New Drug Application (NDA) submission in the second half of 2024, with potential FDA approval in 2025. Dr. Lederman emphasized that diagnosing fibromyalgia in Long COVID patients could significantly increase market potential compared to pre-pandemic estimates.
Read more →TNXPTonix Pharmaceuticals Announces Poster Presentation at the IASP 2024 World Congress on Pain
Tonix Pharmaceuticals announced a poster presentation at the IASP 2024 World Congress on Pain, highlighting positive Phase 3 trial results for Tonmya™, a treatment for fibromyalgia. The presentation will be made by CEO Seth Lederman and showcases the drug's impact on pain and sleep quality. Additionally, Tonx has received FDA Fast Track Designation for Tonmya™, with plans to submit a New Drug Application in the latter half of 2024. This event aims to increase awareness of their innovative treatments targeting central nervous system disorders.
Read more →TNXP▲ +10%on this newsshared move
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya for Fibromyalgia Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need Fast
Tonix Pharmaceuticals Holding Corp. received Fast Track designation from the FDA for Tonmya, a non-opioid treatment for fibromyalgia. This designation acknowledges fibromyalgia as a serious condition, affecting millions in the U.S., and aims to expedite the review process for Tonmya. The company plans to submit its New Drug Application (NDA) in the second half of 2024, with the drug potentially serving as the first new pharmacotherapy for fibromyalgia in over 15 years. Positive outcomes from pivotal Phase 3 trials support the drug's anticipated effectiveness and its role in addressing patient dissatisfaction with current treatment options.
Read more →TNXPTonix Pharmaceuticals Holding Corp. Corporate Presentation Abbreviated July 2024 NASDAQ: TNXP Version P0578 July 15 , 2024 (Doc 1475 ) 2 2024 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking State
Tonix Pharmaceuticals Holding Corp. presented a corporate overview focusing on its strategic plans and product development, particularly for producing therapeutics for fibromyalgia. A significant aspect of the presentation was the upcoming NDA submission for its lead candidate Tonmya (TNX-102 SL), a sublingual formulation aimed at managing fibromyalgia symptoms. Despite the potential benefits, the presentation also highlighted various risks related to regulatory approvals, competition, and market acceptance for their products. Overall, Tonix is positioning itself for impactful developments in the CNS therapeutic area.
Read more →TNXPTonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
Tonix Pharmaceuticals Holding Corp. has successfully closed a public offering, raising $4 million through the sale of common stock and pre-funded warrants. The funds will be allocated for working capital and supporting their new drug application for the fibromyalgia treatment Tonmya. The company is also advancing its portfolio in treating various CNS disorders and autoimmune diseases. Dawson James Securities acted as the sole placement agent, with legal representation provided by Lowenstein Sandler and ArentFox Schiff LLP.
Read more →TNXP▼ -15.5%on this newsshared move
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
Tonix Pharmaceuticals Holding Corp. has announced a public offering of approximately $4.0 million through the sale of 7,096,740 shares of common stock at a price of $0.57 per share. This offering is expected to close around July 10, 2024, pending customary closing conditions. The company intends to use the proceeds from this offering for working capital and general corporate purposes, particularly in relation to the preparation of a New Drug Application for its Tonmya product candidate addressing fibromyalgia. Dawson James Securities, Inc. is acting as the sole placement agent for this offering.
Read more →TNXP▼ -11%on this news· ran to -25% by day 1shared move
Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya for the Management of Fibromyalgia Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibrom
Tonix Pharmaceuticals announced successful outcomes from its final pre-NDA meeting with the FDA regarding Tonmya, a new potential treatment for fibromyalgia. The FDA agreed that Tonix's data package supports the NDA submission, slated for the second half of 2024, with an expected approval in 2025. Fibromyalgia affects millions of adults in the U.S., highlighting the need for effective non-opioid treatments. Tonmya's development follows positive results from two pivotal Phase 3 clinical trials, reinforcing its potential role in pain management.
Read more →TNXP▼ -11%on this news· ran to -25% by day 1shared move
Tonix Pharmaceuticals Announces Proposed Public Offering CHATHAM, N.J.
Tonix Pharmaceuticals Holding Corp. has announced its intention to conduct a public offering of its common stock to bolster working capital and support its corporate activities. This funding is intended to facilitate the preparation for a New Drug Application of its product candidate, Tonmya, aimed at treating fibromyalgia. The offering's success is contingent on market conditions, which introduces an element of uncertainty. The company has completed significant clinical studies and is focused on addressing various CNS disorders and other therapeutic areas.
Read more →TNXPTonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program
Tonix Pharmaceuticals has been awarded a contract by the U.S. Department of Defense for up to $34 million to accelerate the development of its broad-spectrum antiviral program. The funding will support the optimization of its TNX-4200 program, which focuses on developing small-molecule antiviral agents. This initiative aims to enhance the medical preparedness of military forces against potential biological threats, and plans to utilize state-of-the-art facilities for research and development. The contract represents a significant validation of Tonix's capabilities and ongoing research.
Read more →TNXP▼ -10%on this news· ran to -45% by day 1shared move
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement CHATHAM, N.J.
Tonix Pharmaceuticals Holding Corp. announced that it has regained compliance with the Nasdaq minimum bid price requirement, having maintained a closing bid price above $1.00 for ten consecutive business days. This development ensures the company's continued listing on The Nasdaq Capital Market. Tonix is actively working towards submitting a New Drug Application for its candidate Tonmya in the second half of 2024, alongside other products targeting various CNS disorders and immunological conditions.
Read more →TNXP▲ +5%on this news· ran to -41% by day 3shared move
Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024
Tonix Pharmaceuticals presented promising data on their vaccine platform at the Vaccine Congress 2024, focusing on TNX-801, a single-dose live virus vaccine designed to protect against mpox and smallpox. The vaccine showed efficacy in preclinical models, effectively preventing disease and decreasing viral shedding in non-human primates. Additionally, Tonix's TNX-1800 vaccine, aimed at COVID-19, has been selected by the NIH for clinical trials, highlighting the company's growing role in infectious disease prevention.
Read more →TNXP▲ +10.7%on this newsshared move
Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya for the Management of Fibromyalgia Company aligned with FDA on key CMC topics Tonix also has completed the second and final pre-New Drug Ap
Tonix Pharmaceuticals announced a positive outcome from its recent pre-New Drug Application meeting with the FDA regarding Tonmya, a treatment for fibromyalgia. The company has achieved alignment on critical Chemistry, Manufacturing, and Controls topics and is set to submit its NDA in the latter half of 2024. Encouraging results were noted from Phase 3 trials, confirming Tonmya's efficacy in pain reduction. CEO Seth Lederman expressed excitement about potentially bringing the first new fibromyalgia treatment to market in over a decade.
Read more →TNXP▲ +8.9%on this news· ran to +21% by day 1shared move
Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS)
Tonix Pharmaceuticals presented research at the AHS Annual Scientific Meeting, comparing real-world treatment of migraines against industry guidelines. The data indicates a significant opportunity for growth in non-oral migraine treatments, specifically with Tonix's approved products, Zembrace SymTouch and Tosymra. While the compliance with the guidelines remains low, the company emphasizes the importance of personalized treatment approaches for enhancing patient relief and satisfaction. The presentation underscores the persistent burden of incomplete responses to traditional oral medications.
Read more →TNXPTonix Pharmaceuticals Presented Poster of Tonmya™ for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024
Tonix Pharmaceuticals presented promising data on Tonmya (TNX-102 SL) at EULAR 2024, showing significant pain reduction in fibromyalgia patients as per the Phase 3 RESILIENT study. The drug met all primary and secondary endpoints, indicating broad symptom improvement. The company is preparing to submit a New Drug Application to the FDA in the second half of 2024. Tonmya's well-tolerated profile suggests it may provide a new therapeutic option for fibromyalgia patients, who have lacked innovative treatments for over a decade.
Read more →TNXPTonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
Tonix Pharmaceuticals announced a public offering of 3,753,558 shares at a price of $1.065 per share, expected to close on June 13, 2024. The offering aims to raise approximately $4.0 million for working capital and to support the submission of a new drug application for its product candidate Tonmya™, targeting fibromyalgia. Dawson James Securities is the sole placement agent for this transaction. The offering is subject to customary closing conditions and follows an effective shelf registration with the SEC.
Read more →TNXPTonix Pharmaceuticals Holding Corp. Corporate Presentation Focus on: Tonmya * (TNX - 102 SL) in Development for the Management of Fibromyalgia June 2024 NASDAQ: TNXP *Tonmya is conditionally accepted by FDA as the traden
Tonix Pharmaceuticals Holding Corp. has filed a corporate presentation focusing on Tonmya (TNX-102 SL), which is in development for managing fibromyalgia. The FDA has conditionally accepted Tonmya as the tradename for this investigational product. There is an expectation for a New Drug Application filing in the second half of 2024 and a subsequent FDA decision on approval anticipated by mid-2025. Tonmya shows promise following positive outcomes in two Phase 3 trials, emphasizing its potential to address a significant unmet need in the treatment of fibromyalgia.
Read more →TNXPTonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split CHATHAM, N.J.
Tonix Pharmaceuticals Holding Corp. announced a 1-for-32 reverse stock split of its common stock, effective for trading on a specified date. This measure is aimed at increasing the stock price to meet NASDAQ's $1.00 minimum bid requirement. Despite the split, the total number of authorized shares will not change. Tonix has emphasized its commitment to developing therapeutics for CNS disorders and plans to submit a New Drug Application for Tonmya in the second half of 2024.
Read more →TNXPTonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024 TNX-1500 displays potential as a monot
Tonix Pharmaceuticals has announced two oral presentations and one poster presentation at the American Transplant Congress 2024, focusing on TNX-1500, an Fc-modified humanized anti-CD40L monoclonal antibody. The research presented suggests that TNX-1500 could enhance outcomes in organ transplantation by preventing rejection in various models. CEO Seth Lederman emphasized the need for new treatments due to existing limitations in solid organ transplantation. The data suggests broad potential for TNX-1500, including applications in autoimmune diseases.
Read more →TNXPTonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024
Tonix Pharmaceuticals has announced a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2024, to be held in Vienna from June 12-15. The presentation will showcase significant Phase 3 results for Tonmya (TNX-102 SL), a treatment for fibromyalgia, and the company aims to submit its New Drug Application (NDA) to the FDA by the second half of 2024. The stated results and upcoming NDA filing indicate progress in Tonix's efforts to address CNS disorders.
Read more →TNXPTonix Pharmaceuticals Presented New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting Tonmya treatment was associated with im
Tonix Pharmaceuticals recently presented data from the Phase 3 RESILIENT trial at the ASCP Annual Meeting, highlighting the potential of Tonmya (TNX-102 SL) to improve depression severity in fibromyalgia patients. The study showed improvement in depressive symptoms as measured by the Beck Depression Inventory-II, among other positive results. With an NDA submission to the FDA planned for the second half of 2024, the company is moving forward with its plans for Tonmya, which has demonstrated significant clinical outcomes across multiple endpoints.
Read more →TNXPTonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting In the Phase 2 PREVAIL trial in fibromyalgia-type Long COVID, bedtime TNX-102 SL resulted
Tonix Pharmaceuticals announced two significant poster presentations at the ASCP Annual Meeting regarding its product TNX-102 SL. Results from the Phase 2 PREVAIL trial indicate the drug showed promising improvements in fatigue, sleep quality, and cognitive function among patients with fibromyalgia-type Long COVID, despite not meeting the primary endpoint of pain reduction. The company is also preparing for the OASIS trial to evaluate TNX-102 SL in treating Acute Stress Disorder following trauma. Additionally, Tonix plans to submit a New Drug Application for TNX-102 SL for managing fibromyalgia in the latter half of 2024.
Read more →TNXPTonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024
Tonix Pharmaceuticals has announced participation in the American Transplant Congress 2024 with two oral presentations and one poster presentation. The presentations will feature research on immunological strategies to improve allograft survival and reduce alloimmunity. The event is set to take place from June 1-5, 2024, at the Pennsylvania Convention Center in Philadelphia. This highlights Tonix's ongoing efforts in the field of immunology and transplant science.
Read more →TNXPTonix Pharmaceuticals Announces Presentation at the 2024 BIO International Convention
Tonix Pharmaceuticals Holding Corp. announced that its Chief Operating Officer, Jessica Morris, will present at the 2024 BIO International Convention. The presentation on June 4, 2024, will focus on the positive Phase 3 results for Tonmya™, a product candidate aimed at managing fibromyalgia. The company is also on track to submit a New Drug Application (NDA) to the FDA in the second half of 2024, furthering its development pipeline in central nervous system disorders.
Read more →TNXPTonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Oral Presentation of Tonmya (TNX-102 SL) for Fibromyalgia; NDA pr
Tonix Pharmaceuticals announced that it will present an oral presentation and two posters at the American Society of Clinical Psychopharmacology Annual Meeting. The presentation will feature findings from studies on Tonmya (TNX-102 SL) for fibromyalgia and its potential to address fibromyalgia-type Long COVID and acute stress disorder. The company plans to submit a New Drug Application (NDA) for Tonmya to the FDA in late 2024, following promising results from previous clinical trials.
Read more →TNXPTonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya for the Management of Fibromyalgia Tonmya is a potential new first-line, centrally acting non-opioid anal
Tonix Pharmaceuticals has shared key findings from the initial phase of a market opportunity analysis for Tonmya, a potential new treatment for fibromyalgia. Tonmya, which is a centrally acting non-opioid analgesic, has received positive feedback from physician research indicating significant interest in its adoption. The company is on track to submit a New Drug Application (NDA) to the FDA in the second half of 2024, with an expected FDA decision in 2025. The analysis suggests an existing dissatisfaction with current FDA-approved fibromyalgia treatments and highlights the prevalence of opioid prescriptions, which Tonmya aims to address.
Read more →TNXPTonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Tonix Pharmaceuticals will participate in a virtual fireside chat at the A.G.P. Healthcare Company Showcase on May 21, 2024. CEO Seth Lederman is expected to discuss the company's development pipeline as well as their marketed products. Notably, Tonix aims to submit a New Drug Application for its candidate Tonmya in the latter half of 2024. The company focuses on central nervous system disorders and has several investigational products, including those addressing autoimmune conditions.
Read more →TNXPTonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights On track to submit NDA in the second half of 2024 for Tonmya for fibromyalgia; pre-NDA meeting with FDA scheduled for second q
Tonix Pharmaceuticals reported its first-quarter financial results and operational highlights, emphasizing its plan to submit a New Drug Application (NDA) for Tonmya, a treatment for fibromyalgia, in the second half of 2024. The company is actively preparing for a U.S. launch pending FDA approval, which they anticipate in 2025. Recent clinical trials have demonstrated Tonmya's efficacy in reducing symptoms and improving quality of life for fibromyalgia patients, while showing a favorable safety profile with minimal side effects. Additionally, Tonix is advancing other pipeline programs across various therapeutic areas.
Read more →TNXPTonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
Tonix Pharmaceuticals announced that CEO Seth Lederman will present at the Planet MicroCap Showcase on May 1, 2024. The presentation will highlight positive findings from the Phase 3 RESILIENT trial related to its drug TNX-102 SL for fibromyalgia management. The company aims to submit a New Drug Application to the FDA later this year. Tonix's diverse pipeline includes therapies for CNS disorders, organ transplant rejection, and autoimmune diseases. However, the company faces risks associated with FDA approvals and competition in the market.
Read more →TNXPTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Positive results from confirmatory Phase 3 RESILIENT study reported in December 2023 position Tonmya for fibrom
Tonix Pharmaceuticals has reported its fourth quarter and full year financial results for 2023, highlighting the positive outcomes from the Phase 3 RESILIENT study of Tonmya, a potential treatment for fibromyalgia. The company plans to submit a New Drug Application (NDA) in the second half of 2024, following a pre-NDA meeting scheduled with the FDA in the second quarter. Tonix is also focusing on commercial planning for Tonmya's U.S. launch while seeking collaborations to enhance its operational capacity. Despite positive clinical results, the company faces financial challenges with decreased cash reserves and increased operational expenses.
Read more →TNXPTonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering CHATHAM, N.J.
Tonix Pharmaceuticals has announced a registered direct offering, pricing 14,666,666 shares of common stock at $0.30 each, aiming to raise approximately $4.4 million. The proceeds are intended for working capital and to alleviate some of the company's debt. The offering is expected to close around April 1, 2024, pending customary conditions. Additionally, the company plans to amend existing warrants to a unified exercise price of $0.33 per share, contingent on shareholder approval.
Read more →TNXPTonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a
Tonix Pharmaceuticals has received Rare Pediatric Disease Designation from the FDA for its drug TNX-2900, designed to treat Prader-Willi syndrome in children and adolescents. This designation recognizes the serious unmet need for effective therapies for this condition, which is the leading genetic cause of life-threatening obesity in children. TNX-2900 is a proprietary formulation of intranasal oxytocin that aims to address existing limitations of traditional oxytocin treatments. If approved, Tonix may also benefit from a priority review voucher that could expedite future drug applications.
Read more →TNXPTonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting Four Phase 2 investigator-initiated studies
Tonix Pharmaceuticals announced a poster presentation at the ACS Spring 2024 Meeting, highlighting the discovery of next-generation oxytocin analogues for treating conditions like pediatric obesity and binge eating disorder. The ongoing Phase 2 investigator-initiated studies are evaluating the efficacy of their product TNX-1900 for various indications, including social anxiety disorder and bone health in autism. CEO Seth Lederman emphasized the analogues' potential therapeutic applications and enhancements in formulations to optimize their effectiveness.
Read more →TNXPTonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya for the Management of Fibromyalgia Tonmya is a potential new first-line, centrally
Tonix Pharmaceuticals announced the selection of two contract manufacturing organizations (CMOs) to assist in the commercial manufacture and launch of Tonmya, a potential new treatment for fibromyalgia. The decision follows positive outcomes from two Phase 3 studies, which demonstrated significant pain reduction in patients. The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024. This marks a crucial step for Tonix as it seeks to introduce a non-opioid analgesic for managing fibromyalgia symptoms.
Read more →TNXPTonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on
Tonix Pharmaceuticals has announced its transition to a fully integrated biopharmaceutical company, which is expected to be completed by April 1, 2024. This transition follows the acquisition of two products aimed at treating migraines and anticipates the potential launch of Tonmya for fibromyalgia management, pending FDA approval in 2025. The company plans to handle distribution and marketing for its products, marking a significant milestone in its evolution. The management expressed optimism about the future of its commercial organization amidst ongoing development efforts for other therapeutic candidates.
Read more →TNXPTonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
Tonix Pharmaceuticals announced the results of a second positive Phase 3 trial for Tonmya, a medication aimed at managing fibromyalgia. The trial showed significant improvements in reducing daily pain compared to a placebo, with plans for a New Drug Application (NDA) submission to the FDA in the latter half of 2024. Additionally, Tonix's CEO will present at the upcoming BIO-Europe Spring Convention in Barcelona, showcasing their commitment to furthering engagement within the biopharmaceutical sector.
Read more →TNXPTonix Pharmaceuticals Reports Improvement in "Brain Fog," in Fibromyalgia Patients Treated with Tonmya in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6 th International Congress on Controversies in Fibromya
Tonix Pharmaceuticals announced positive results from its Phase 3 RESILIENT trial for Tonmya (TNX-102 SL) in fibromyalgia patients, achieving significant improvements in pain reduction and associated symptoms, including 'brain fog'. The study met its primary endpoint with a p-value of 0.00005 and reported additional efficacy on secondary measures related to sleep and fatigue. Tonix plans to submit a New Drug Application to the FDA in the second half of 2024, following a pre-NDA meeting in the second quarter. These results may position Tonmya as a new treatment option for fibromyalgia, a condition affecting millions.
Read more →TNXPTonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy Data support evaluation of th
Tonix Pharmaceuticals announced the publication of a study in Psychiatry Research demonstrating the efficacy and tolerability of its treatment TNX-102 SL for military-related PTSD symptoms. The study showed nominal improvements in PTSD severity and sleep quality within the first four weeks. A Phase 2 trial, funded by the U.S. Department of Defense, is set to evaluate the treatment's immediate effects following traumatic events. Despite promising results in initial stages, it is noted that the primary endpoint in the Phase 3 HONOR study did not statistically succeed.
Read more →TNXPTonix Pharmaceuticals Selects EVERSANA to Support Launch Strategy and Commercialization Planning of Tonmya for the Management of Fibromyalgia Tonmya is a potential new first-line, centrally acting non-opioid analgesic fo
Tonix Pharmaceuticals announced the selection of EVERSANA to assist in the launch strategy and commercialization of Tonmya, a potential non-opioid treatment for fibromyalgia. Tonmya has demonstrated significant efficacy in two Phase 3 clinical trials, with an NDA submission anticipated in the second half of 2024. The collaboration with EVERSANA aims to create an efficient market entry strategy for this new therapeutic option, which addresses a longstanding gap in treatment for fibromyalgia. CEO Seth Lederman highlighted their commitment to delivering novel therapeutics to patients in need.
Read more →TNXPTonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans TNX-1500, a third generation anti-CD40L mAb,
Tonix Pharmaceuticals announced promising preclinical pharmacokinetic results for TNX-1500, an Fc-modified anti-CD40L monoclonal antibody. The studies suggest that TNX-1500 can achieve a human half-life of around three weeks, allowing for monthly dosing. With multiple potential applications, including preventing organ rejection and treating autoimmune diseases, the company is awaiting Phase 1 trial results, which are expected in the third quarter of 2024. This development indicates advancement beyond previous generations of anti-CD40L therapies, which faced issues like thrombosis risk.
Read more →TNXPTonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia
Tonix Pharmaceuticals announced that its CEO, Seth Lederman, will present at The 6th International Congress on Controversies in Fibromyalgia in Brussels on March 7, 2024. The presentation will include positive data from the Phase 3 RESILIENT trial for Tonmya (TNX-102 SL), a candidate for fibromyalgia management. The company plans to submit a New Drug Application (NDA) to the FDA in the latter half of 2024 for Tonmya, following two successful Phase 3 studies. Tonix also has a diverse portfolio, including candidates for CNS disorders and immunology.
Read more →TNXPTonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers Topline results expected in the third quarter of 2024; planning a Phase 2 Trial fo
Tonix Pharmaceuticals has successfully completed the clinical stage of its Phase 1 trial for TNX-1500, an Fc-modified monoclonal antibody. The trial aimed to assess safety and tolerability among healthy volunteers, paving the way for future Phase 2 trials targeting the prevention of kidney transplant rejection. Results from this trial are anticipated in the third quarter of 2024, reflecting the company's strong focus on advancing TNX-1500 for various indications, including autoimmune diseases. The CEO emphasized the potential benefits of TNX-1500 in promoting transplant tolerance and reducing long-term toxicity risks associated with current immunosuppressive therapies.
Read more →TNXPTonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya to Support Development and Partnering in Japan and China Tonix plans to File a Clinical Trial Notification (CTN) in
Tonix Pharmaceuticals announced positive findings from a clinical pharmacokinetic bridging study for Tonmya, indicating comparable pharmacokinetic parameters in ethnic Japanese and Chinese volunteers to those in Caucasian participants. This supports the company’s plans to file a Clinical Trial Notification in Japan and an Investigational New Drug application in China to facilitate further studies. With patents securing market exclusivity until 2034, Tonix aims to enhance therapeutic options in East Asia for fibromyalgia patients. A New Drug Application to the US FDA for Tonmya is expected in late 2024.
Read more →TNXPTonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference
Tonix Pharmaceuticals has announced its participation in the 2024 BIO CEO & Investor Conference, where CEO Seth Lederman will present. The company is set to submit a New Drug Application for its product Tonmya for fibromyalgia later this year following successful Phase 3 studies. Additionally, Tonix is advancing various programs in its development portfolio, including the Breakthrough Therapy-designated TNX-1300 for cocaine intoxication and candidates for rare diseases and infectious diseases. The company continues to face challenges such as the need for FDA approvals and competition in the market.
Read more →TNXPTonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024
Tonix Pharmaceuticals hosted a webinar to present positive Phase 3 trial results for Tonmya™, a treatment for fibromyalgia. The results showed significant reductions in pain, fatigue, and sleep disturbances. With plans to submit a New Drug Application (NDA) for FDA approval in the second half of 2024, Tonix aims to provide a new option for patients suffering from fibromyalgia symptoms. The drug's favorable tolerability suggests it could become a primary treatment after FDA approval.
Read more →TNXPTonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya for the Management of Fibromyalgia Tonmya is a potential new first-line therapy, no
Tonix Pharmaceuticals has announced that it will engage Rho, a contract research organization, to assist in preparing for the submission of a New Drug Application (NDA) to the FDA for its product Tonmya, intended for the management of fibromyalgia. This follows encouraging results from two Phase 3 clinical trials, indicating Tonmya's effectiveness compared to placebo. The NDA submission is expected to occur in the second half of 2024, demonstrating the company's commitment to addressing a significant medical need for those suffering from fibromyalgia.
Read more →TNXPTonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD Bedtime TNX-102 SL improves sleep quality in PTSD and is also being d
Tonix Pharmaceuticals has received FDA clearance for its Investigational New Drug (IND) application to conduct a Phase 2 trial for TNX-102 SL, aimed at reducing acute stress reactions and preventing PTSD. This trial will utilize a $3 million grant from the Department of Defense and will involve around 180 trauma patients after motor vehicle collisions. The study aims to investigate the efficacy of TNX-102 SL in improving sleep quality and overall mental health outcomes in patients experiencing trauma. The trial supports Tonix's broader efforts in developing therapeutics for central nervous system disorders.
Read more →TNXPTonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVID Retrospective observational study of electronic medical records of more than 90 m
Tonix Pharmaceuticals has announced research suggesting that pre-existing fibromyalgia-type symptoms may increase the risk of developing long COVID. The findings, derived from a study involving over 90 million U.S. medical records, indicate that patients with chronic overlapping pain conditions are more susceptible to long COVID symptoms. The company is advancing its product Tonmya, designed for fibromyalgia management, into the New Drug Application process with the FDA. This research highlights a potential link between fibromyalgia and long COVID, supporting the need for improved diagnosis and management strategies.
Read more →TNXPTonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Trade Name for TNX-102 SL for the Management of Fibromyalgia Results from two positive Phase 3 studies point to Tonmya's (TNX-102 SL) potential as a new
Tonix Pharmaceuticals Holding Corp. has announced that the FDA conditionally accepted the trade name 'Tonmya' for its drug TNX-102 SL, aimed at managing fibromyalgia. This follows positive results from two Phase 3 clinical trials demonstrating significant pain reduction in patients. The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024, marking a significant step towards offering a new treatment for fibromyalgia, a condition affecting millions of adults in the U.S.
Read more →TNXPTonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P.
Tonix Pharmaceuticals has announced a key opinion leader webinar scheduled for January 31, 2024, to discuss the positive Phase 3 data regarding TNX-102 SL for fibromyalgia management. The Phase 3 RESILIENT study demonstrated a significant reduction in pain severity among participants. Tonix is aiming to submit a New Drug Application to the FDA later in 2024 to seek approval for TNX-102 SL. The company is also exploring its use for additional indications related to fibromyalgia-type Long COVID.
Read more →TNXPTonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia
Tonix Pharmaceuticals announced promising results from its Phase 3 RESILIENT study for TNX-102 SL in fibromyalgia management, achieving a significant daily pain reduction over placebo. The treatment exhibited a favorable safety profile, notably improving female sexual function without adverse side effects like weight gain or increased blood pressure. Following these successes, Tonix plans to submit a New Drug Application to the FDA in the latter half of 2024. This could position TNX-102 SL as a new first-line option for a condition that affects 6-12 million adults in the U.S.
Read more →TNXPTonix Pharmaceuticals Holding Corp. Biotech Showcase Focus on: TNX - 102 SL in Development for the Management of Fibromyalgia January 2024 NASDAQ: TNXP Version P0519 January 5 , 2024 (Doc 1365 ) 2 2024 Tonix Pharmaceutic
Tonix Pharmaceuticals Holding Corp. showcased its development of TNX-102 SL for fibromyalgia at the Biotech Showcase. The company has successfully completed two Phase 3 trials, with a New Drug Application (NDA) filing anticipated in the second half of 2024. Despite previous challenges, including a missed primary endpoint in one study, recent positive results bolster hopes for regulatory approval by the FDA in 2025. TNX-102 SL aims to address critical unmet needs in fibromyalgia treatment.
Read more →TNXPTonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 Trial
Tonix Pharmaceuticals announced that it will present at two investor conferences in January 2024, focusing on TNX-102 SL, a treatment for fibromyalgia that has shown positive results in phase 3 trials. The drug demonstrated effective daily pain reduction and plans for a New Drug Application to the FDA are set for the second half of 2024. The company also reported its ongoing efforts in various therapeutic areas, including developments for Long COVID and rare diseases. This strong performance may position Tonix favorably within the biopharma landscape as it seeks further investments.
Read more →TNXPTonix Pharmaceuticals Holding Corp. Corporate Presentation Focus on: TNX - 102 SL in Development for the Management of Fibromyalgia January 2024 NASDAQ: TNXP Version P0517 January 2 , 2024 (Doc 1362 ) 2 2024 Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is focusing on TNX-102 SL, a sublingual formulation of cyclobenzaprine for fibromyalgia management. Recent developments include positive Phase 3 topline results reported in December 2023, leading to plans for a New Drug Application (NDA) slated for submission in the latter half of 2024. However, previous Phase 3 trials faced challenges, including missed endpoints and increased discontinuation rates due to adverse events. The FDA's decision on the NDA approval is expected in late 2025.
Read more →TNXPTonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia Phase 3 RESILIENT stud
Tonix Pharmaceuticals announced highly statistically significant results from its Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia management. The study showed a significant reduction in daily pain over placebo, meeting its primary endpoint with an impressive p-value of 0.00005. Additionally, several key secondary endpoints related to sleep quality and fatigue improved significantly. Tonix aims to submit a New Drug Application to the FDA in the latter half of 2024, potentially offering a new treatment option for the estimated 6 million to 12 million adults with fibromyalgia in the U.S.
Read more →TNXPTonix Pharmaceuticals Announces Registered Direct Offering of up to $ 144 Million Led by healthcare-focused institutional investors. $30 million financing upfront with up to an additional $114 million tied to the exercis
Tonix Pharmaceuticals Holding Corp. announced a registered direct offering aimed at raising up to $144 million, with an initial upfront financing of $30 million. The offering involves issuing approximately 54 million shares and warrants linked to the exercise of additional shares. The company plans to use the proceeds for preparing a new drug application for TNX-102 SL, aimed at treating fibromyalgia, among other general corporate purposes. The closing of this offering is anticipated on December 22, 2023, pending standard closing conditions.
Read more →TNXPTonix Pharmaceuticals Holding Corp. Corporate Presentation December 2023 NASDAQ: TNXP Version P05 08
Tonix Pharmaceuticals Holding Corp. recently presented its corporate strategy and pipeline updates. The company emphasizes its commitment to developing innovative therapeutics in areas such as pain and neurology, with two late-stage clinical programs awaiting results by the end of December 2023. However, Tonix acknowledges considerable risks associated with FDA approvals, competition, and funding dependencies, underscoring the pharmaceutical industry's inherent challenges in drug development.
Read more →TNXPTonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public Meeting
Tonix Pharmaceuticals announced that CEO Seth Lederman will present at a public meeting organized by the National Academies regarding smallpox countermeasures on December 14, 2023. The meeting will include discussions on lessons learned from the COVID-19 pandemic and the mpox outbreak to aid in evaluating smallpox readiness. Tonix has a range of candidates in development, including TNX-102 SL, which is in mid-Phase 3 for fibromyalgia, and TNX-1300, which has received Breakthrough Therapy designation from the FDA. The company's focus includes CNS, rare disease, immunology, and infectious disease products.
Read more →TNXPTonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity TNX-2900 is a proprie
Tonix Pharmaceuticals has announced that the FDA has cleared the IND application for TNX-2900, an intranasal formulation of magnesium-potentiated oxytocin, to treat Prader-Willi Syndrome (PWS). The Phase 2 trial will include approximately 36 patients and aims to identify safe dosage levels. PWS is a condition leading to life-threatening obesity among children and adolescents, with no currently approved treatments for its hallmark symptom of hyperphagia. Tonix is looking for a partner to further advance TNX-2900 in clinical development.
Read more →TNXPTonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December
Tonix Pharmaceuticals will present at two upcoming investor conferences in December 2023. The COO, Jessica Morris, will present at the NobleCon 19 conference on December 4, while the CEO, Seth Lederman, will host a presentation at the Virtual Investor Summit on December 7. Both events aim to engage investors and disseminate information about Tonix's product candidates and ongoing developments. The meetings will include opportunities for investor discussions and will be followed by webcasts available on Tonix's website.
Read more →TNXPTonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia Topline results expected late December 2023 RESILIENT is expected to be the final efficacy trial
Tonix Pharmaceuticals has completed the clinical phase of its Phase 3 RESILIENT study for TNX-102 SL, aimed at treating fibromyalgia. The study enrolled 457 patients and showed a favorable preliminary discontinuation rate of 4.8% related to adverse events, which is lower than rates seen in earlier trials. Topline results are expected by late December 2023, and if positive, this data will facilitate a New Drug Application to the FDA. The drug aims to alleviate symptoms by improving sleep quality among fibromyalgia patients.
Read more →TNXPTonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder Ch
Tonix Pharmaceuticals has announced the initiation of enrollment for a Phase 2 study assessing TNX-1900, an intranasal potentiated oxytocin, aimed at enhancing bone health in children with Autism Spectrum Disorder (ASD). The BOX study, sponsored by Massachusetts General Hospital, will explore the efficacy and safety of TNX-1900 in increasing bone density and improving bone strength among affected children. Preliminary data suggest that oxytocin could positively influence bone health, addressing a significant issue in this population. The study represents a hopeful step toward developing specific treatment options for bone density problems associated with ASD.
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights Topline Results from Phase 3 Potentially NDA-Enabling Study of TNX-102 SL in Fibromyalgia Expected Late December 2023: Central
Tonix Pharmaceuticals has reported its financial results for Q3 2023, highlighting upcoming topline data from two crucial studies on TNX-102 SL for fibromyalgia and TNX-1900 for chronic migraines. The company anticipates potentially enabling a New Drug Application if the Phase 3 results are favorable. Additionally, partnerships with U.S. government agencies are expected to help fund clinical trials, although the company is facing significant financial losses and reduced cash reserves compared to the previous year.
Read more →TNXPTonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials NIAID is conducting early phase clinical trials on select next generation COVID-19 vaccine candid
Tonix Pharmaceuticals announced that its vaccine candidate TNX-1800 has been selected by NIAID for inclusion in early phase clinical trials under Project NextGen. The Phase 1 trial is expected to begin in the second half of 2024, aiming to evaluate safety and immunogenicity in healthy volunteers. TNX-1800 is a live virus vaccine candidate designed to provide protection against COVID-19 by eliciting a robust T-cell response and is based on the recombinant pox virus platform. NIAID will cover the full costs of the trial, which positions Tonix well for potential FDA approvals in the future.
Read more →TNXPTonix Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder The study did not achieve statistical significance on the primary endpoint
Tonix Pharmaceuticals announced that its Phase 2 study of TNX-601 ER for treating major depressive disorder did not achieve statistical significance on the primary endpoint. Consequently, the company will discontinue the development of TNX-601 ER. However, patients and researchers involved in the study were thanked for their participation. Tonix plans to release topline data for two other studies, TNX-1900 in chronic migraine and TNX-102 SL in fibromyalgia, in December 2023.
Read more →TNXPTonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress Research Dire
Tonix Pharmaceuticals has announced new data regarding its product TNX-1500, a monoclonal antibody currently in Phase 1 development aimed at preventing organ transplant rejection. The data, presented at prestigious medical congresses, show encouraging results in preclinical studies of heart xenotransplantation using genetically engineered pig hearts. The company plans to continue developing TNX-1500 for various indications, including prevention of kidney allograft rejection and autoimmune disorders. Tonix is actively enrolling participants in its Phase 1 trial with hopes for further advancements in xenotransplantation.
Read more →TNXPTonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs Topline results expected early December 2023 Novel formulation of int
Tonix Pharmaceuticals has completed the clinical stage of its Phase 2 PREVENTION study evaluating TNX-1900, an intranasal formulation of oxytocin, aimed at preventing chronic migraine headaches. With 88 patients enrolled, the trial is a double-blind, randomized, and placebo-controlled study focusing on the efficacy and safety of TNX-1900. Results from this proof-of-concept study are anticipated to be available in early December 2023, potentially guiding future discussions with the U.S. FDA on the drug's development. This innovative approach addresses a significant unmet need for migraine prevention in patients suffering from chronic migraines.
Read more →TNXPTonix Pharmaceuticals Presents Data from its Horsepox-Based Vaccine Development Platform at the World Vaccine Congress Europe Preclinical Data Demonstrate Attenuation of TNX-801 (horsepox live virus vaccine) Compared to
Tonix Pharmaceuticals presented its horsepox-based vaccine, TNX-801, at the World Vaccine Congress Europe. The preclinical data suggests that TNX-801 is significantly more attenuated than modern vaccinia vaccines, indicating a potentially safer profile. It aims to provide protection against smallpox and Mpox, with recent evidence supporting its capacity to engage durable T cell responses. The company believes this vaccine platform could enhance preparedness for public health emergencies. Positive feedback from the FDA suggests a pathway for upcoming clinical trials.
Read more →TNXPTonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models Research Di
Tonix Pharmaceuticals announced the publication of data in 'Nature' regarding its TNX-1500 monoclonal antibody aimed at preventing organ rejection in kidney xenotransplantation. Research conducted at Massachusetts General Hospital demonstrated the efficacy of TNX-1500 in animal models, showing promise for preventing rejection during transplants. The company is currently enrolling patients in a Phase 1 trial for this treatment, which could also be expanded to address autoimmune conditions.
Read more →TNXPTonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder Topline Results Expected Early November 2023 Tianeptine, the Active Ingredient in TNX-60
Tonix Pharmaceuticals has announced the completion of the clinical stage for its Phase 2 UPLIFT study concerning TNX-601 ER, a tianeptine-based treatment for major depressive disorder (MDD). The study reportedly involved 132 participants and is expected to deliver topline results in early November 2023. TNX-601 ER aims to offer benefits such as avoiding sexual dysfunction and weight gain linked with many traditional antidepressants, thanks to its distinct mechanism of action. Following the analysis of the study results, Tonix plans to engage further with the U.S. Food and Drug Administration regarding next steps for this potential treatment.
Read more →TNXPTonix Pharmaceuticals Holding Corp. Corporate Presentation October 2023 NASDAQ: TNXP Version P0496
Tonix Pharmaceuticals has presented its corporate strategy and pipeline during the October 2023 presentation. The company is advancing several late-stage programs in the central nervous system (CNS) space, with key topline data anticipated by the end of this year. Tonix is also preparing for an expected increase in demand for its migraine therapies as a major competitor plans to discontinue certain products. However, significant regulatory and market risks remain, particularly concerning FDA approvals and competitive pressures in the pharmaceutical landscape.
Read more →TNXPTonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference
Tonix Pharmaceuticals Holding Corp. will present at the ThinkEquity Conference on October 19, 2023, featuring COO Jessica Morris. The company's product pipeline includes candidates for treating fibromyalgia, major depressive disorder, and rare diseases. Upcoming topline data for lead candidate TNX-102 SL and ongoing studies across its diverse portfolio are anticipated in the coming months. Additionally, investors can arrange meetings with the management during the conference.
Read more →TNXPTonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe
Tonix Pharmaceuticals has announced an oral presentation by Dr. Zeil Rosenberg at the World Vaccine Congress Europe on October 18, 2023. The presentation will cover Tonix's pipeline and its marketed products, including therapies for migraines and chronic conditions. The company is also advancing multiple candidates in clinical trials with key results expected in the coming months. Notably, the FDA has granted Breakthrough Therapy designation to TNX-1300 for cocaine intoxication treatment. Tonix is focused on developing therapeutics for a range of diseases, including rare conditions and infectious diseases.
Read more →TNXPTonix Pharmaceuticals Provides Overview of TNX-2900 Program for the Treatment of Prader-Willi Syndrome at the Foundation for Prader-Willi Research Family Conference
Tonix Pharmaceuticals announced an overview of its TNX-2900 program aimed at treating hyperphagia in Prader-Willi syndrome at the FPWR Family Conference. The presentation detailed promising preclinical data demonstrating enhanced efficacy of niased oxytocin with magnesium. TNX-2900 has received Orphan Drug designation from the FDA and plans to submit an IND application in Q4 2023. Currently, there are no approved treatments for hyperphagia in patients with Prader-Willi syndrome.
Read more →TNXPTonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain New patent expected to expire in 2036 Proof of concept data from Phase 2 study for preve
Tonix Pharmaceuticals Holding Corp. announced the issuance of a new European patent covering its intranasal potentiated oxytocin formulation, TNX-1900, for pain treatment. This patent, expected to provide exclusivity in the EU until 2036, adds to existing patents granted in the U.S. The company also revealed it completed enrollment for a Phase 2 study on TNX-1900 aimed at preventing chronic migraine headaches, with topline results anticipated in early December 2023. The CEO highlighted the uniqueness of their formulation as a significant advantage for chronic migraine sufferers.
Read more →TNXPTonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering
Tonix Pharmaceuticals Holding Corp. has announced the pricing of a public offering, generating approximately $4.5 million. The offering includes 9 million shares of common stock at a price of $0.50 per share, alongside warrants for potential future stock purchases. The proceeds will be utilized for working capital, enhancing manufacturing and R&D capabilities, and potentially acquiring or licensing products. The closing of this offering is anticipated around October 3, 2023, pending customary closing conditions.
Read more →TNXPTonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina's Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Dis
Tonix Pharmaceuticals announced that the University of North Carolina's Institute for Trauma Recovery received a $3 million grant from the DoD for an investigator-sponsored trial. This trial, named OASIS, will evaluate TNX-102 SL's potential to alleviate the effects of acute stress reactions, acute stress disorder, and PTSD among trauma patients. Approximately 180 participants will be enrolled in the trial, expected to begin in 2024, pending FDA clearance. This initiative builds on insights from the AURORA study, aimed at enhancing the understanding and treatment of trauma-related disorders.
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P04 88 September 25 , 2023 (Doc 1321 ) 2 2023 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain sta
Tonix Pharmaceuticals Holding Corp. presented its latest investor update on September 25, 2023, highlighting its development pipeline and strategic initiatives. The presentation included details on multiple therapeutic candidates focused on central nervous system disorders and other unmet medical needs. Notably, Tonix is anticipating key clinical results for several products, including those addressing chronic migraine and depression, expected by the end of this year. Despite the promising developments, the company also acknowledged substantial market and regulatory challenges that could impact their future operations.
Read more →TNXPTonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023
Tonix Pharmaceuticals has presented promising preclinical data for its novel fusion protein, mTNX-1700, at the Seventh International Cancer Immunotherapy Conference 2023. Research shows that mTNX-1700 effectively suppresses tumor growth and increases survival rates in syngeneic mouse models of advanced colorectal and gastric cancer. Furthermore, the compound demonstrates single-agent activity and adds therapeutic effects when used in combination with anti-PD-1 therapy. These findings suggest a potential new approach to cancer treatment by targeting myeloid-derived suppressor cells.
Read more →TNXPTonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congress Oxytocin receptors and CGRP are co-e
Tonix Pharmaceuticals presented non-clinical studies on TNX-1900, an intranasal potentiated oxytocin, at the 2023 International Headache Congress in Seoul. The presented data reveal the co-expression of oxytocin receptors with calcitonin gene-related peptide (CGRP) in human trigeminal ganglia, suggesting a potential mechanism for treating chronic migraines. The findings indicate that oxytocin treatment may inhibit CGRP release, which is crucial to migraine pathogenesis. Additionally, results from the Phase 2 PREVENTION study of TNX-1900 are expected in Q4 2023.
Read more →TNXPTonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023 CHATHAM, N.J.
Tonix Pharmaceuticals has announced the presentation of a poster on its clinical candidate TNX-1700 at the Seventh International Cancer Immunotherapy Conference 2023 in Milan, Italy. The poster, which focuses on preclinical models of colorectal cancer, will be presented on September 21, 2023. This event signifies Tonix's commitment to advancing its cancer treatment candidates and collaboration within the oncology field.
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0482
Tonix Pharmaceuticals Holding Corp. presented its investor briefing, outlining its strategic plans and therapeutic pipeline. The company focuses on treating central nervous system disorders while also targeting other therapeutic areas like immunology and infectious diseases. Two FDA-approved products for migraine treatment are currently marketed as part of their portfolio. However, the company faces various risks including dependence on FDA approvals and the need for further financing for its development efforts.
Read more →TNXPTonix Pharmaceuticals Announces Commitment to Supply Tosymra (sumatriptan Nasal Spray) 10 mg for Treatment of Acute Migraine to Meet Potential Increased Demand Following GSK's Planned Discontinuation of Imitrex (sumatrip
Tonix Pharmaceuticals has announced its commitment to supply Tosymra (sumatriptan nasal spray) 10 mg to address anticipated increased demand following GlaxoSmithKline's planned discontinuation of Imitrex nasal spray products after January 2024. This move aims to alleviate potential drug shortages for migraine patients. Although Tosymra offers a proprietary technology for quicker absorption, it is important to note that it is not interchangeable with Imitrex at the pharmacy level. Tonix is preparing to inform healthcare providers about the option to prescribe Tosymra for those who may benefit from a nasal formulation of sumatriptan.
Read more →TNXPTonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID TNX-102 SL showed a robust effect size of 0.5 in improving fati
Tonix Pharmaceuticals announced topline results from its Phase 2 PREVAIL study of TNX-102 SL for managing fibromyalgia-type Long COVID. The treatment demonstrated a significant effect size in fatigue improvement and showed trends towards benefits in sleep quality, cognitive function, and disability. However, it did not achieve its primary endpoint of pain reduction at 14 weeks. Tonix intends to discuss the next steps with the FDA, potentially moving towards Phase 3 trials focusing on fatigue measures.
Read more →TNXPTonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox Phase 1/2 Clinical Trial of TNX-801 for the Prevention of Mpox and Smallpox to Commence
Tonix Pharmaceuticals has announced the results of its Pre-IND meeting with the FDA regarding TNX-801, a potential vaccine for mpox and smallpox. The FDA's feedback indicates agreement on the trial design, paving the way for a Phase 1/2 clinical trial. TNX-801 has shown promise in preclinical tests, successfully protecting animals from lethal doses of mpox. The vaccine is designed to stimulate durable T-cell immunity and does not require ultra-cold storage, improving logistics for distribution.
Read more →TNXPTonix Pharmaceuticals to Present at the August Virtual Investor Summit
Tonix Pharmaceuticals will present at the August 2023 Virtual Investor Summit, showcasing its pipeline of development candidates. The company has various projects in the CNS, rare diseases, and infectious diseases, including therapies for fibromyalgia and major depressive disorder. Tonix's portfolio includes investigational drugs that hold promise, but the company faces risks regarding regulatory approvals and financial uncertainties. The presentation will provide insights into their ongoing clinical studies and future development plans.
Read more →TNXPTonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Ph
Tonix Pharmaceuticals has announced the initiation of a Phase 1 clinical trial for TNX-1500, a monoclonal antibody targeting CD40L, in healthy volunteers. The trial seeks to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of TNX-1500, which is being developed for the prevention of kidney transplant rejection and other autoimmune disorders. Preliminary animal studies indicate promising outcomes, including organ preservation and improved long-term graft survival. This study represents a significant step for Tonix as TNX-1500 is the first internally developed biologic candidate to reach clinical testing.
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Highlights Topline Results from Four CNS Clinical Trials Expected in the Third and Fourth Quarters of 2023 Fibromyalgia Topline Results
Tonix Pharmaceuticals Holding Corp. reported its second quarter 2023 financial results, highlighting the successful enrollment of four CNS clinical trials and expectations for data readouts in the upcoming months. The acquisition of two marketed migraine products strengthens its portfolio as it aims for a potential NDA for TNX-102 SL, targeting fibromyalgia. However, the company has faced financial pressures, leading to a shift in focus away from COVID-19 projects. Despite these challenges, the firm shows optimism in its future prospects and pipeline advancements.
Read more →TNXPTonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID Topline Results Expected Third Quarter 2023 Long COVID Afflicts Approximate
Tonix Pharmaceuticals has completed the clinical phase of the Phase 2 PREVAIL proof-of-concept study, evaluating TNX-102 SL for treating fibromyalgia-type Long COVID. Results from this study, which focuses on a significant portion of Long COVID patients suffering from multi-site pain, are expected to be available in the third quarter of 2023. The company expresses optimism about TNX-102 SL's potential benefits in addressing sleep quality and other associated symptoms commonly found in this patient population. As Long COVID currently lacks FDA-approved treatments, this study is considered crucial for developing therapeutic options.
Read more →TNXPTonix Pharmaceuticals Announces Closing of $7 Million Public Offering
Tonix Pharmaceuticals has completed a public offering of 7 million shares, raising $7 million before expenses. The company plans to utilize the net proceeds for working capital, R&D, and facility development, as well as to acquire or license new products. The offering included warrants that are exercisable at $1.00 per share and have a five-year expiration. This move is part of Tonix's strategy to strengthen its development pipeline across various therapeutic areas.
Read more →TNXPTonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia Topline Data Expected Fourth Quarter 2023 Final Trial Required for Submission of
Tonix Pharmaceuticals has completed enrollment in its Phase 3 RESILIENT trial for TNX-102 SL, a treatment aimed at managing fibromyalgia. The trial, essential for NDA submission, involved 457 participants and is designed to evaluate the drug's efficacy and safety. Positive results from a prior Phase 3 trial, RELIEF, underscore TNX-102 SL's potential in alleviating fibromyalgia symptoms. Topline data from this trial is expected in the fourth quarter of 2023, marking a crucial step toward potential FDA approval.
Read more →TNXPTonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 STROBE' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder Preliminary Data Show that Oxytocin Decreases
Tonix Pharmaceuticals has initiated enrollment for the Phase 2 STROBE study of TNX-1900, aimed at treating binge-eating disorder. This study at Massachusetts General Hospital will assess the efficacy and safety of intranasal potentiated oxytocin, particularly its effects on binge eating frequency. Preliminary data suggests that oxytocin has potential benefits such as decreased impulsivity and reduced food intake. The trial seeks to enroll at least 60 participants over an 8-week period, employing a placebo-controlled design.
Read more →TNXPTonix Pharmaceuticals Announces Pricing of $7 Million Public Offering
Tonix Pharmaceuticals announced a public offering to raise approximately $7 million by selling 7 million shares at a price of $1.00 each, alongside warrants. The funds raised will support working capital and enhance its manufacturing and R&D capabilities. The offering, facilitated by A.G.P./Alliance Global Partners, is expected to close around August 1, 2023, subject to regulatory conditions. The company is actively developing various therapeutics, with significant clinical milestones projected for the upcoming quarters.
Read more →TNXPTonix Pharmaceuticals Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023 Reallocatin
Tonix Pharmaceuticals has announced an acceleration in the completion of enrollment for its Phase 2 UPLIFT study of TNX-601 ER for major depressive disorder, with topline data now expected by Q4 2023. The company will reallocate resources to prioritize the development of TNX-4300, a single isomer of tianeptine that has shown promising results in preclinical studies regarding neuroplasticity and cognitive enhancement. The decision reflects the company’s strategic focus on creating potentially safer treatment options for mood disorders and neurodegenerative conditions. Tonix also aims to complete enrollment in another trial for TNX-102 SL, with data forthcoming in the same timeframe.
Read more →TNXPTonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S) -Tianeptine, but not (R) -Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test New F
Tonix Pharmaceuticals announced positive data indicating that both racemic tianeptine and (S)-tianeptine significantly enhance memory and cognition, as evidenced in rat Novel Object Recognition tests. These findings may support the development of these compounds as first-in-class oral therapies for Alzheimer's disease and other neurodegenerative disorders. The company is preparing for the upcoming Phase 2 UPLIFT trial results expected in early 2024 for TNX-601 ER. However, there are concerns regarding the (R)-isomer's safety profile and the potential for abuse of tianeptine.
Read more →TNXPTonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder Social Anxiety Dis
Tonix Pharmaceuticals has announced the enrollment of the first participant in a Phase 2 clinical trial for TNX-1900, a potentiated intranasal oxytocin, to treat social anxiety disorder. Conducted in collaboration with the University of Washington, this study will focus on enhancing social safety learning in individuals with social anxiety. The trial aims to enroll 100 participants, half diagnosed with social anxiety disorder and the other half healthy controls, to evaluate TNX-1900's effectiveness compared to a placebo.
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0461
Tonix Pharmaceuticals Holding Corp. presented an investor update highlighting its diverse pipeline and progress in clinical development. The company is focusing on CNS disorders while also addressing various unmet needs, with several candidates in different stages of development. Financially, Tonix is well-positioned with $72 million in cash and no debt, although the presentation includes caution about the risks associated with regulatory approvals and market competition. Upcoming milestones are anticipated in the next few quarters for key programs such as TNX-102 SL and TNX-1900.
Read more →TNXPTonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 POWER' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity Preliminary Data Suggest that Oxytocin May Sim
Tonix Pharmaceuticals has announced the initiation of enrollment for the Phase 2 POWER study of TNX-1900, which is aimed at treating pediatric obesity. This study will assess the drug's efficacy and safety in adolescents aged 12-18, funded by the National Institutes of Health. Preliminary data suggests that TNX-1900 can help reduce calorie intake and increase energy expenditure, making it a promising candidate for weight loss therapies in this population. A total of 75 participants will be enrolled for this 12-week, double-blind study.
Read more →TNXPTonix Pharmaceuticals Comments on Two Long COVID Conferences Sponsored by the U.S. National Academies
Tonix Pharmaceuticals has commented on two recent conferences focused on Long COVID, emphasizing the definition of subgroups based on overlapping symptoms with chronic conditions such as fibromyalgia. The company is advancing its Phase 2 PREVAIL study of TNX-102 SL for managing Fibromyalgia-type Long COVID, with topline results expected in the third quarter of 2023. The discussions at these conferences may facilitate the development of more targeted treatments for various Long COVID subpopulations.
Read more →TNXPTonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products Strategic Acquisition Helps Build Tonix's Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for
Tonix Pharmaceuticals has successfully acquired two FDA-approved migraine medications, Zembrace SymTouch and Tosymra, from Upsher-Smith Laboratories. This acquisition not only bolsters Tonix’s product lineup, but it also enhances the company's commercial capabilities in anticipation of the potential launch of TNX-102 SL for fibromyalgia management. The two migraine treatments, which generated approximately $23 million in sales in 2022, are expected to meet significant unmet patient needs in migraine management while supporting Tonix's ongoing clinical development programs.
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0456
Tonix Pharmaceuticals Holding Corp. recently presented its investor update, highlighting its diverse pipeline focusing on central nervous system disorders and other therapeutic areas. The company emphasizes strategic partnerships to accelerate development, and it boasts a solid financial position with $72 million in cash and no debt. However, it also acknowledges substantial risks related to FDA approvals and market competition, which may impact its future operations.
Read more →TNXPTonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray) are
Tonix Pharmaceuticals has entered into an agreement to acquire Zembrace SymTouch and Tosymra, two FDA-approved migraine treatments from Upsher-Smith Laboratories. This strategic acquisition aims to bolster Tonix's commercial infrastructure as they prepare for the launch of their TNX-102 SL product for fibromyalgia. Both migraine products offer rapid relief and are designed to meet unmet needs in acute migraine treatment. The transaction includes established manufacturing relationships to facilitate a seamless transition.
Read more →TNXPTonix Pharmaceuticals Announces Publication of Results from Phase 3 RELIEF Trial of TNX-102 SL for the Management of Fibromyalgia Previously Disclosed Data Demonstrated that TNX-102 SL Achieved Statistically Significant
Tonix Pharmaceuticals has published results from the Phase 3 RELIEF trial for TNX-102 SL, a novel treatment for fibromyalgia, showing significant pain reduction compared to placebo. The study reported that the treatment was well tolerated and associated with improvements in sleep and fatigue. TNX-102 SL met its primary endpoint, with additional analysis indicating a higher responder rate for pain relief. The company is currently enrolling participants for the confirmatory RESILIENT trial, with results expected in the fourth quarter of 2023.
Read more →TNXPTonix Pharmaceuticals Holding Corp. 2023 Tonix Pharmaceuticals Holding Corp. TNX - 1700 Gastric and Colorectal Cancers NASDAQ: TNXP Version P0451 June 13 , 2023 (Doc 1243) 2023 Tonix Pharmaceuticals Holding Corp. 2 2023
Tonix Pharmaceuticals has detailed advancements in its candidate TNX-1700, a fusion protein aimed at treating gastric and colorectal cancers. The drug is designed to alter the tumor microenvironment and enhance the efficacy of cancer therapies, particularly with PD-1 inhibitors. Currently, TNX-1700 is in the preclinical phase, and the company is conducting ongoing animal studies to evaluate its therapeutic potential. The initiative is notable due to the significant unmet needs in cancer treatment, particularly gastrointestinal cancers which impose a substantial health burden.
Read more →TNXPTonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2023 American Transplant Congre
Tonix Pharmaceuticals announced that data from studies involving TNX-1500 (anti-CD40L monoclonal antibody) was presented at the 2023 American Transplant Congress. The research indicates that TNX-1500 effectively prevents organ rejection in animal models, with favorable tolerability. The company plans to begin Phase 1 clinical trials for TNX-1500 in the third quarter of 2023. This candidate also holds potential for treating various autoimmune conditions, expanding its therapeutic applications beyond transplantation.
Read more →TNXPTonix Pharmaceuticals Announces Presentation of Data Supporting Development of Racemic and Single (S) -Isomer Tianeptine, Plastogen Anti-Depressants, at the American Society of Clinical Psychopharmacology Meeting Tianept
Tonix Pharmaceuticals presented promising data at the ASCP meeting about the racemic and single (S)-isomer Tianeptine as treatments for psychiatric and neurodegenerative conditions. They are currently enrolling patients for a pivotal Phase 2 study of TNX-601 ER for major depressive disorder, with interim results expected in the fourth quarter of 2023. The research highlights Tianeptine's mechanism of enhancing neuroplasticity and neurogenesis through PPAR agonism, distinguishing it from traditional antidepressants. Meanwhile, TNX-4300 is in preclinical development for several neuropsychiatric disorders.
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0447
Tonix Pharmaceuticals Holding Corp. has presented its strategy and pipeline through its latest investor presentation. The company focuses on developing innovative therapies and vaccines, particularly for central nervous system disorders. Noteworthy is their financial position, boasting $72 million in cash and no debt, which supports their diverse pipeline, including candidates in mid-Phase 3 and Phase 2 trials. However, investors are cautioned about the risks associated with FDA approvals and setbacks in previous studies.
Read more →TNXPTonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant Congress Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Ho
Tonix Pharmaceuticals Holding Corp. announced that its TNX-1500 anti-CD40L monoclonal antibody will be presented at the 2023 American Transplant Congress, organized by the Center for Transplantation Sciences at Massachusetts General Hospital. Oral and poster presentations will take place from June 3-7, 2023, in San Diego, California. The research focuses on TNX-1500's potential in preventing renal and cardiac allograft rejection, showcasing the company's commitment to advancing treatment options for transplant patients. This follows multiple ongoing clinical trials within Tonix's diverse therapeutic portfolio.
Read more →TNXPTonix Pharmaceuticals Announces Presentation at the 2023 BIO International Convention
Tonix Pharmaceuticals announced that its CEO, Seth Lederman, will present at the 2023 BIO International Convention in Boston on June 6. The presentation is part of the company's efforts to showcase its clinical-stage biopharmaceutical portfolio, which includes therapies for CNS conditions, rare diseases, and infectious diseases. Notable upcoming data releases for several products are anticipated in the latter half of 2023, although all candidates are still investigational and have not yet received regulatory approval.
Read more →TNXPConfidential Tonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting CHATHAM, N.J.
Tonix Pharmaceuticals announced that Dr. Gregory Sullivan will present a poster at the 2023 ASCP Annual Meeting, detailing the Phase 2 UPLIFT study of TNX-601 ER for major depressive disorder (MDD). The poster will also discuss new insights into tianeptine's mechanism and the development of TNX-4300 for MDD and other neurological conditions. This presentation marks a significant advancement in the company's research and showcases their ongoing commitment to tackling major mental health disorders.
Read more →TNXPTonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Tonix Pharmaceuticals has announced that Dr. Gregory Sullivan will present a poster at the ASCP Annual Meeting, scheduled for May 30 to June 2, 2023. The presentation will focus on updates from the Phase 2 UPLIFT study concerning TNX-601 ER, an extended-release treatment for major depressive disorder. Additionally, it will explore advancements in understanding tianeptine's mechanism of action and details on TNX-4300 for MDD and neurodegenerative diseases. The poster will be available on the company's website following the conference.
Read more →TNXPTonix Pharmaceuticals to Present at the June 1st Virtual Investor Summit
Tonix Pharmaceuticals Holding Corp. announced that Jessica Morris, the Chief Operating Officer, will present at the Virtual Investor Summit on June 1, 2023. The company is focused on developing therapeutics for a variety of human diseases, with key upcoming data on several product candidates expected in the coming months, including treatments for fibromyalgia and chronic migraine. Additionally, Tonix's initiatives include innovative research in the fields of rare diseases and immunology.
Read more →TNXPTonix Pharmaceuticals Announces the Isolation and Characterization of the (S) -Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative Diseases TNX-4300 is a Dual PPAR-
Tonix Pharmaceuticals has isolated and characterized the (S)-isomer of tianeptine, designated TNX-4300, which is now under development for treating psychiatric and neurodegenerative diseases such as MDD, bipolar disorder, Alzheimer's, and Parkinson's disease. TNX-4300 acts as a dual PPAR agonist and is noted for restoring neuroplasticity in neuronal tissue while being free of -opioid receptor activity, which may limit undesirable side effects associated with traditional antidepressants. The company is poised to submit findings for upcoming scientific presentations and publications in peer-reviewed journals.
Read more →TNXPTonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin) Intranasal Oxytocin Blocks the Release of CGRP in Animal Models Intranasal Oxytocin is the Core Technology of
Tonix Pharmaceuticals announced a clinical proof-of-concept study for TNX-1900, an intranasal potentiated oxytocin formulation aimed at treating migraine and related conditions. This study will evaluate TNX-1900's impact on blood flow response in healthy volunteers, leveraging its distinctive mechanism of blocking calcitonin gene-related peptide (CGRP) release. The company anticipates topline results from its concurrent Phase 2 PREVENTION study for chronic migraine by the fourth quarter of 2023. With no known addiction potential, TNX-1900 could represent a promising non-addictive treatment alternative in migraine management.
Read more →TNXPTonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
Tonix Pharmaceuticals will participate in the A.G.P. Virtual Healthcare Conference on May 23-24, 2023, where CEO Seth Lederman will discuss new approaches to depression. The company is involved in multiple clinical-stage developments across various therapeutic areas, including CNS and rare diseases. With several clinical trials expected to yield topline data in 2023, Tonix aims to advance its portfolio and engage with potential investors during the conference.
Read more →TNXPTonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression Research Supports Dire
Tonix Pharmaceuticals announced significant findings related to tianeptine, the active ingredient in TNX-601 ER, which elucidate its mechanism of action in treating major depressive disorder. The research indicates that tianeptine acts as an agonist for specific PPAR isoforms, promoting neuroplasticity rather than relying on neurotransmitter levels. These breakthroughs suggest that tianeptine has advantages over traditional antidepressants, including fewer side effects. Tonix aims to explore TNX-601 ER further for use in a range of psychiatric and neurodegenerative conditions.
Read more →TNXPTonix Pharmaceuticals Announces 1-for-6.25 Reverse Stock Split CHATHAM, N.J.
Tonix Pharmaceuticals has announced a 1-for-6.25 reverse stock split of its common shares, effective May 10, 2023. This action aims to increase the company's stock price to meet NASDAQ's minimum bid price requirement of $1.00 for continued listing. Following the split, the number of authorized shares will reduce from 1 billion to 160 million. Despite ongoing clinical developments for various therapeutic candidates, risks such as potential delays in FDA approvals and financial challenges remain notable.
Read more →TNXPTonix Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights Prioritizing Late-Stage Clinical CNS Programs in Fibromyalgia, Depression, Migraine, and Cocaine Intoxication Topline Results
Tonix Pharmaceuticals has released its financial results for Q1 2023 and highlighted the progress of its clinical programs focusing on fibromyalgia, major depressive disorder, and other CNS-related indications. The company has approximately $72 million in cash reserves and is expecting key topline results from its clinical trials later this year, which may pave the way for FDA applications. Despite these advancements, Tonix reported a net loss of $33 million during the quarter, reflecting escalating operational expenses.
Read more →TNXPTonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant Multiple Additional Indications Possible, Including Autoimmune D
Tonix Pharmaceuticals has received FDA clearance for its IND application for TNX-1500, a monoclonal antibody aimed at preventing organ rejection in kidney transplant patients. The company plans to initiate a Phase 1 clinical trial by the third quarter of 2023. TNX-1500 may also have broader applications for various autoimmune diseases. Preclinical studies demonstrated that TNX-1500 effectively prolonged renal and heart allograft survival in non-human primates.
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0 440
Tonix Pharmaceuticals released its 2023 investor presentation, outlining its focus on central nervous system disorders and other therapeutic areas. The company reported a strong financial position with approximately $120 million in cash and no debt. However, it highlighted various risks including potential FDA compliance issues, uncertainties in clinical development timelines, and mixed results from recent studies. Overall, Tonix aims to improve population health through innovative therapies and strategic partnerships.
Read more →TNXPTonix Pharmaceuticals Announces Presentations of Pre-Clinical Data on TNX-1700 in Syngeneic Models of Colorectal and Gastric Cancer at the American Association for Cancer Research Annual Meeting 2023 CHATHAM, N.J.
Tonix Pharmaceuticals announced the presentation of research results on TNX-1700 at the AACR Annual Meeting 2023. The presented posters revealed that TNX-1700, when targeting myeloid-derived suppressor cells, showed enhanced anti-tumor efficacy alongside PD-1 blockade therapy in mouse models of colorectal and gastric cancer. These findings indicate potential new avenues for combined cancer treatment strategies. Tonix is developing TNX-1700 under a license from Columbia University, highlighting ongoing efforts in cancer therapeutics.
Read more →TNXPTonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft Survival Research Directed by Facul
Tonix Pharmaceuticals announced the online publication of two studies in the American Journal of Transplantation, focusing on TNX-1500, an anti-CD40L monoclonal antibody. The studies show that TNX-1500 effectively prevents organ transplant rejection in non-human primates without significant side effects. The company aims to start a Phase 1 clinical trial in adults receiving kidney transplants in the second quarter of 2023, highlighting TNX-1500's potential as a safe and effective treatment option in organ transplantation.
Read more →TNXPTonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft Survival
Tonix Pharmaceuticals announced the publication of two studies in the American Journal of Transplantation regarding its candidate TNX-1500, aimed at preventing organ transplant rejection. The studies indicated that TNX-1500 was effective in prolonging the survival of kidney and heart allografts in nonhuman primates while demonstrating a good safety profile. The company plans to begin a Phase 1 clinical trial of TNX-1500 for kidney transplant patients in Q2 2023. Experts believe that TNX-1500 could address a significant need for improved treatments in organ transplantation.
Read more →TNXPTonix Pharmaceuticals Expedites Fibromyalgia and Chronic Migraine Programs Streamlining Phase 3 Fibromyalgia and Phase 2 Chronic Migraine Trials by Eliminating Interim Analyses Topline Results Expected for Both Programs
Tonix Pharmaceuticals announced a strategic modification to its clinical trials for TNX-102 SL and TNX-1900, focusing on fibromyalgia and chronic migraine, respectively. By eliminating interim analyses, the company aims to streamline the Phase 3 and Phase 2 studies, respectively, facilitating more efficient data collection. This change is expected to allow for topline results by the fourth quarter of 2023, which the company anticipates will align with its goal of FDA approval. The targeted enrollment for the chronic migraine study has been adjusted to expedite timelines.
Read more →TNXPTonix Pharmaceuticals Presents Data from its Vaccine Development Program at the World Vaccine Congress Preclinical data demonstrate the efficacy of TNX-801 vaccination against mpox virus challenge in a non-human primate
Tonix Pharmaceuticals has presented data on its TNX-801 vaccine candidate at the World Vaccine Congress, demonstrating its efficacy in providing protection against the mpox virus in non-human primates. TNX-801 is designed for safe widespread use and is based on a historical vaccine method that shows reduced virulence. The company plans to initiate a Phase 1 trial of TNX-801 for mpox and smallpox in the latter half of 2023.
Read more →TNXPTonix Pharmaceuticals Announces Poster Presentations at the American Association for Cancer Research Annual Meeting 2023 Data from Animal Studies on TNX-1700 (recombinant TFF2 - albumin fusion peptide) in Syngeneic Model
Tonix Pharmaceuticals Holding Corp. announced that it will present new data on its investigational compound TNX-1700 at the American Association for Cancer Research Annual Meeting 2023. The research highlights the therapeutic potential of TNX-1700 in synergy with PD-1 blockade therapy, demonstrating its efficacy in preclinical models of colorectal and gastric cancer. The presentations are scheduled for April 16 and April 18, 2023, at the conference in Orlando, Florida. This highlights Tonix's ongoing commitment to advancing its oncology pipeline.
Read more →TNXPConfidential Tonix Pharmaceuticals Announces Pipeline Prioritization Update for 2023 Prioritizing Clinical-Stage CNS Programs in Fibromyalgia, Depression, Migraine, and Cocaine Intoxication Deprioritizing COVID-19 Relate
Tonix Pharmaceuticals has announced a strategic update prioritizing its central nervous system (CNS) programs, including trials for fibromyalgia, chronic migraine, and depression, while deprioritizing several COVID-19 related initiatives. The company reported cash reserves of approximately $120.2 million and expressed confidence in its upcoming clinical trials, including a Phase 3 trial for fibromyalgia. However, Tonix is delaying the start of a PTSD study in Kenya and discontinuing the enrollment of new patients in a Phase 2 trial for fibromyalgia-type Long COVID.
Read more →TNXPTonix Pharmaceuticals Announces Pipeline Prioritization Update for 2023
Tonix Pharmaceuticals announced a strategic pipeline prioritization update for 2023, focusing resources on its mid- and late-stage clinical programs in fibromyalgia, depression, migraine, and cocaine intoxication within its central nervous system (CNS) portfolio. The company plans to deprioritize several longer-term programs, especially those related to COVID-19, and delay the initiation of a PTSD study in Kenya. Tonix holds approximately $120.2 million in cash, which supports its operational efficiency and development objectives. Upcoming milestones include interim and topline results for various studies expected later in 2023.
Read more →TNXPTonix Pharmaceuticals Presents Positive Efficacy and Safety Data from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 5th International Congress on Controversies in Fibromyalgia
Tonix Pharmaceuticals announced positive results from its Phase 3 RELIEF study of TNX-102 SL for fibromyalgia management. The study confirmed that TNX-102 SL significantly reduced pain compared to placebo and was well-tolerated among participants. An interim analysis for the ongoing RESILIENT study is anticipated in the next quarter. This presentation took place at the 5th International Congress on Controversies in Fibromyalgia in Vienna, Austria.
Read more →TNXPTonix Pharmaceuticals Presents Positive Efficacy and Safety Data from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 5th International Congress on Controversies in Fibromyalgia Interim An
Tonix Pharmaceuticals presented favorable efficacy and safety data from the Phase 3 RELIEF Study of TNX-102 SL for fibromyalgia management at a recent congress. The interim analysis indicated that TNX-102 SL met its primary endpoint, showing significant reductions in daily pain compared to placebo. Additionally, the treatment was well-tolerated by participants, with minimal adverse effects noted. The company anticipates further results from the RESILIENT study, which may bolster the drug's development pathway.
Read more →TNXPTonix Pharmaceuticals Announces Oral Presentations at the World Vaccine Congress
Tonix Pharmaceuticals announced that key executives, Dr. Zeil Rosenberg and Dr. Farooq Nasar, will deliver oral presentations at the upcoming World Vaccine Congress in Washington D.C. The presentations will cover topics like the development of Horsepox vaccine for Mpox and Smallpox, as well as the evaluation of TNX-1800 as a vaccine platform for SARS-CoV-2. Additionally, Dr. Sina Bavari will moderate a panel discussing challenges and opportunities in vaccine development. These events will take place from April 3 to April 6, 2023.
Read more →TNXPTonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership Summit
Tonix Pharmaceuticals presented promising data on TNX-2900, aimed at treating hyperphagia in adolescents and young adults with Prader-Willi syndrome, at the Rare Disease Innovation and Partnership Summit. The presentation highlighted the Mg2+ enhanced formulation for better activation of oxytocin receptors. TNX-2900 received Orphan Drug designation from the FDA, indicating its potential value in addressing a currently untreated condition. Tonix Pharmaceuticals is also conducting further research to understand the therapeutic actions of oxytocin in this rare genetic disorder.
Read more →TNXPTonix Pharmaceuticals Announces Oral Presentation and Poster at the 5th International Congress on Controversies in Fibromyalgia
Tonix Pharmaceuticals announced that CEO Seth Lederman will deliver an oral presentation regarding the efficacy and safety of TNX-102 SL for fibromyalgia at the upcoming 5th International Congress on Controversies in Fibromyalgia. The event, occurring on March 30-31, 2023, in Vienna, Austria, will also feature a poster presentation on the same subject. Results from the randomized, placebo-controlled RELIEF trial will be highlighted, with the company's abstract published in a relevant medical journal supplement. This presentation underscores Tonix's active role in addressing fibromyalgia and advancing its clinical research initiatives.
Read more →TNXPTonix Pharmaceuticals to Present at the 2023 Virtual March Investor Summit
Tonix Pharmaceuticals has announced that its Chief Operating Officer, Jessica Morris, will present at the Virtual March Investor Summit on March 29, 2023. The presentation will cover the company's diverse portfolio, which includes drug candidates for various conditions such as fibromyalgia, chronic migraine, and Long COVID. Tonix is also advancing its immunology and infectious disease pipelines with several clinical trials planned for initiation soon. Investors interested in engaging with management can arrange meetings through the conference coordinators.
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0424 March 20 , 2023 (Doc 1182 ) 2 2023 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statemen
Tonix Pharmaceuticals Holding Corp. has presented an investor update detailing its strategic plans and pipeline developments. The presentation highlights their focus on central nervous system disorders while also targeting areas in immunology and infectious diseases. The company boasts a strong financial position with $120 million in cash and no debt, and mentions ongoing clinical trials for multiple product candidates. However, risks associated with FDA approvals and the need for future financing were noted.
Read more →TNXPTonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit
Tonix Pharmaceuticals Holding Corp. is set to present at the Rare Disease Innovation and Partnership Summit in Philadelphia on March 23, 2023. The presentation will focus on TNX-2900, a therapy in development for treating hyperphagia in adolescents and young adults with Prader-Willi Syndrome. Additionally, Tonix's comprehensive pipeline includes various candidates addressing CNS disorders, rare diseases, and other significant medical conditions. The presentation's details will be available on Tonix's website following the event.
Read more →TNXPTonix Pharmaceuticals Initiates Enrollment in Phase 2 UPLIFT' Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD) Results from Planned Interim Analys
Tonix Pharmaceuticals has begun enrollment for the Phase 2 UPLIFT study of TNX-601 ER, an extended-release formulation of tianeptine for major depressive disorder (MDD). The study targets 300 participants across approximately 30 sites in the U.S. Results from an interim analysis are expected in the fourth quarter of 2023. TNX-601 ER is designed to enhance neuroplasticity and neurogenesis, presenting an alternative to traditional antidepressant mechanisms.
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0419 March 13 , 2023 (Doc 1177 ) 2 2023 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statemen
Tonix Pharmaceuticals Holding Corp. recently presented its investor outlook, highlighting its commitment to developing innovative therapies and vaccines across various therapeutic areas. The company has multiple programs in its pipeline, including potential pivotal studies for fibromyalgia and cocaine intoxication. Despite having a strong financial position and strategic partnerships, Tonix faces challenges related to regulatory approvals, potential financing needs, and delays from external factors such as the COVID-19 pandemic.
Read more →TNXPTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights Interim Analysis of Registration-Enabling Phase 3 Fibromyalgia Trial of TNX-102 SL Expected Second Quarter 2023
Tonix Pharmaceuticals announced its 2022 financial results along with operational highlights, revealing a strong focus on advancing its clinical programs. A pivotal Phase 3 trial for its fibromyalgia drug, TNX-102 SL, is expected to produce interim data in Q2 2023, with potential FDA application following successful results. The company's financial report indicated a cash position of approximately $120.2 million; however, it also disclosed a significant net loss for the year. Tonix is expanding its portfolio, with multiple Phase 2 trials set to commence in 2023.
Read more →TNXPTonix Pharmaceuticals Announces Results from a Preclinical Study of Murine TNX-1700 Presented in a Poster at the Keystone Symposia, "Cancer Immunotherapy: Mechanisms of Response Versus Resistance" Murine TNX-1700 (mTNX-1
Tonix Pharmaceuticals has announced positive results from a preclinical study of its therapy mTNX-1700, which was presented at the Keystone Symposia. The study indicates that mTNX-1700 can enhance anti-tumor activity when used with PD-1 checkpoint inhibitors in mouse models of colorectal cancer. This treatment appears to activate cancer-fighting CD8+ T cells while limiting immunosuppressive elements contributed by myeloid-derived suppressor cells. The company plans to further investigate the efficacy of mTNX-1700 in clinical settings.
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0414 February 27 , 2023 (Doc 11 72 ) 2 2023 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain stat
Tonix Pharmaceuticals Holding Corp. has provided an investor presentation outlining its strategic planning and development pipeline. The company focuses on central nervous system disorders and other therapeutic areas, indicating a commitment to innovation and partnership to expedite product development. Despite solid financial standing and ongoing clinical trials, Tonix faces significant risks related to FDA approvals and previously missed clinical study endpoints. The company also highlights its diverse pipeline, including investigational products for fibromyalgia, cocaine intoxication, and Long COVID, among others.
Read more →TNXPTonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell CHATHAM, N.J.
Tonix Pharmaceuticals announced the appointment of R. Newcomb Stillwell to its Board of Directors, effective March 15, 2023. Stillwell has nearly 40 years of experience in corporate law, primarily at Ropes & Gray LLP, where he advised on private equity and life science transactions. His addition is anticipated to bring strategic guidance to help advance Tonix's product candidates in drug development. The company is focused on various therapeutic areas, including central nervous system disorders and infectious diseases.
Read more →TNXPTonix Pharmaceuticals Describes Emerging Research on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients During Event Titled, “Long COVID: What Will it Take to Accelerate Therapeutic Progress?”
Tonix Pharmaceuticals announced emerging research on the relationship between Long COVID symptoms, such as multi-site pain, and chronic pain syndromes like fibromyalgia during a virtual event co-hosted with BIO and Solve M.E. The company's ongoing Phase 2 study of TNX-102 SL aims to address these symptoms in Long COVID patients. Dr. Seth Lederman emphasized the connection between Long COVID and conditions like fibromyalgia, supported by recent survey findings. However, no approved treatment exists for Long COVID, and patient enrollment in the study is continuing, indicating both potential and uncertainty in this area of research.
Read more →TNXPTonix Pharmaceuticals to Participate in Event Titled, “Long COVID: What Will it Take to Accelerate Therapeutic Progress?”
Tonix Pharmaceuticals will participate in a virtual event titled "Long COVID: What Will it Take to Accelerate Therapeutic Progress?" on February 21, 2023. CEO Seth Lederman will discuss clinical studies and new therapeutic approaches in the context of Long COVID. The event, co-hosted by BIO and Solve M.E., aims to highlight emerging research on Long COVID and related conditions, offering insights from various stakeholders in the healthcare sector. Registration is available to the general public, and the presentation will also be accessible afterward on Tonix's website.
Read more →TNXPTonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies Immunocompromised Individuals, Including Organ Transplant Recipients
Tonix Pharmaceuticals announced it has secured an exclusive license from Columbia University to develop fully human and murine monoclonal antibodies for treating and preventing SARS-CoV-2 infection, targeting immunocompromised individuals. This initiative comes as existing monoclonal antibody therapies are no longer authorized due to the evolving nature of the virus. The company’s newly licensed antibodies aim to provide better protection against emerging variants, responding to an urgent medical need. Tonix believes its approach could yield broader neutralization capabilities compared to previous treatments.
Read more →TNXPTonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Company's Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801) Preclinical data demonstrate the efficacy of TNX-801
Tonix Pharmaceuticals announced the publication of a paper in the journal Viruses detailing the effectiveness of their vaccine, TNX-801, against monkeypox. The preclinical data showed that all vaccinated macaques achieved complete protection from monkeypox infection. A Phase 1 clinical trial is anticipated to commence in the latter half of 2023, reflecting the ongoing development of the vaccine as part of the company’s efforts to address viral threats, such as monkeypox and smallpox. TNX-801 is designed as a single-dose, live virus vaccine based on horsepox.
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION THE WALL STREET CONFERENCE NASDAQ: TNXP Version P0406
Tonix Pharmaceuticals recently presented an investment overview at The Wall Street Conference, highlighting its commitment to developing innovative therapies and vaccines. The company outlined its diverse pipeline focusing on central nervous system disorders, immunology, and infectious diseases, with several candidates in various clinical trial stages. Tonix reported a solid financial position with $120 million in cash and no debt, emphasizing strategic partnerships to enhance development capabilities. Despite these strengths, the company faces significant risks associated with FDA approvals, pandemic-related delays, and competition in the pharmaceutical industry.
Read more →TNXPTonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVENTION' Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic Migraineurs Results from Planned Interim Analysis
Tonix Pharmaceuticals has initiated enrollment for the Phase 2 PREVENTION study of TNX-1900, an intranasal formulation of potentiated oxytocin aiming to prevent migraine headaches in chronic migraineurs. This double-blind, placebo-controlled trial targets 300 participants across 25 sites in the U.S., with an interim analysis anticipated in the fourth quarter of 2023. The study seeks to evaluate the efficacy and safety of TNX-1900, which also plans to target episodic migraines and other conditions. The development team emphasizes the drug's potential due to its unique mechanism of action and improved delivery system.
Read more →TNXPTonix Pharmaceuticals to Participate in BIO CEO & Investor Conference
Tonix Pharmaceuticals announced that its CEO, Seth Lederman, will participate virtually in the BIO CEO & Investor Conference from February 6-9, 2023. During the conference, a pre-recorded presentation will be available for registered participants, highlighting the company’s developments and clinical-stage products. Tonix is focused on therapeutics across a range of areas including CNS disorders and infectious diseases, with upcoming studies expected to advance significantly. However, the company faces challenges related to FDA approvals and market competition.
Read more →TNXPTonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc. The Acquired Portfolio of Infectious Disease Assets Includes a Class of Potential Broad Spectrum Oral Antivir
Tonix Pharmaceuticals has announced the acquisition of a preclinical infectious disease portfolio from Healion Bio, including the TNX-3900 series of potential broad-spectrum oral antiviral agents. These agents work through a novel mechanism targeting cathepsin proteases, essential for various viral infections, including SARS-CoV-2. The firm is optimistic about developing these assets, leveraging its advanced facilities and expertise to bring these therapies into clinical trials. The ability to combine TNX-3900 with other antivirals could enhance the antiviral treatment landscape significantly.
Read more →TNXPTonix Pharmaceuticals Announces Research Agreement with University of Maryland, Baltimore, to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Heart Xenograft Transplantation in Animals Rese
Tonix Pharmaceuticals Holding Corp. has announced a research agreement with the University of Maryland, Baltimore to study TNX-1500 for preventing rejection in heart xenograft transplantation. The research will utilize genetically-modified porcine hearts, and aims to strengthen regulatory filings for TNX-1500. Initial preclinical findings have shown that TNX-1500 effectively prevents organ rejection in earlier studies, and a Phase 1 study is expected to begin in the second quarter of 2023. Successful results could enable future clinical applications in humans.
Read more →TNXPTonix Pharmaceuticals Announces Presentation of Clinical and Non-Clinical TNX-1900 Data at the Annual Headache Cooperative of the Pacific (HCOP) Winter Conference Preliminary Results from Human PET Study Show that Intran
Tonix Pharmaceuticals announced the presentation of encouraging clinical and non-clinical data for TNX-1900 at the HCOP Winter Conference. The data suggests that intranasal application of magnesium-potentiated oxytocin effectively reaches the trigeminal ganglia, associated with migraine headaches. Additionally, there are indications of sex differences in oxytocin potency, which may have significant implications for future dosing strategies in migraine treatment. The company is preparing to initiate a Phase 2 study of TNX-1900 for chronic migraines in early 2023.
Read more →TNXPTonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 2 nd Wnt & -catenin Targeted Drug Development Conference Oral Presentation Describes Activity of Wnt/ -catenin Signaling Pathway I
Tonix Pharmaceuticals recently announced a significant presentation at the 2nd Wnt & β-catenin Targeted Drug Development Conference in Boston. Dr. Tom Hobman from the University of Alberta presented promising data on the use of Wnt/β-catenin signaling pathway inhibitors as broad-spectrum antivirals targeting SARS-CoV-2. This research, sponsored by Tonix, emphasizes the importance of developing effective therapeutic strategies against emerging viruses. The collaboration aims to ready the scientific community for immediate response to future viral outbreaks.
Read more →TNXPTonix Pharmaceuticals Announces Publication of Paper in Antiviral Research Highlighting the Company's Development of Monoclonal Antibody Therapeutics for Monkeypox and Smallpox Data Represent Research and Development Wor
Tonix Pharmaceuticals has published a paper in Antiviral Research detailing the development of monoclonal antibody therapeutics targeting monkeypox and smallpox. The research presents advancements in high-content image-based assays designed to identify effective antibodies for combating these viruses. The findings underscore the capabilities of Tonix's TNX-3400 platform and the ongoing research being conducted at their Infectious Disease R&D Center in Frederick, Maryland. This publication may play a crucial role in the future development of therapies aimed at addressing these infectious diseases.
Read more →TNXPTonix Pharmaceuticals Holding Corp. Biotech Showcase COVID antiviral agents: anti - SARS - CoV - 2 Spike Protein Monoclonal Antibodies for Treatment and Prevention of COVID - 19 Version 1145
Tonix Pharmaceuticals is showcasing its development of antiviral agents, specifically anti-SARS-CoV-2 monoclonal antibodies targeted for COVID-19 treatment and prevention. The company emphasizes its commitment to innovative therapies through a diverse pipeline and strategic partnerships while highlighting its robust financial position with $140 million in cash. However, it cautions about the inherent risks in pharmaceutical development, such as regulatory hurdles and the competitive landscape. Tonix aims to address unmet medical needs efficiently while managing uncertainties associated with product development.
Read more →TNXPTonix Pharmaceuticals Appoints Zeil Rosenberg, M.D., M.P.H., as Executive Vice President, Medical for Infectious Disease Programs Dr. Rosenberg Will Lead Clinical Development of Tonix's Vaccine and Antiviral Programs CHA
Tonix Pharmaceuticals has appointed Dr. Zeil Rosenberg, M.D., M.P.H., as Executive Vice President, Medical for Infectious Disease Programs. In this pivotal role, he will oversee the clinical development of several vaccine and antiviral candidates, including TNX-801 for smallpox and monkeypox, and TNX-1850 for COVID-19. Dr. Rosenberg's extensive background in infectious disease drug development is anticipated to significantly advance Tonix's initiatives in its infectious disease portfolio.
Read more →TNXPTonix Pharmaceuticals to Present at Biotech Showcase 2023
Tonix Pharmaceuticals Holding Corp. has announced that its CEO, Dr. Seth Lederman, will present at the upcoming Biotech Showcase 2023, scheduled for January 10 in San Francisco. The event will provide insight into the company's ongoing developments in therapeutics for various conditions, including their lead candidate for fibromyalgia and treatments for Long COVID. Tonix's diverse portfolio encompasses multiple therapeutic areas with significant clinical activity anticipated in 2023.
Read more →TNXPTonix Pharmaceuticals Achieves Enrollment of First 50 Percent of Participants in the RESILIENT Study, a Potentially Pivotal Confirmatory Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia Results from Planned
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Achieves Enrollment of First 50 Percent of Participants in the RESILIENT Study, a Potentially Pivotal Confirmatory Phase 3 Study of TNX-102 SL for the Management of Results from Planned Interim Analysis of First 50
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0399 December , 15 2022 (Doc 1140) 2 2022 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statem
Tonix Pharmaceuticals 2022 Tonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0399 December , 15 2022 (Doc 1140) 2 2022 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regar
Read more →TNXPTonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Curia Global, Inc. Immunocompromised Individuals, Including Organ Transplant
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Immunocompromised Individuals, Including Organ Transplant Recipients, are at Increased Risk of Seve
Read more →TNXPTonix Pharmaceuticals Announces Collaboration with Boston Children's Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transp
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Collaboration with Boston Children's Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Anim
Read more →TNXPTonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress TNX-801 is Based on the Sequence of a Natural
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress TNX-801 is Based on the Sequence of a Natural Isolate of Hor
Read more →TNXPTonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress Research Being Conducted in Collaboration with Scientists at
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress Research Being Conducted in Collaboration with Scientists at Columbia Univers
Read more →TNXPTonix Pharmaceuticals to Participate in the A.G.P. Biotech Conference
CHATHAM, N.J., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that management will participate virtually in the A.G.P. Biotech Conference and host investor meetings. The conference
Read more →TNXPTonix Pharmaceuticals Announces Oral Presentation at the World Vaccine and Immunotherapy Congress
CHATHAM, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver an oral presentation at the Wo
Read more →TNXPTonix Pharmaceuticals Announces Data from an in vitro Study of the Impact of Oxytocin on Human Neurons at Neuroscience 2022 , the Annual Meeting of the Society for Neuroscience CHATHAM, N.J.
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Data from an in vitro Study of the Impact of Oxytocin on Human Neurons at Neuroscience 2022, the Annual Meeting of the Society CHATHAM, N.J., November 16, 2022 - Tonix Pharmaceuticals Holding Corp. (Nasda
Read more →TNXPTonix Pharmaceuticals Announces Poster Presentation at Neuroscience 2022 by the Society for Neuroscience
CHATHAM, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced a poster presentation by an academic collaborator at Neuroscience 2022 by the Society for Neuroscience being held Novem
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights Five Potentially Pivotal Phase 2 or 3 Studies for CNS Programs Expected to be in the Clinic by First Quarter 2023 Data from Pl
Tonix Pharmaceuticals Holdings Corp. 8-K Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights Five Potentially Pivotal Phase 2 or 3 Studies for CNS Programs Expected to be in the Clinic by First Quarter 2023 Data from Planned Interim
Read more →TNXPTonix Pharmaceuticals to Present at the 2022 BioFuture Conference
CHATHAM, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at BioFuture on Tuesday, November 8
Read more →TNXPTonix Pharmaceuticals Announces Pricing of $15 Million Private Placement of Convertible Redeemable Preferred Stock CHATHAM, N.J.
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Tonix Pharmaceuticals Announces Pricing of $15 Million Private Placement of Convertible Redeemable Preferred Stock CHATHAM, N.J., October 25, 2022 - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical
Read more →TNXPTonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference
CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on We
Read more →TNXPTonix Pharmaceuticals to Participate in the 2022 BIO-Europe Conference
CHATHAM, N.J., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will participate in one-on-one meetings at
Read more →TNXPTonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder TNX-601 ER, Tianeptine Hemioxalate, is an Extended-Release Tablet for Once-a-Day Dosing Phase 2 Clinical
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder TNX-601 ER, Tianeptine Hemioxalate, is an Extended-Release Tablet for Once-a-Day Dosing Phase 2 Clinical Trial of TNX-6
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0382
TONIX PHARMACEUTICALS HOLDING CORP. 8-K 2022 Tonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0382 October 3, 2022 (Doc 1107) 2 2022 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this pre
Read more →TNXPTonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients at IASP 2022 World Congress on Pain Approximately 40% of Long COVID
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients at IASP 2022 World Congress on Pain Approximately 40% of Long COVID Patients Experien
Read more →TNXPTonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTS 2022)
TNX-1500 Treatment Prevents Organ Rejection and Preserves Function for Both Allograft and Xenograft Transplants in Animal Studies CHATHAM, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biophar
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0376
TONIX PHARMACEUTICALS HOLDING CORP. 8-K 2022 Tonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0376 September 6, 2022 (Doc 1097) 2 2022 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this p
Read more →TNXPTonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the International Congress of The Transplantation Society (TTS 2022)
CHATHAM, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced three oral presentations by academic collaborators at the 29th International Congress of The Tr
Read more →TNXPTonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID Results from Planned Interim Analysis Expected First Half 2023 Long COVID Afflicts More Than 30% of Patien
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID Results from Planned Interim Analysis Expected First Long COVID Afflicts More Than 30% of Patients Following Infection wi
Read more →TNXPTonix Pharmaceuticals to Present at the 2022 Virtual Q3 Investor Summit
CHATHAM, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the Virtual Q3 Investor Sum
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights Phase 1 Study of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and Smallpox, Expected to Initiate in Firs
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights Phase 1 Study of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and Smallpox, Expected to Initiate in First Half 2023 in K
Read more →TNXPTonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine Intoxication There is No FDA-Approved Product for Cocaine Intoxi
Tonix Pharmaceuticals Holding Tonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine Intoxication There is No FDA-Approved Product for Cocaine Intoxication TNX-1300 Has Been G
Read more →TNXPTonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain New patent expected to expire in 2036 Phase 2 Study for Prevention of Migraine Headach
Tonix Pharmaceuticals Holding Corp.8-K Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain New patent expected to expire in 2036 Phase 2 Study for Prevention of Migraine Headache Expected to St
Read more →TNXPTonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection Phase 1 Clinical Study Expected to be In
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection Phase 1 Clinical Study Expected to be Initiated in Kenya
Read more →TNXPTonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development CHATHAM, N.J.
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development N.J., July 25, 2022 - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clini
Read more →TNXPTonix Pharmaceuticals Holding Corp. TNX - 2900* (Intranasal Oxytocin + Magnesium) in Development for the Treatment of Hyperphagia in Adolescents and Young Adults with Prader - Willi Syndrome *TNX - 2900 is an investigati
Tonix Pharmaceuticals Holding Corp. 8-K 2022 Tonix Pharmaceuticals Holding Corp. TNX - 2900* (Intranasal Oxytocin + Magnesium) in Development for the Treatment of Hyperphagia in Adolescents and Young Adults with Prader - Willi Syndrome *TNX - 2900 is an investigational drug in t
Read more →TNXPTonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder Naloxone-Free Formulation of Tiane
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Formulation of Tianeptine is an Extended-Release Tablet that
Read more →TNXPTonix Pharmaceuticals Announces Presentation at the World Orphan Drug Congress USA
CHATHAM, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will present at the World Orphan Drug Congress USA 2022 being held July 11-13, 2022 at the Hy
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0361
TONIX PHARMACEUTICALS HOLDING CORP. 8-K 2022 Tonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0361 July 5, 2022 (Doc 1052) 2 2022 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presen
Read more →TNXPTonix Pharmaceuticals Announces Trial Design of New Phase 2 Clinical Study of TNX-1300 for Cocaine Intoxication New Trial Design is Single-Blind, Placebo-Controlled, Potential Pivotal Study, Pending FDA Agreement Expecte
TONIX PHARMACEUTICALS HOLDING CORP. Tonix Pharmaceuticals Announces Trial Design of New Phase 2 Clinical Study of TNX-1300 for Cocaine Intoxication New Trial Design is Single-Blind, Placebo-Controlled, Potential Pivotal Study, Pending FDA Agreement Expected to Include Women
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0360
Tonix Pharmaceuticals Holding Corp. 8-K 2022 Tonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0360 June 22, 2022 (Doc 1049) 2 2022 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this prese
Read more →TNXPTonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred Stock CHATHAM, N.J.
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Tonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred Stock CHATHAM, N.J., June 22, 2022 - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical co
Read more →TNXPTonix Pharmaceuticals Announces Publication of Paper in Pharmaceutics on the Enhancing Effect That Magnesium Contributes to in vivo Intranasal Oxytocin Analgesia Intranasal Oxytocin with Magnesium Demonstrated Augmented
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Publication of Paper in Pharmaceutics on the Enhancing Effect That Magnesium Contributes to in vivo Intranasal Intranasal Oxytocin with Magnesium Demonstrated Augmented Craniofacial Analgesia in an Animal
Read more →TNXPTonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Programs in Massachusetts
The ADC is Expected to Accelerate Clinical-Scale Manufacturing of Live Virus Vaccines, Including Vaccines for Monkeypox, Smallpox and COVID-19 Internal Manufacturing Capabilities Expected to Support U.S. Pandemic Preparedness CHATHAM, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Ton
Read more →TNXPTonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2022 American Trans
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2022 American Transplant Congress R
Read more →TNXPTonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for Virology
CHATHAM, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Tom Hobman, Ph.D., Professor, Department of Cell Biology, University of Alberta, presented
Read more →TNXPTonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4 th Symposium of the Canadian Society for Virology Poster Presentation Includes Preclinical Data from Tonix's Program t
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Tonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4th Symposium of the Canadian Society for Virology Poster Presentation Includes Preclinical Data from Tonix's Program to Develop a Vacci
Read more →TNXPINVESTOR PRESENTATION NASDAQ: TNXP 2022 Tonix Pharmaceuticals Holding Corp. Version P03 53 June 1 May 9 , 2022 (Doc 10 30 ) Cautionary Note on Forward - Looking Statements 2 2022 Tonix Pharmaceuticals Holding Corp. Certa
TONIX PHARMACEUTICALS HOLDING CORP. 8-K INVESTOR PRESENTATION NASDAQ: TNXP 2022 Tonix Pharmaceuticals Holding Corp. Version P03 53 June 1 May 9 , 2022 (Doc 10 30 ) Cautionary Note on Forward - Looking Statements 2 2022 Tonix Pharmaceuticals Holding Corp. Certain statements in t
Read more →TNXPTonix Pharmaceuticals Announces Presentation at the 2022 BIO International Convention
CHATHAM, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will p
Read more →TNXPTonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-801 Smallpox and Monkeypox Vaccine and Recombinant Pox Virus (RPV) Platform Technology Strengthens Patent Portfolio Protecting Horsepox-Based Live Virus Vac
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-801 Smallpox and Monkeypox Vaccine and Recombinant Pox Virus (RPV) Platform Technology Strengthens Patent Portfolio Protecting Horsepox-Based TNX-1840 and TNX-1850 are Pote
Read more →TNXPTonix Pharmaceuticals Announces Share Repurchase Program CHATHAM, N.J.
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Share Repurchase Program CHATHAM, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announ
Read more →TNXPTonix Pharmaceuticals Announces Two Oral Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) on Prevention of Rejection in Kidney and Heart Allograft Transplantation at the 2022 American Transplant Congress Res
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Two Oral Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) on Prevention of Rejection in Kidney and Heart Allograft Transplantation at the 2022 American Transplant Congress Research Directed b
Read more →TNXPTonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2 Tonix Exercises Option to License Antiviral Technology Platform
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2 Tonix Exercises Option to License Antiviral NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceutica
Read more →TNXPTonix Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights Fibromyalgia Phase 3 Trial of TNX-102 SL Enrollment Initiated; Results from Interim Analysis Expected First Quarter 2023 Long
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights Fibromyalgia Phase 3 Trial of TNX-102 SL Enrollment Initiated; Results from Interim Analysis Expected First Quarter 2023 Long COVID IND Clear
Read more →TNXPTonix Pharmaceuticals to Present at the 2022 Q2 Investor Summit
CHATHAM, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the 2022 Q2 Investor Summit on
Read more →TNXPTonix Pharmaceuticals to Present at B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
CHATHAM, N.J., April 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals, will present at B. Riley Securitie
Read more →TNXPTonix Pharmaceuticals Announces Results of Retrospective Observational Database Study In Over 50,000 Long COVID Patients Over 40% of Long COVID Patients Had Fibromyalgia-Like Multi-Site Pain Symptoms Rate of Opioid Use i
Tonix Pharmaceuticals Tonix Pharmaceuticals Announces Results of Retrospective Observational Database Study In Over 50,000 Long COVID Patients Over 40% of Long COVID Patients Had Fibromyalgia-Like Multi-Site Pain Symptoms Rate of Opioid Use in Long COVID Patients with Multi
Read more →TNXPTonix Pharmaceuticals to Participate in the NobleCon18 Investor Conference
CHATHAM, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals, will present and conduct investor
Read more →TNXPTonix Pharmaceuticals Initiates Enrollment in the RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia Results from Planned Interim Analysis Expected First Quarter 2023 A
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Initiates Enrollment in the RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia Results from Planned Interim Analysis Expected First A Positive Outcome in RESILIENT
Read more →TNXPTonix Pharmaceuticals Announces IND Clearance for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC) Phase 2 Clinical Trial of TNX-102 SL for the Treatment o
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces IND Clearance for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC) Phase 2 Clinical Trial of TNX-102 SL for the Treatment of Long COVID Exp
Read more →TNXPTonix Pharmaceuticals Announces Extension of Sponsored Research Agreement with Kansas State University to Develop Live-Virus Vaccine Against COVID-19 TNX-2300, a Live Virus Vaccine Based on a Bovine Parainfluenza Virus V
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Extension of Sponsored Research Agreement with Kansas State University to Develop Live-Virus Vaccine Against COVID-19 TNX-2300, a Live Virus Vaccine Based on a Bovine Parainfluenza Virus Vector, in Develo
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0345
Tonix Pharmaceuticals Holding Corp. 8-K 2022 Tonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0345 March 28, 2022 (Doc 0984) 2 2022 Tonix Pharmaceuticals Holding Corp. CAUTIONARY NOTE ON FORWARD - LOOKING STATEMENTS Certain statements in this pres
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0343
Tonix Pharmaceuticals Holding Corp. 8-K 2022 Tonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0343 March 22, 2022 (Doc 0979) 2 2022 Tonix Pharmaceuticals Holding Corp. CAUTIONARY NOTE ON FORWARD - LOOKING STATEMENTS Certain statements in this pres
Read more →TNXPTonix Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
CHATHAM, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals, has been invited to present at the
Read more →TNXPTonix Pharmaceuticals Announces Phase 3 RALLY Study Results for TNX-102 SL 5.6 mg for the Management of Fibromyalgia As Expected Based on Interim Analysis Results Reported in July 2021, TNX-102 SL Did Not Achieve Statist
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Phase 3 RALLY Study Results for TNX-102 SL 5.6 mg for the Management of Fibromyalgia As Expected Based on Interim Analysis Results Reported in July 2021, TNX-102 SL Did Not Achieve Statistical Significanc
Read more →TNXPTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights Immunology and CNS Programs Entering the Clinic in 2022 for Organ Transplantation, Cocaine Intoxication, Fibrom
Tonix Pharmaceuticals 8-K Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights Immunology and CNS Programs Entering the Clinic in 2022 for Organ Transplantation, Cocaine Intoxication, Fibromyalgia, PTSD, Migraine Headach
Read more →TNXPTonix Pharmaceuticals Announces Appointment of Jeffrey Rosenfeld, Ph.D., as Executive Director, Genomics and Bioinformatics CHATHAM, N.J.
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Appointment of Jeffrey Rosenfeld, Ph.D., as Executive Director, Genomics and Bioinformatics CHATHAM, N.J., March 9, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or th
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0338
Tonix Pharmaceuticals Holding Corp. 8-K 2022 Tonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0338 March 8, 2022 (Doc 0963) 2 2022 Tonix Pharmaceuticals Holding Corp. CAUTIONARY NOTE ON FORWARD - LOOKING STATEMENTS Certain statements in this prese
Read more →TNXPTonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Evaluate TNX-1900 (Intranasal Potentiated Oxytocin) for Treating Binge Eating Disorder An Investigator Initiated Phase 2 Clinical Trial
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Evaluate TNX-1900 (Intranasal Potentiated Oxytocin) for Treating Binge Eating Disorder An Investigator Initiated Phase 2 Clinical Trial of TNX-1900 In
Read more →TNXPTonix Pharmaceuticals Announces FDA Orphan-Drug Designation for TNX-2900 for the Treatment of Prader-Willi Syndrome CHATHAM, N.J.
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces FDA Orphan-Drug Designation for TNX-2900 for the Treatment of Prader-Willi Syndrome N.J., March 3, 2022 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-sta
Read more →TNXPTonix Pharmaceuticals Announces Research Agreement with the French National Institute of Health and Medical Research (Inserm) to Study the Mechanism of Oxytocin-Mediated Improvement of Eating Behaviors in Prader-Willi Mi
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces Research Agreement with the French National Institute of Health and Medical Research (Inserm) to Study the Mechanism of Oxytocin-Mediated Improvement of Eating Behaviors in Prader-Willi Mice is Developing TNX-29
Read more →TNXPTonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic Skin Test to Measure Functional T Cell Immunity to SARS-CoV-2 Potential Uses Include: Biomarker of Immunity to SARS-CoV-2; Personaliz
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic Skin Test to Measure Functional T Cell Immunity to SARS-CoV-2 Potential Uses Include: Biomarker of Immunity to SARS-CoV-2; Personalized Approach to T
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0335
TONIX PHARMACEUTICALS HOLDING CORP. 8-K 2022 Tonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0335 January 11, 2022 (Doc 0953) 2 2022 Tonix Pharmaceuticals Holding Corp. CAUTIONARY NOTE ON FORWARD - LOOKING STATEMENTS Certain statements in this pr
Read more →TNXPTonix Pharmaceuticals to Participate in Upcoming January Conferences
CHATHAM, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will p
Read more →TNXPTonix Pharmaceuticals Announces Exclusive Option and Research Collaboration with Kansas State University to Develop LNP-Free mRNA Vaccines New Zinc Nanoparticle (ZNP) Technology Replaces the Lipid Nanoparticle (LNP) Tech
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Exclusive Option and Research Collaboration with Kansas State University to Develop LNP-Free mRNA Vaccines Nanoparticle (ZNP) Technology Replaces the Lipid Nanoparticle (LNP) Technology Employed in Current
Read more →TNXPTonix Pharmaceuticals Added to the Nasdaq Biotechnology Index CHATHAM, N.J.
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Added to the Nasdaq Biotechnology Index CHATHAM, N.J., December 15, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today ann
Read more →TNXPTonix Pharmaceuticals Announces IND Clearance for Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity First-in-Human Study Expected to be Initiated in the First Quarter of 2022 An Approved Test Would
Tonix Pharmaceuticals Holding Corp. Form 8-K Tonix Pharmaceuticals Announces IND Clearance for Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity First-in-Human Study Expected to be Initiated in the First Quarter of 2022 An Approved Test Would Lead to Id
Read more →TNXPTonix Pharmaceuticals Announces Research Collaboration with Columbia University to Study Recombinant Trefoil Factor 2 (rTFF2)-Based Therapy (TNX-1700) for Gastric and Colorectal Cancers TNX-1700 is Under Development as M
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Research Collaboration with Columbia University to Study Recombinant Trefoil Factor 2 (rTFF2)-Based Therapy (TNX-1700) for Gastric and Colorectal Cancers TNX-1700 is Under Development as Monotherapy and
Read more →TNXPTonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic Migraineurs Approximately Four Million in U.S. Suffer from Chroni
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic Migraineurs Million in U.S. Suffer from Chronic Migraine Development of TNX-1900
Read more →TNXPTonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight Early Studies in vitro Show that TNX-3500 is a Potent Antiviral Against Multiple Variants of SARS-CoV-2, th
Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight Studies in vitro Show that TNX-3500 is a Potent Antiviral Against Multiple Variants of SARS-CoV-2, the Cause of COVID-19, and Potentiates
Read more →TNXPTonix Pharmaceuticals Announces Issuance of U.S. Patent for Use of TNX-1700, a Stabilized Recombinant Form of Trefoil Factor 2 (TFF2), for Treating Gastric and Pancreatic Cancers CHATHAM, N.J.
Tonix Pharmaceutcials Holding Corp. 8-K Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Use of TNX-1700, a Stabilized Recombinant Form of Trefoil Factor 2 (TFF2), for Treating Gastric and Pancreatic Cancers N.J., November 15, 2021 (GLOBE NEWSWIRE) - Tonix Pharmac
Read more →TNXPTonix Pharmaceuticals to Present at the Q4 Investor Summit
CHATHAM, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will p
Read more →TNXPTonix Pharmaceuticals Presents Phase 1 Formulation Development Data for TNX-601 CR in a Poster Presentation at CNS Summit 2021
CHATHAM, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced a poster presentation of results from its open-label, Phase 1 clinical study of TNX-601 CR (tian
Read more →TNXPTNX - 601 CR*: a Once - Daily Formulation of Tianeptine in Development for the Treatment of Major Depressive Disorder Gregory M Sullivan 1 , David T Hsu 1 , Ashild Peters 1 , Perry Peters 1 , Siobhan Fogarty 1 , Regina K
Tonix Pharmaceuticals Holding Corp. 8-K TNX - 601 CR*: a Once - Daily Formulation of Tianeptine in Development for the Treatment of Major Depressive Disorder Gregory M Sullivan 1 , David T Hsu 1 , Ashild Peters 1 , Perry Peters 1 , Siobhan Fogarty 1 , Regina Kiu 1 , Bernd Meiboh
Read more →TNXPTonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the American College of Rheumatology Convergence 2021
CHATHAM, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an oral presentation of positive results from its Phase 3 clinical study, RELIEF, of TNX-102 SL
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights Expansion of Internal Research and Development Capabilities Underway to Accelerate Infectious Disease Programs and Prepare for
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights Expansion of Internal Research and Development Capabilities Underway to Accelerate Infectious Disease Programs and Prepare for Future Pandemic
Read more →TNXPTonix Pharmaceuticals to Participate in BIO-Europe Digital 2021
CHATHAM, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company
Read more →TNXPTonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Infectious Disease R&D Center in Maryland Internal R&D Capabilities Expected to Support U.S. Pandemic Preparedness with Accelerated Discovery and Developmen
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Infectious Disease R&D Center in Maryland R&D Capabilities Expected to Support U.S. Pandemic Preparedness with Accelerated Discovery and Development of Vaccines and Antivirals Aga
Read more →TNXPTonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0326
Tonix Pharmaceuticals Holding Corp. 8-K 2021 Tonix Pharmaceuticals Holding Corp. INVESTOR PRESENTATION NASDAQ: TNXP Version P0326 October 12, 2021 (Doc 0914) 2 2021 Tonix Pharmaceuticals Holding Corp. CAUTIONARY NOTE ON FORWARD - LOOKING STATEMENTS Certain statements in this pr
Read more →TNXPTonix Pharmaceuticals Announces Completion of Acquisition of Infectious Disease R&D Center in Frederick, Maryland R&D Center is Expected to Accelerate Internal Discovery and Development of Vaccines and Antiviral Drugs Ag
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces Completion of Acquisition of Infectious Disease R&D Center in Frederick, Maryland Center is Expected to Accelerate Internal Discovery and Development of Vaccines and Antiviral Drugs Against COVID-19, Other Infec
Read more →TNXPTonix Pharmaceuticals Announces Oral Presentation at the American College of Rheumatology Convergence 2021
CHATHAM, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announces the acceptance and details of an oral presentation at the American College of Rheumatology (ACR) Conv
Read more →TNXPTonix Pharmaceuticals Expands Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics Collaboration Will Continue to Work Towards Identifying Biomarkers for Protective Immun
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Expands Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics Collaboration Will Continue to Work Towards Identifying Biomarkers for Protective Immunity Against SARS
Read more →TNXPTonix Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
CHATHAM, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the 2
Read more →TNXPTonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-19 TNX-1800 is a Live Virus Vaccine Designed to Elicit Durable T-cell Immunity TNX-1800 is a Modifi
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-19 TNX-1800 is a Live Virus Vaccine Designed to Elicit Durable T-cell Immunity TNX-1800 is a Modified Version of D
Read more →TNXPTonix Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
CHATHAM, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the H
Read more →TNXPTonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC) Company Plans to Submit an IND to
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC) Company Plans to Submit an IND to Support a Phase
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights Central Nervous System Pipeline Progressing with Two Phase 2 Studies (TNX-1300 and TNX-1900) and One Phase 3 Study (TNX-102 S
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights Nervous System Pipeline Progressing with Two Phase 2 Studies (TNX-1300 and TNX-1900) and One Phase 3 Study (TNX-102 SL) Expected to Start Pip
Read more →TNXPTonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine Programs
CHATHAM, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a groundbreaking ceremony at the Company’s planned 45,000 square foot clinical scal
Read more →TNXPTonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral Drugs R&D Facility in Frederick, MD is Expected to Provide Internal Capacity to Dis
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral Drugs R&D Facility in Frederick, MD is Expected to Provide Internal Capacity to Discover and Develo
Read more →TNXPTonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia RALLY Study Will Stop Enrolling New Participants Following Recommendation from an Interi
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia Study Will Stop Enrolling New Participants Following Recommendation from an Interim Analysis Indicating Inadequa
Read more →TNXPTonix Pharmaceuticals Announces New Board Member, Carolyn E. Taylor.
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Announces New Board Member, Carolyn E. Taylor. YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), a clinical-stage biopharmaceutical company, today announced the appointmen
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 June 2021 Version P0306 6 - 28 - 2021 (Doc 0854) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain
Tonix Pharmaceuticals Holding Corp. 8-K 2021 Tonix Pharmaceuticals Holding Corp. 1 June 2021 Version P0306 6 - 28 - 2021 (Doc 0854) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in
Read more →TNXPTonix Pharmaceuticals Added to Russell 2000 and Russell 3000 Indexes
CHATHAM, N.J., June 28, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Tonix was added to the broad-market Russell 3000® index and the small-cap Russell 2000® Ind
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 June 2021 Version P0304 6 - 22 - 2021 (Doc 0852) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain
Tonix Pharmaceuticals Holding Corp. 8-K 2021 Tonix Pharmaceuticals Holding Corp. 1 June 2021 Version P0304 6 - 22 - 2021 (Doc 0852) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in
Read more →TNXPTonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC) Long COVID Symptoms of Pain, Sleep Disturbance, Fatigue and Bra
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC) Long COVID Symptoms of Pain, Sleep Disturbance, Fatigue and Brain Fog Overlap w
Read more →TNXPTonix Pharmaceuticals to Present at Raymond James Human Health Innovation Conference
CHATHAM, N.J., June 16, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the Ra
Read more →TNXPTonix Pharmaceuticals to Participate in BIO Digital Conference
CHATHAM, N.J., June 10, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in th
Read more →TNXPRESULTS DISCUSSION & CONCLUSIONS Figures 6 & 7: MCFB in PROMIS Sleep Disturbance and PROMIS Fatigue Figures 4 & 5: MCFB in FIQ - R Symptom Domain and FIQ - R Function Domain Figure 2: Mean Change from Baseline in Weekly
Tonix Pharmaceuticals Holding Corp. 8-K RESULTS DISCUSSION & CONCLUSIONS Figures 6 & 7: MCFB in PROMIS Sleep Disturbance and PROMIS Fatigue Figures 4 & 5: MCFB in FIQ - R Symptom Domain and FIQ - R Function Domain Figure 2: Mean Change from Baseline in Weekly Averages of Daily N
Read more →TNXPTonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
CHATHAM, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the poster presentation of positive results from its Phase 3 clinical study, RELIEF, of TNX-102
Read more →TNXPTonix Pharmaceuticals Announces Presentation of Two Posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
CHATHAM, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced that it will present two posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annu
Read more →TNXPTonix Pharmaceuticals to Present at May Investor Summit Virtual Conference
CHATHAM, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will pre
Read more →TNXPTonix Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights Announced Positive Efficacy Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800 Interim Analysis of Second Confir
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights Positive Efficacy Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800 Analysis of Second Confirmatory Phase 3 Study in Fibromyalgia in
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 May 2021 Version P0293 5 - 3 - 2021 (Doc 0829) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain st
Tonix Pharmaceuticals Holding Corp. 8-K 2021 Tonix Pharmaceuticals Holding Corp. 1 May 2021 Version P0293 5 - 3 - 2021 (Doc 0829) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in t
Read more →TNXPTonix Pharmaceuticals to Participate in Fourth Annual Neuroscience Innovation Forum
CHATHAM, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, was invited to deliver
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 April 2021 Version P0289 4 - 19 - 2021 (Doc 0822) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain
Tonix Pharmaceuticals Holding Corp. 8-K 2021 Tonix Pharmaceuticals Holding Corp. 1 April 2021 Version P0289 4 - 19 - 2021 (Doc 0822) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements i
Read more →TNXPTonix Pharmaceuticals Enters into Exclusive Worldwide Licensing Agreement with OyaGen to Develop Antiviral SARS-CoV-2 Inhibitor, TNX-3500, for the Treatment of COVID-19 Early Studies Show TNX-3500 Significantly Inhibits
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Enters into Exclusive Worldwide Licensing Agreement with OyaGen to Develop Antiviral SARS-CoV-2 Inhibitor, TNX-3500, for the Treatment of COVID-19 Early Studies Show TNX-3500 Significantly SARS-CoV-2, the Cause of
Read more →TNXPTonix Pharmaceuticals to Present at Needham Virtual Healthcare Conference
CHATHAM, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will p
Read more →TNXPTonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder Company Expects to Initiate a Phase 2 Clinical Trial in the Fourth Quarter of 2021, Pending
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder Company Expects to Initiate a Phase in the Fourth Quarter of 2021, Pending Results of Toxicology Studies
Read more →TNXPTonix Pharmaceuticals Announces Issuance of U.S. Patent for Compositions and Uses of Tianeptine Oxalate Salt, the Active Ingredient of TNX-601
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Compositions and Uses of Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 CR CHATHAM, N.J., March 19, 2021 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasd
Read more →TNXPTonix Pharmaceuticals Reports Positive COVID-19 Vaccine Efficacy Results in Non-Human Primates Vaccinated with TNX-1800 and Challenged with Live SARS-CoV-2 Vaccine Candidate TNX-1800 Protected Both Upper and Lower Airway
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Reports Positive COVID-19 Vaccine Efficacy Results in Non-Human Primates Vaccinated with TNX-1800 and Challenged with Live SARS-CoV-2 Vaccine Candidate TNX-1800 Protected Both Upper and Lower Airways After Challeng
Read more →TNXPTonix Pharmaceuticals Achieves 50 Percent Enrollment in RALLY, the Second Phase 3 Study of TNX-102 SL for Management of Fibromyalgia
Enrollment Continues in Phase 3 RALLY Study, with Interim Analysis of the First 50 Percent of Participants Expected Third Quarter 2021 Topline Results of Approximately 670 Participants in RALLY Expected Fourth Quarter 2021 Positive Topline Results from RELIEF, the First Phase 3
Read more →TNXPTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Announced Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia Interim Analysis Results
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia Analysis Results from Second Confirmatory Phase 3 Study, R
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 March 2021 Version P0280 3 - 11 - 2021 (Doc 0796) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain
Tonix Pharmaceuticals Holding Corp. 8-K 2021 Tonix Pharmaceuticals Holding Corp. 1 March 2021 Version P0280 3 - 11 - 2021 (Doc 0796) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements i
Read more →TNXPTonix Pharmaceuticals to Participate in Upcoming March Investor Conferences
CHATHAM, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in th
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 March 2021 Version P0276 3 - 3 - 2021 (Doc 0789) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain
Tonix Pharmaceuticals Holding Corp. 8-K 2021 Tonix Pharmaceuticals Holding Corp. 1 March 2021 Version P0276 3 - 3 - 2021 (Doc 0789) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 February 2021 Version P0274 2 - 19 - 2021 (Doc 0787) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Cert
Tonix Pharmaceuticals Holding Corp. 8-K 2021 Tonix Pharmaceuticals Holding Corp. 1 February 2021 Version P0274 2 - 19 - 2021 (Doc 0787) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statement
Read more →TNXPTonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm) Expands Proprietary Uses of Tonix's
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research Expands Proprietary Uses of Tonix's Potentiated Oxytocin for
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 February 2021 Version P0271 2 - 09 - 2021 (Doc 0774) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Cert
Tonix Pharmaceuticals Holding Corp. 8-K 2021 Tonix Pharmaceuticals Holding Corp. 1 February 2021 Version P0271 2 - 09 - 2021 (Doc 0774) Investor Presentation NASDAQ:TNXP 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statement
Read more →TNXPTonix Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
CHATHAM, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in th
Read more →TNXPTonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules
CHATHAM, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market, w
Read more →TNXPTONIX PHARMACEUTICALS HOLDINGS CORP. PRICES $70M COMMON STOCK OFFERING PRICED AT-THE-MARKET
PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDINGS CORP. PRICES $70M COMMON STOCK OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES CHATHAM, NJ, February 8, 2021 - TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) ("Tonix" or the "Company"), a clinical-stage bi
Read more →TNXPTonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity Pre-IND Meeting Written Response from FDA Provides Guidance on Product Development and Clinical Testing Pr
PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure Exposure and T Cell Immunity Meeting Written Response from FDA Provides Guidance on Product Development and Test is Designed to Measure SARS-CoV-2 Specific Delayed Type Hyper
Read more →TNXPTonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditio
PHARMACEUTICALS HOLDING CORP. 8-K Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions GMP Production of T
Read more →TNXPTonix Pharmaceuticals Holdings Corp. Closes $40M Common Stock Offering Priced At-the-Market Under Nasdaq Rules
CHATHAM, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market, w
Read more →TNXPTONIX PHARMACEUTICALS HOLDINGS CORP. PRICES $40M COMMON STOCK OFFERING PRICED AT-THE-MARKET
TONIX PHARMACEUTICALS HOLDING CORP. 8-K PHARMACEUTICALS HOLDINGS CORP. PRICES $40M COMMON STOCK OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES NJ, January 11, 2021 - TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) ("Tonix" or the "Company"), a clinical-stage biopharmaceu
Read more →TNXPTonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix's Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Tran
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix's Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection
Read more →TNXPTonix Pharmaceuticals Plans Commercial Scale Vaccine Manufacturing Facility Hamilton, MT Facility Is Planned to Manufacture Vaccines at Commercial Scale, Including Vaccines Under Development for COVID-19 CHATHAM, N.J.
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Plans Commercial Scale Vaccine Manufacturing Facility Hamilton, MT Facility Is Planned to Manufacture Vaccines at Commercial Scale, Including Vaccines Under Development for COVID-19 CHATHAM, N.J., December 23, 202
Read more →TNXPTonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxyt
Read more →TNXPTonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans
Primary Endpoint For Full Cohort of Enrolled Participants Did Not Achieve Statistical Significance (P=0.343), Consistent with Previously Reported Interim Analysis Encouraging Activity of TNX-102 SL Observed in Secondary Endpoints: Clinical Global Impression – Severity (P=0.024),
Read more →TNXPCONFIDENTIAL - NOT FOR DISTRIBUTION Tonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans Primary Endpoint For Full Cohort of Enrolled Parti
TONIX PHARMACEUTICALS HOLDING CORP. 8-K - NOT FOR DISTRIBUTION Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans Endpoint For Full Cohort of Enrolled Participants Did Not Achieve Statistical Signific
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 December 2020 Version P0264 12 - 14 - 2020 (Doc 0747) Investor Presentation NASDAQ:TNXP 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Cer
TONIX PHARMACEUTICALS HOLDING CORP. 8-K 2020 Tonix Pharmaceuticals Holding Corp. 1 December 2020 Version P0264 12 - 14 - 2020 (Doc 0747) Investor Presentation NASDAQ:TNXP 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statemen
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 December 2020 Version P0261 12 - 8 - 2020 (Doc 0743) Investor Presentation NASDAQ:TNXP 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Cert
TONIX PHARMACEUTICALS HOLDING CORP. 8-K 2020 Tonix Pharmaceuticals Holding Corp. 1 December 2020 Version P0261 12 - 8 - 2020 (Doc 0743) Investor Presentation NASDAQ:TNXP 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statement
Read more →TNXPTonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia New 5.6 mg Dose Achieved Statistically Significant Pain Reduction Over Placebo at Week 14 (Primary Endpoint, p=0
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia New 5.6 mg Dose Achieved Statistically Significant Pain Reduction Over Placebo at Week 14 (Primary Endpoint, p=0.01) TNX-102
Read more →TNXPVaccine Genome Researchers Report 99.7% Colinear Identity Between a U.S. Civil War Era Smallpox Vaccine and Horsepox Virus Findings Published in the Current Issue of the Journal Genome Biology Horsepox is the Vector for
Tonix Pharmaceuticals Holding Corp. 8-K Vaccine Genome Researchers Report 99.7% Colinear U.S. Civil War Era Smallpox Vaccine and Horsepox Virus Findings Published in the Current Issue of the Journal Genome Biology Horsepox is the Vector for Tonix's Experimental TNX-1800 COV
Read more →TNXPTonix Pharmaceuticals Reports Positive Immune Response Results from COVID-19 Vaccine Candidate TNX-1800, Following Vaccination of Non-Human Primates
Anti-SARS-CoV-2 Neutralizing Antibodies Elicited in All Eight TNX-1800 Vaccinated Animals Skin Reaction or “Take,” a Validated Biomarker of Functional T cell Immunity, Elicited in All Eight TNX-1800 Vaccinated Animals CHATHAM, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharm
Read more →TNXPTonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit
Increasing Placebo Responses in PTSD Drug Trials Raise Questions About Current Methods of Measuring or Analyzing PTSD Symptom Change Over Time The U.S. 21st Century Cures Act Provides Direction on New Statistical Analyses Using Simulations Tonix Plans to Study TNX-102 SL in a N
Read more →TNXPTonix Pharmaceuticals to Participate in Upcoming November Conferences
CHATHAM, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, has been invited to pr
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 November 2020 Version P0253 11 - 10 - 20 (Doc 0726) Investor Presentation NASDAQ:TNXP 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certa
PHARMACEUTICALS HOLDING CORP. 8-K 2020 Tonix Pharmaceuticals Holding Corp. 1 November 2020 Version P0253 11 - 10 - 20 (Doc 0726) Investor Presentation NASDAQ:TNXP 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in th
Read more →TNXPTonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit
CHATHAM, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will b
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected in Fourth Quarter 2020 Phase 1 Safety Study in Huma
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected in Fourth Quarter 2020 1 Safety Study in Humans of TNX-1800 Expected to be Init
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 October 2020 NASDAQ: TNXP Version P0252 (Doc 0725) TNX - 1800: Horsepox - Vector Based Potential COVID - 19 Vaccine 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forw
Tonix Pharmaceuticals Holdings Corp. 8-K 2020 Tonix Pharmaceuticals Holding Corp. 1 October 2020 NASDAQ: TNXP Version P0252 (Doc 0725) TNX - 1800: Horsepox - Vector Based Potential COVID - 19 Vaccine 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Lookin
Read more →TNXPTonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Faciliate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics Study May Lead to Biomarkers
Tonix Pharmaceuticals Holdings Corp. 8-K Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Faciliate Development of Precision Medicine Techniques for COVID-19 Vaccines Study May Lead to Biomarkers for Tailoring COVID-19 Vaccines
Read more →TNXPTonix Pharmaceuticals to Participate in BIO Investor Forum Digital
CHATHAM, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company
Read more →TNXPTonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis
Topline Results of Full Study Expected Fourth Quarter 2020 RELIEF Study Protocol Was Formally Amended Mid-Study to Conform to FDA Guidance During COVID-19 Public Health Emergency Currently Enrolled 503 Participants Represents More than Original Target of 470 Company is Current
Read more →TNXPTonix Pharmaceuticals Completes Purchase of Facility to House Advanced Development Center (ADC) for Vaccine Programs Facility Addresses the Shortage of Vaccine Production Capacity in the U.S. When Fully Operational the A
Tonix Pharmaceuticals Holdings Corp. 8-K Tonix Pharmaceuticals Completes Purchase House Advanced Development Center (ADC) for Vaccine Programs Facility Addresses the Shortage of Vaccine Production Capacity in the U.S. When Fully Operational the ADC Is Expected to be Capabl
Read more →TNXPTonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?
Webinar to be Moderated by Clive Cookson of the Financial Times on September 24, 2020 Panelists Include Representatives from IAVI, Merck and Tonix Pharmaceuticals NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Compa
Read more →TNXPTonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19 Results from COV-LOGIC Study Expected in First Half o
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19 Results from COV-LOGIC Study Expected in First Half of 2021 NEW YORK
Read more →TNXPTonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia
Interim Analysis Results from Ongoing Phase 3 RELIEF Study Expected in September; Topline Results Expected in Fourth Quarter 2020 Positive Outcomes in Both Trials Would Support Submission of NDA in Second Half 2022 NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceutic
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 September 2020 Version P0246 9 - 3 - 20 (Doc 0699) Investor Presentation NASDAQ:TNXP 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certai
Tonix Pharmaceuticals Holding Corp. 8-K 2020 Tonix Pharmaceuticals Holding Corp. 1 September 2020 Version P0246 9 - 3 - 20 (Doc 0699) Investor Presentation NASDAQ:TNXP 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements
Read more →TNXPTonix Pharmaceuticals to Participate in Upcoming September Virtual Investor Conferences
NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, has been invited to present a Company overview during the following Sept
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 August 2020 Version P0244 8 - 17 - 20 (Doc 0695) Investor Presentation NASDAQ:TNXP 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain
Tonix Pharmaceuticals Holding Corp. 8-K 2020 Tonix Pharmaceuticals Holding Corp. 1 August 2020 Version P0244 8 - 17 - 20 (Doc 0695) Investor Presentation NASDAQ:TNXP 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights Preclinical data for TNX-1800, a Vaccine Candidate to Protect Against COVID-19, Expected in Fourth Quarter 2020 Interim Analy
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights data for TNX-1800, a Vaccine Candidate to Protect Against COVID-19, Expected in Fourth Quarter 2020 Analysis Results for Phase 3 RELIEF Trial of TNX
Read more →TNXPTonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder 2020 - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today an
Read more →TNXPTonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement NEW YORK, August 4, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical
Read more →TNXPTonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference
NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1900 (oxytocin solution for intranasal delivery) are posted at the Am
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 August 2020 Version P0239 8 - 3 - 20 (Doc 0679) Investor Presentation NASDAQ:TNXP 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain s
Tonix Pharmaceuticals Holding Corp. 8-K 2020 Tonix Pharmaceuticals Holding Corp. 1 August 2020 Version P0239 8 - 3 - 20 (Doc 0679) Investor Presentation NASDAQ:TNXP 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in
Read more →TNXPTonix Pharmaceuticals to Participate in SNN Network Virtual Investor Conference
NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company presentation during the SNN Network Virtual Inves
Read more →TNXPTonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Virtual Conference
NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1900 (oxytocin solution for intranasal delivery) will be presented in
Read more →TNXPTonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it is rescheduling the date of the Company’s Special Meeting of Stockholders (the “Special Meeti
Read more →TNXPTonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics Dissecting the Immune Response to SARS-CoV-2 in Healthy Recovered or Asymptomatic Vol
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics Dissecting the Immune Response to SARS-CoV-2 in Healthy Recovered or Asymptomatic Volunteers May Lea
Read more →TNXPTONIX PHARMACEUTICALS HOLDING CORP. CLOSES $10.5
Tonix Pharmaceuticals Holding Corp. 8-K PHARMACEUTICALS HOLDING CORP. CLOSES $10.5 MILLION COMMON STOCK REGISTERED DIRECT OFFERING YORK, July 15, 2020 - TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) ("Tonix" or the "Company"), a clinical-stage biopharmaceutical company,
Read more →TNXPTonix Pharmaceuticals Holding Corp. Closes $10.5 Million Common Stock Registered Direct Offering
NEW YORK, July 15, 2020 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, with gross proceeds of approx
Read more →TNXPTonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University to Develop Vaccine Against COVID-19 Research to Develop Live Replicating Vaccine (TNX-2300) to Protect Agains
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University to Develop Vaccine Against COVID-19 Research to Develop Live Replicating Vaccine (TNX-2300) to Protect Against COVID-19 Based
Read more →TNXPTONIX PHARMACEUTICALS HOLDING CORP. PRICES $10,500,000
TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. PRICES $10,500,000 COMMON STOCK OFFERING NEW YORK, July 13, 2020 - TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) ("Tonix" or the "Company"), a clinical-stage biopharmaceutical company, today ann
Read more →TNXPTonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia Target Enrollment Completed Ahead of Schedule Topline Data Expected Fourth Quarter 2020 Results of Interim A
Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia Enrollment Completed Ahead of Schedule Data Expected Fourth Quarter 2020 of Interim Analysis from the First 50 Percent of Participants E
Read more →TNXPTonix Pharmaceuticals Plans Massachusetts R&D Facility to Accelerate Clinical Development of Vaccines and Protein-Based Therapeutics Tonix's Advanced Development Center Will House Laboratories Dedicated to Process and An
Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Plans Massachusetts R&D Facility to Accelerate Development of Vaccines and Protein-Based Therapeutics Advanced Development Center Will House Laboratories Dedicated to Process and Analytical Development YORK, July 7, 2020 (GLOB
Read more →TNXPTonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule Topline Results Expected Fourth Quarter 2020 Due to Faster than Previously Projected En
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule Results Expected Fourth Quarter 2020 Due to Faster than Previously Projected Enrollment of Trial Enrollment An
Read more →TNXPTonix Pharmaceuticals Announces Results from Preclinical Study of TNX-1700 Presented in a Poster at AACR Virtual Annual Meeting 2020
TNX-1700 (Stabilized Recombinant Trefoil Factor 2) (rTFF2-CTP) Enhances Anti-tumor Activity of PD-1 blockade in Mouse Models of Colorectal Cancer NEW YORK, June 22, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-st
Read more →TNXPTonix Pharmaceuticals and Southern Research Announce Expansion of COVID-19 Vaccine Collaboration Plan to Produce Blueprint of How the Human Immune System Responds to Infection Caused by SAR-CoV-2, the Virus that Causes C
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals and Southern Research Announce Expansion of Vaccine Collaboration to Produce Blueprint of How the Human Immune System Responds to Infection Caused by SAR-CoV-2, the Virus that Causes COVID-19 Expected to Support Tonix's
Read more →TNXPTonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020
NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1700 (rTFF2) will be presented in a poster at the American Associatio
Read more →TNXPTonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of License TNX-1900 Intranasal Oxytocin has the Potential to Treat Migraine and Craniofacial
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of License Intranasal Oxytocin has the Potential to Treat Migraine and Craniofacial Pain YORK, June 11, 2020 (GLOBE
Read more →TNXPTonix Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of Directors
Tonix Pharmaceuticals Holdings Corp. 8-K Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of Directors NEW YORK, June 10, 2020 - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today anno
Read more →TNXPTonix Pharmaceuticals to Participate in Two June Virtual Investor Conferences
NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will participate and host one-on-one meetings at two virtual investor conferences in June. Details are as follows: Event
Read more →TNXPTonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800 Collaboration includes Development of Manufacturing Processes and to Supply Clinical T
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800 Collaboration includes Development of Manufacturing Processes and to Supply Clinical Trial Material to
Read more →TNXPTonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology
NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, posted two posters for the American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting to be held onlin
Read more →TNXPTonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine YORK, May 19, 2020 - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage bio
Read more →TNXPTonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights Four Potential Vaccines in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company's Horse
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights Potential Vaccines in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company's Horsepox Virus Vaccine Platform
Read more →TNXPTonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-1
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19 TNX-1810, TNX-
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 April 2020 Version P0229 4 - 24 - 20 (Doc 0625) Investor Presentation 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in
TONIX PHARMACEUTICALS HOLDING CORP. 8-K 2020 Tonix Pharmaceuticals Holding Corp. 1 April 2020 Version P0229 4 - 24 - 20 (Doc 0625) Investor Presentation 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this present
Read more →TNXPTonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia
Enrollment Continues in Phase 3 RELIEF Study, with Interim Results of the First 50 Percent of Participants Expected in September 2020 Topline Results of Approximately 470 Participants with Fibromyalgia Expected in the First Quarter of 2021 NEW YORK, April 24, 2020 (GLOBE NEWSWI
Read more →TNXPTonix Pharmaceuticals to Deliver Virtual Presentation and Participate in Panel Discussion for Planet MicroCap Showcase Virtual Investor Conference 2020
NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be conducting a virtual presentation in conjunction with the Plane
Read more →TNXPTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights Potential Vaccine, TNX-1800 in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on
Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights Vaccine, TNX-1800 in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company's Horsepox Virus Vaccine Platform Vaccine, TNX-801 in Develop
Read more →TNXPTonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit
NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be conducting a virtual presentation in conjunction with the Sprin
Read more →TNXPTonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering
NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, with gross proceeds of $16,0
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 March 2020 Version P0222 2 - 28 - 20 (Doc 0604) Investor Presentation 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in
Tonix Pharmaceuticals Holding Corp. 8-K 2020 Tonix Pharmaceuticals Holding Corp. 1 March 2020 Version P0222 2 - 28 - 20 (Doc 0604) Investor Presentation 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this present
Read more →TNXPTONIX PHARMACEUTICALS, INC. PRICES $16,005,000 COMMON STOCK OFFERING PRICED AT-THE-MARKET NEW YORK, FEBRUARY 28, 2020 - TONIX PHARMACEUTICALS, INC. (NASDAQ: TNXP) ("Tonix" or the "Company "), a clinical-stage biopharmace
Tonix Pharmaceuticals Holding Corp. 8-K TONIX PHARMACEUTICALS, INC. PRICES $16,005,000 COMMON STOCK OFFERING PRICED AT-THE-MARKET NEW YORK, FEBRUARY 28, 2020 - TONIX PHARMACEUTICALS, INC. (NASDAQ: TNXP) ("Tonix" or the "Company"), a clinical-stage biopharmaceutical company, tod
Read more →TNXPTonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 ( COVID-19 ) Based on Horsepox Virus (TNX-1800)
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800) YORK, February 26, 2020 (GLOBE NEWSWIRE)
Read more →TNXPTonix Pharmaceuticals Announces Closing of $7.5 million Public Offering
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Announces Closing of $7.5 million Public Offering YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced to
Read more →TNXPTonix Pharmaceuticals Prices $7.5 million Public Offering
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Prices $7.5 million Public Offering YORK, February 7, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pri
Read more →TNXPTonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya (TNX-102 SL) in PTSD
RECOVERY Study has Stopped Enrollment Due to Inadequate Separation from Placebo at Week-12 Based on Interim Analysis Results of the First 50% of Enrolled Participants Company Plans to Unblind and Report Top Line Results in the Second Quarter After Currently Enrolled Study Partic
Read more →TNXPTonix Pharmaceuticals to Participate in Upcoming February Investor Conferences
NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will participate in three upcoming investor conferences. Details of the Tonix presentations and webcasts are as follows:
Read more →TNXPTonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, presented preclinical results of TNX-801 (live virus vaccine for percutaneous administration) to potentially prevent
Read more →TNXPSynthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox* Ryan Noyce 1 , Landon Westfall 2 , Siobhan Fogarty 3 , Karen Gilbert 2 , Onesmo Mpanju 4 , Helen Stillwell 3 , Jose Esparza 5 , Fus
Tonix Pharmaceuticals Holding Corp. 8-K Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox* Ryan Noyce 1 , Landon Westfall 2 , Siobhan Fogarty 3 , Karen Gilbert 2 , Onesmo Mpanju 4 , Helen Stillwell 3 , Jose Esparza 5 , Fusataka Koide 2 , Dav
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 February 2020 Version P0220 2 - 5 - 20 (Doc 0593) Investor Presentation 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements
TONIX PHARMACEUTICALS HOLDING CORP. 8-K 2020 Tonix Pharmaceuticals Holding Corp. 1 February 2020 Version P0220 2 - 5 - 20 (Doc 0593) Investor Presentation 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this prese
Read more →TNXPTonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL Tonix Expects the Data to Satisfy Pharmacokinetic Requirements for Potential New Drug Applications for T
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL Expects the Data to Satisfy Pharmacokinetic Requirements for Potential New Drug Applications for TNX-102 SL for PTSD and Fibromy
Read more →TNXPTonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference
Tonix Pharmaceuticals Holding Corp 8-K Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference NEW YORK, January 23, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceu
Read more →TNXPTonix Pharmaceuticals Holding Corp. 1 Biotech Showcase 2020 Version P0217 1 - 13 - 20 (Doc 0584) Investor Presentation 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain st
TONIX PHARMACEUTICALS HOLDING CORP. 8-K 2020 Tonix Pharmaceuticals Holding Corp. 1 Biotech Showcase 2020 Version P0217 1 - 13 - 20 (Doc 0584) Investor Presentation 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in t
Read more →TNXPTonix Pharmaceuticals to Present at Biotech Showcase 2020
NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and conduct investor meetings at Biotech Showcase 2020 bein
Read more →TNXPTonix Pharmaceuticals Holding Corp. January 2020 Version P0215 1 - 6 - 20 (Doc 0580) Investor Presentation 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in
TONIX PHARMACEUTICALS HOLDING CORP. 8-K 2020 Tonix Pharmaceuticals Holding Corp. January 2020 Version P0215 1 - 6 - 20 (Doc 0580) Investor Presentation 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presenta
Read more →TNXPTonix Pharmaceuticals Holding Corp. December 2019 Version P0213 12 - 17 - 19 (Doc 0577) Investor Presentation 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements
TONIX PHARMACEUTICALS HOLDING CORP. 8-K 2019 Tonix Pharmaceuticals Holding Corp. December 2019 Version P0213 12 - 17 - 19 (Doc 0577) Investor Presentation 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this prese
Read more →TNXPTonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study TNX-601 CR Activ
PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition Successful Completion of Phase 1 Pharmacokinetic Study CR Active Ingredient, Tianeptine, is Approved and Marketed
Read more →TNXPTonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Announces New European Patent for the and Formulation of TNX-102 SL YORK, December 11, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutica
Read more →TNXPTonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia Interim Analysis Results Expected Second Half 2020 Topline Results Expected First Half 2021 Based on th
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia Interim Analysis Results Expected Second Topline Results Expected First Half 2021 Based on the Currently-Planned Sampl
Read more →TNXPTonix Pharmaceuticals to Present at 12th Annual LD Micro Main Event
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at the 12th Annual LD Micro Main Event being held December 10-12, 2019, in Bel-Air, Calif. Details of the To
Read more →TNXPTonix Pharmaceuticals Holding Corp. November 2019 Version P0206 11 - 26 - 19 (Doc 0560) Investor Presentation 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements
Tonix Pharmaceuticals Holding Corp. 8-K 2019 Tonix Pharmaceuticals Holding Corp. November 2019 Version P0206 11 - 26 - 19 (Doc 0560) Investor Presentation 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this prese
Read more →TNXPTonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya as a Potential New Treatment for PTSD
Minutes are Consistent with Guidance Received at FDA Meeting More Than 50 Percent of Enrollment Completed for Phase 3 RECOVERY Trial of Tonmya for PTSD Results from RECOVERY Interim Analysis Expected First Quarter 2020 Topline Data from RECOVERY Expected Second Quarter 2020, B
Read more →TNXPTonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be conducting investor meetings at Benchmark’s 8th Annual Discovery
Read more →TNXPTonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that, having successfully closed an underwritten public equity offering for $9.0 million, it has init
Read more →TNXPTonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering NEW YORK, November 20, 2019 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), clinical-stage biopharmaceutical company,
Read more →TNXPTonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder FDA Official Meeting Minutes Support Tonix's Plan to file an Investigational New Drug (IND) Applica
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder Official Meeting Minutes Support Tonix's Plan to file an Investigational New Drug (IND) Application in the First Quarter o
Read more →TNXPTonix Pharmaceuticals Prices $9.0 million Public Offering
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Prices $9.0 million Public Offering YORK, November 15, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pr
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights 50% of Enrollment Complete for Phase 3 RECOVERY Trial of Tonmya for the Treatment of PTSD Results from RECOVERY Interim Analys
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights of Enrollment Complete for Phase 3 RECOVERY Trial of Tonmya for the Treatment of PTSD from RECOVERY Interim Analysis Expected First Quarter 2020 Dat
Read more →TNXPTonix Pharmaceuticals Holding Corp. November 2019 Version P0203 11 - 4 - 19 (Doc 0549) Investor Presentation 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements i
Tonix Pharmaceuticals Holding Corp. 8-K 2019 Tonix Pharmaceuticals Holding Corp. November 2019 Version P0203 11 - 4 - 19 (Doc 0549) Investor Presentation 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presen
Read more →TNXPTonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya for PTSD, Following FDA Meeting Primary Endpoint Will be Mean
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya for PTSD, Following FDA Meeting Primary Endpoint Will be Mean Change from Ba
Read more →TNXPTonix Pharmaceuticals Holding Corp. - Confidential - Do not duplicate or distribute 1
Tonix Pharmaceuticals Holding Corp. 8-K 2019 Tonix Pharmaceuticals Holding Corp. - Confidential - Do not duplicate or distribute 1 November 1, 2019 Investor Presentation Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333 - 234263 2 2019 Tonix Pharmac
Read more →TNXPTonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces 1-for-10 NEW YORK, October 31, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will e
Read more →TNXPTonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Issuance Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 NEW YORK, October 23, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a c
Read more →TNXPTonix Pharmaceuticals Holding Corp. October 2019 Version P0201 10 - 16 - 19 (Doc 0544) Investor Presentation 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements i
Tonix Pharmaceuticals Holding Corp. 8-K 2019 Tonix Pharmaceuticals Holding Corp. October 2019 Version P0201 10 - 16 - 19 (Doc 0544) Investor Presentation 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presen
Read more →TNXPTonix Pharmaceuticals Joins the Alliance for Biosecurity
NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has joined the Alliance for Biosecurity (the Alliance). The Alliance is a coalition of biopha
Read more →TNXPTonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD Patent Expected to
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD Patent Expected to Provide Intellec
Read more →TNXPTonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg Company Expects this Long-Term Safety Exposure Data to Satisfy Long-Ter
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg Company Expects this Long-Term Safety Exposure Data to Satisfy Long-Term Exposure Requi
Read more →TNXPTonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers First-in-C
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers First-in-Class Biologic fo
Read more →TNXPTonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology NEW YORK, September 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (N
Read more →TNXPTonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans’ Research and Education Foundations (NAVREF) Conference
NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will speak at the 2019 annual National Association of Veterans’ Resear
Read more →TNXPTonix Pharmaceuticals to Present at Upcoming September Investor Conferences
NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at three upcoming investor conferences. Details of the Tonix Pharmaceuticals presentations and webcasts are
Read more →TNXPTonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder YORK, September 4, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Read more →TNXPTonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix's Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplan
Pharmaceuticals Holding Corp. 8-K Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix's Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection YORK, August 21
Read more →TNXPTonix Pharmaceuticals Holding Corp. August 2019 Version P0193 8 - 21 - 19 (Doc 0521) Investor Presentation 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in
Tonix Pharmaceuticals Holding Corp. 8-K 2019 Tonix Pharmaceuticals Holding Corp. August 2019 Version P0193 8 - 21 - 19 (Doc 0521) Investor Presentation 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presenta
Read more →TNXPTonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD NEW YORK, August 20, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company),
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights Enrollment Continues for Phase 3 RECOVERY Trial of Tonmya for the Treatment of PTSD; Topline Data Expected First Half of 2020
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights Continues for Phase 3 RECOVERY Trial of Tonmya for the Treatment of PTSD; Topline Data Expected First Half of Expanded in Addiction Medicine with Co
Read more →TNXPTonix Pharmaceuticals Announces Director Stepping Down
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Tonix Pharmaceuticals Announces Director NEW YORK, August 2, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced that Patrick Grace stepped down from the Company's Board of Directors, effective
Read more →TNXPTonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL NEW YORK, July 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical
Read more →TNXPTonix Pharmaceuticals Announces Closing of Public Offering of Common Stock
NEW YORK, July 18, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the closing of an underwritten public offering of 9,000,000 shares of its common stock at a price to
Read more →TNXPTonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Announces Pricing of Public Offering of Common Stock YORK, July 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today ann
Read more →TNXPTonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL Patent Expected to Provide Intellectual Property Protection until 2034 in China
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL Patent Expected to Provide Intellectual Property Protection until 2034 in China NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Tonix
Read more →TNXPTonix Pharmaceuticals Holding Corp. June 2019 Version P0185 6 - 3 - 19 (Doc 0496) Investor Presentation 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in thi
TONIX PHARMACEUTICALS HOLDING CORP. 8-K 2019 Tonix Pharmaceuticals Holding Corp. June 2019 Version P0185 6 - 3 - 19 (Doc 0496) Investor Presentation 2019 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentatio
Read more →TNXPSteady - State Pharmacokinetic Properties of a Sublingual Formulation of Cyclobenzaprine (CBP) HCl (TNX - 102 SL*): Comparison to Simulations of Oral Immediate Release CBP Gregory Sullivan 1 , Regina Kiu 1 , Helen Stillw
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Steady - State Pharmacokinetic Properties of a Sublingual Formulation of Cyclobenzaprine (CBP) HCl (TNX - 102 SL*): Comparison to Simulations of Oral Immediate Release CBP Gregory Sullivan 1 , Regina Kiu 1 , Helen Stillwell 1 , Bernd Meibo
Read more →TNXPTonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing small molecules and biologics to treat psychiatric, pain and addiction conditions as well as to im
Read more →TNXPTonix Pharmaceuticals to Present at BIO 2019 International Convention
NEW YORK, May 28, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix will present at the BIO 2019 International Convention held June 3-6, 2019,
Read more →TNXPTonix Pharmaceuticals Expands Pipeline with Mid-stage Biologic Candidate TNX-1300 for Cocaine Intoxication Phase 2 Program Granted Breakthrough Therapy Designation by FDA Emergency Room Visits for Cocaine Abuse Total Mor
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Expands Pipeline with Mid-stage Biologic Candidate TNX-1300 Cocaine Intoxication 2 Program Granted Breakthrough Therapy Designation by FDA Room Visits for Cocaine Abuse Total More than 500,000 Annually in U.S. YORK, May
Read more →TNXPTonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will speak at the first annual Second Chance Digital Impact Recipient Ga
Read more →TNXPTonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that it will be presenting pharmacokinetic analyses of TNX-102 SL* in a poster at the American Society of Clinical Psychopharmacology (ASCP) 2019 A
Read more →TNXPTonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights Phase 3 RECOVERY Trial of Tonmya for the Treatment of PTSD is Enrolling; Topline Data Expected First Half of 2020
TONIX PHARMACEUTICALS HOLDING CORP. 8-K Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights Phase 3 RECOVERY Trial of Tonmya for the Treatment of PTSD is Enrolling; Topline Data Expected First Half of 2020 NEW YORK, May 13, 2019 (GLOBE NEWS
Read more →TNXPTonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D.
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA YORK, May 8, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) today announced the appointment of Daniel Goodman, MD, MBA to its Boar
Read more →TNXPTonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA) The Termination Does Not Affect Tonix's Finances o
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA) Termination Does Not Affect Tonix's Finances or the Ongoing RECOVERY Tri
Read more →TNXPTonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya for the Treatment of Posttraumatic Stress Disorder Company Will Meet with FDA in June to Address the "Intent to Rescind"
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya for the Treatment of Posttraumatic Stress Disorder Company Will Meet with FDA in June to Address the "Intent to Rescind" Notice 2019 (GL
Read more →TNXPTonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia Encouraging FDA Meeting Minutes Support Phase 3 Development of TNX-102 SL 5.6 mg in Fibromyalgia
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia FDA Meeting Minutes Support Phase 3 Development of TNX-102 SL 5.6 mg in Fibromyalgia YORK, April 4, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuti
Read more →TNXPTonix Pharmaceuticals to Present at Upcoming Investor Conferences
NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at two upcoming investor conferences. Details of the Tonix Pharmaceuticals presentations and webcasts are a
Read more →TNXPTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights Phase 3 RECOVERY Trial of Tonmya for the Treatment of PTSD Initiated and Enrolling Topline Data Expected First
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operational Highlights 3 RECOVERY Trial of Tonmya for the Treatment of PTSD Initiated and Enrolling Data Expected First Half 2020 YORK, March 18, 2019 (GLOBE NEWSW
Read more →TNXPTonix Pharmaceuticals to Participate at Upcoming Investor Conferences
NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will participate and host investor meetings at the following two investor conferences: Event: 31 st Annual ROTH Confere
Read more →TNXPTonix Pharmaceuticals Enrolls First Participant in the "RECOVERY" Study -- a New Phase 3 Trial of Tonmya for the Treatment of Posttraumatic Stress Disorder Topline Data Expected First Half 2020
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Enrolls First Participant in the "RECOVERY" Study -- a New Phase 3 Trial of Tonmya for the Treatment of Posttraumatic Topline Data Expected First Half 2020 NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Tonix Pharm
Read more →TNXPTonix Pharmaceuticals Announces New European Use Patent for TNX-601
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to
Read more →TNXPTonix Pharmaceuticals Provides Update on Tonmya for the Treatment of Posttraumatic Stress Disorder
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Provides Update on Tonmya for the Treatment of Posttraumatic Stress Disorder YORK, Mar. 1, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceuti
Read more →TNXPTonix Pharmaceuticals Announces Share Repurchase Program
Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Announces Share Repurchase NEW YORK, March 1, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that its Board of Directors has approved a share repur
Read more →TNXPTonix Pharmaceuticals Announces New Board Member, James Treco
Tonix Pharmaceuticals Holding Corp. 8-K Pharmaceuticals Announces New Board Member, James Treco YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced the appointment of James Treco to its Board of Direc
Read more →TNXPTonix Pharmaceuticals to Present at BIO CEO & Investor Conference
NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at the 21st Annual BIO CEO & Investor Co
Read more →TNXPTonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion
NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at two investor conferences in January 2
Read more →TNXPTonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering
NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to
Read more →TNXPTonix Pharmaceuticals Prices $15,000,000 Public Offering
Pharmaceuticals Prices $15,000,000 Public Offering YORK, December 7, 2018 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neur
Read more →TNXPTonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya for PTSD, Following Receipt of FDA Minutes New Phase 3 RECOVERY Trial to Include Approximately 250 Participants Trial to Commence Firs
Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya for PTSD, Following Receipt of FDA Minutes Phase 3 RECOVERY Trial to Include Approximately 250 Participants to Commence First Quarter 2019 With Topline Data Expected First Half 2020 YORK, November
Read more →TNXPTonix Pharmaceuticals Holding Corp. November 2018 Version P0149 11 - 30 - 18 (Doc 0420) Investor Presentation 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements
2018 Tonix Pharmaceuticals Holding Corp. November 2018 Version P0149 11 - 30 - 18 (Doc 0420) Investor Presentation 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expect
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights New Phase 3 Trial of Tonmya for the Treatment of PTSD to Commence First Quarter 2019
Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights Phase 3 Trial of Tonmya for the Treatment of PTSD to Commence First Quarter 2019 YORK, November 9, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the C
Read more →TNXPTonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya
Pharmaceuticals Announces New Patent Coverage Protecting Tonmya YORK, November 7, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,117
Read more →TNXPTonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018
Retrospective Analysis Revealed Clinically Meaningful Response to Tonmya® in Female PTSD Participants Overall and for Non-Combat-Related Traumas Experienced Within Nine Years Prior to Screening Results from Phase 3 P301 HONOR Study Retrospective Analyses Inform Design of a New P
Read more →TNXPTime Since Trauma in PTSD: Phase 3 Multi - Center, Double - Blind, Placebo - Controlled Trial of TNX - 102 SL*, a Sublingual Formulation of Cyclobenzaprine, in Military - Related PTSD (Study TNX - CY - P301) Gregory Sull
Time Since Trauma in PTSD: Phase 3 Multi - Center, Double - Blind, Placebo - Controlled Trial of TNX - 102 SL*, a Sublingual Formulation of Cyclobenzaprine, in Military - Related PTSD (Study TNX - CY - P301) Gregory Sullivan, MD 1 , R Michael Gendreau, MD, PhD 2 , Judy Gendreau,
Read more →TNXPTonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the 24th Annual BIO-Europe International Partnering Conference on Wedne
Read more →TNXPTonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya for PTSD, Following FDA Meeting New Phase 3 Trial of Tonmya for the treatment of PTSD to Commence First Quarter 2019 Primary Endpoint of N
Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya for PTSD, Following FDA Meeting New Phase 3 Trial of Tonmya for the treatment of PTSD to Commence First Quarter 2019 Primary Endpoint of New Study will be Week 4 Change from Baseline in CAPS-5
Read more →TNXPTonix Pharmaceuticals Holding Corp. November 2018 Version P0143 11 - 1 - 18 (Doc 0406) Investor Presentation 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements i
2018 Tonix Pharmaceuticals Holding Corp. November 2018 Version P0143 11 - 1 - 18 (Doc 0406) Investor Presentation 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expect
Read more →TNXPTonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018
NEW YORK, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that it will be presenting findings and retrospective analyses from the Phase 3 HONOR study and Phase 2 AtEase Study in two posters at CNS Summit 2018 being held
Read more →TNXPTonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the Dawson James Securities 4th Annual Small
Read more →TNXPTonix Pharmaceuticals Holding Corp. October 2018 Version P0140 10 - 1 - 18 (Doc 0401) Investor Presentation 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in
2018 Tonix Pharmaceuticals Holding Corp. October 2018 Version P0140 10 - 1 - 18 (Doc 0401) Investor Presentation 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectat
Read more →TNXPTonix Pharmaceuticals to Present at the MicroCap Conference
NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the MicroCap Conference being held October
Read more →TNXPTonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference
NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the Sidoti & Company Fall 2018 Investor Con
Read more →TNXPTonix Pharmaceuticals Holding Corp. September 2018 Version P0137 9 - 10 - 18 (Doc 0395) Investor Presentation 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements
2018 Tonix Pharmaceuticals Holding Corp. September 2018 Version P0137 9 - 10 - 18 (Doc 0395) Investor Presentation 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expect
Read more →TNXPTonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D. NEW YORK, September 7 , 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) today announced the appointment of Adeoye "
Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D. YORK, September 7, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) today announced the appointment of Adeoye "Oye" Olukotun, M.D. to its Board of Directors, effective immediately
Read more →TNXPEffect of Time Since Trauma on Response to TNX 102 SL* (Cyclobenzaprine Sublingual Tablets) in Military Related PTSD: Results of Two Double Blind Randomized Placebo Controlled StudiesGregory Sullivan, MD , R Michael Gend
Effect of Time Since Trauma on Response to TNX 102 SL* (Cyclobenzaprine Sublingual Tablets) in Military Related PTSD: Results of Two Double Blind Randomized Placebo Controlled StudiesGregory Sullivan, MD , R Michael Gendreau, MD, PhD , Judy Gendreau, MD , Ashild Peters, RN , Pe
Read more →TNXPTonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya in Military-Related PTSD at the 2018 Military Health System Research Symposium
Retrospective Analysis of the Discontinued Phase 3 P301 “HONOR” Study Revealed Clinically Meaningful Response to Tonmya in PTSD Participants with Trauma Experienced Within Nine Years Prior to Screening but Not in Participants with Trauma Experienced More Than Nine Years Prior to
Read more →TNXPTonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that it will be presenting findings and retrospective analyses from the Phase 3 HONOR study and Phase 2 AtEase Study in a poster, at the 2018 Military Health Sys
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights HONOR Study Results to be Included in Poster Presentation at a Scientific Conference in August 2018 FDA Meeting in October 20
Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights HONOR Study Results to be Included in Poster Presentation at a Scientific Conference in August 2018 FDA Meeting in October 2018 Confirmed to Discuss New Phase 3 Study for Tonmya in PTSD
Read more →TNXPTonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya in Military-Related PTSD HONOR Study will Stop due to Inadequate Separation from Placebo at Week-12 Results at Week-4 Demonstr
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya in Military-Related PTSD HONOR Study will Stop due to Inadequate Separation from Placebo at Week-12 Results at Week-4 Demonstrated Meaningful Clinical Improvement Company Plans to
Read more →TNXPTonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer's Disease
Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for of Agitation in Alzheimer's Disease NEW YORK, July 16, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), today announced that the U.S. Food and Drug Administ
Read more →TNXPAn AFSP/ASCP Workshop: Inclusion of Suicidal Individuals in Treatment Trials: Now is the Time Wed May 30 th 2:45 - 4:45PM Poinciana 1 - 2 2018 Tonix Pharmaceuticals Holding Corp Including Suicidal Individuals in Treatmen
1 An AFSP/ASCP Workshop: Inclusion of Suicidal Individuals in Treatment Trials: Now is the Time Wed May 30 th 2:45 - 4:45PM Poinciana 1 - 2 2018 Tonix Pharmaceuticals Holding Corp Including Suicidal Individuals in Treatment Trials: Treatment of Military - Related PTSD with TNX -
Read more →TNXPTonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology
NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), presented data from the Phase 2 AtEase study of Tonmya®* (cyclobenzaprine HCl sublingual tablets) for the treatment posttraumatic stress disorder (PTSD). The presentation focused
Read more →TNXPTonix Pharmaceuticals to Present at the 2018 BIO International Convention
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present an overview of the Company, focusing on Tonix’s lead product candidate, Ton
Read more →TNXPTonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya or TNX-102 SL Results from Preliminary PK Analyses Confirm the Applicability of the 505
Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya from Preliminary PK Analyses Confirm the Applicability of the 505(b)(2) Regulatory Pathway for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) New
Read more →TNXPTonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology
NEW YORK, May 23, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix) announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix, will present at the 2018 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being h
Read more →TNXPTonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update Interim Analysis for Phase 3 HONOR study of Tonmya in Military-Related PTSD Expected in Third Quarter of 2018
Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update Interim Analysis for Phase 3 HONOR study of Tonmya in Military-Related PTSD Expected in Third Quarter of 2018 NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Co
Read more →TNXPTonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefens
Read more →TNXPTonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to support the initiation of a Phase 2, potential pivo
Read more →TNXPTonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York
First 50 Percent of Participants Enrolled in Phase 3 HONOR Study of Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of Military-Related PTSD Interim Results of HONOR Study Expected in Third Quarter 2018 NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Tonix Pharm
Read more →TNXPTonix Pharmaceuticals Holding Corp. April 2018 Version P0106 4 - 3 - 18 (Doc 0334) Investor Presentation 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in th
2018 Tonix Pharmaceuticals Holding Corp. April 2018 Version P0106 4 - 3 - 18 (Doc 0334) Investor Presentation 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectation
Read more →TNXPTonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
Phase 3 HONOR Study Enrollment Continues and Interim Results of the First 50 Percent of Participants Expected in Third Quarter 2018 Topline Results of Approximately 550 Participants with Military-Related PTSD Expected in Fourth Quarter 2018 NEW YORK, April 03, 2018 (GLOBE NEWSW
Read more →TNXPTonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL
U.S. Patent Issued Covering the Use of Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for treating Posttraumatic Stress Disorder (PTSD) Patent Will Provide Intellectual Property Protection until at least 2030 for Use of Cyclobenzaprine in the Treatment of PTSD NEW YORK, March
Read more →TNXPTonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that it will present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) being held March 15-17, 2018, in Hangzhou, China.
Read more →TNXPTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update Interim Analysis for Phase 3 HONOR study of Tonmya (Cyclobenzaprine HCl Sublingual Tablets) in Military-Relat
Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update Analysis for Phase 3 HONOR study of Tonmya (Cyclobenzaprine HCl Sublingual Tablets) in Military-Related PTSD Expected in Third Quarter of 2018; Topline Results Expected in
Read more →TNXPTonix Pharmaceuticals to Present at the 30th Annual ROTH Conference
NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense
Read more →TNXPTonix Pharmaceuticals Appoints David L. Grange to the Board of Directors
Pharmaceuticals Appoints David L. Grange to the Board of Directors YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), today announced the appointment of David L. Grange, a retired U.S. Army Brigadier General, to the Board of Direc
Read more →TNXPTonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense t
Read more →TNXPTonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that it will present at Noble Capital Markets’ Fourteenth Annual Investor Conference being held January 29-30, 2018 in Fort Lauderdale. Tonix is in Phase 3 deve
Read more →TNXPTonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya (Cyclobenzaprine HCl Sublingual Tablets) Patent Will Provide Intellectual Property Protection until 2030 for Use
Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya (Cyclobenzaprine HCl Patent Will Provide Intellectual Property Protection until 2030 for Use of Cyclobenzaprine in the Treatment of Posttraumatic Stress Disorder (PTSD) NEW YOR
Read more →TNXPTonix Pharmaceuticals Holding Corp. January 2018 Version P0094 1 - 19 - 18 (Doc 0313) Investor Presentation 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in
2018 Tonix Pharmaceuticals Holding Corp. January 2018 Version P0094 1 - 19 - 18 (Doc 0313) Investor Presentation 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectat
Read more →TNXPTonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus from Cell Culture) Successful Developme
Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus from Cell Culture) Development of TNX-801 May Lead to an Improved Smallpox-Preventing Vaccine YORK, J
Read more →TNXPTonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer
Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer NEW YORK, Jan. 9, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challe
Read more →TNXPTonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in San Francisco
NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challenges, announced today that it will participate in two upcoming confer
Read more →TNXPTonix Pharmaceuticals Holding Corp. December 2017 Version P0089 12 - 12 - 17 (Doc 0303) Investor Presentation 2017 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements
2017 Tonix Pharmaceuticals Holding Corp. December 2017 Version P0089 12 - 12 - 17 (Doc 0303) Investor Presentation 2017 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expect
Read more →TNXPTonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease
NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical and biological products to address public health challenges and diseases with significant unmet needs, announced today th
Read more →TNXPTonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company in Phase 3 development of Tonmya®* (cyclobenzaprine HCI sublingual tablets), or TNX-102 SL, a U.S. Food and Drug Administration-designated Breakthrough Therapy for the
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update Enrolling Phase 3 HONOR study of Tonmya (Cyclobenzaprine HCl Sublingual Tablets) in Military-Related PTSD: Interim Analysis
Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update Phase 3 HONOR study of Tonmya (Cyclobenzaprine HCl Sublingual Tablets) in Military-Related PTSD: Interim Analysis Expected 1H18 and Topline Results Expected 2H18 FDA Feedback on Manufactu
Read more →TNXPTonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challenges, announced today that it will present at the 23rd Annual BIO-Eu
Read more →TNXPTonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya (Cyclobenzaprine HCI Sublingual Tablets) for PTSD
NEW YORK, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical and biological products to address public health challenges, announced today the receipt of official minutes from a chemis
Read more →TNXPTonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference
NEW YORK, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challenges, announced today that it will present at the Dawson James Securi
Read more →TNXPTonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C.
NEW YORK, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challenges, announced today that Seth Lederman, M.D., president and chief
Read more →TNXPTonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya (Cyclobenzaprine HCl Sublingual Tablets) Patent Will Provide Intellectual Property Protection until 2030 for Use of Cyclobenzaprine in th
Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya (Cyclobenzaprine HCl Sublingual Tablets) Intellectual Property Protection until 2030 for Use of Cyclobenzaprine in the Treatment of Posttraumatic Stress Disorder (PTSD) NEW YORK, Sept. 14, 2017 (GLOBE
Read more →TNXPTonix Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors
Pharmaceuticals Elects Margaret Smith Bell to the Board of Directors 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company in Phase 3 development of Tonmya * (cyclobenzaprine HCI sublingual tablets), or TNX-102 SL, a U.S. Food and Drug Ad
Read more →TNXPTonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challenges, announced today that it will present at the Rodman & Renshaw 1
Read more →TNXPTonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium
Phase 2 Study of U.S. FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) in PTSD Indicates Early Sleep Quality Improvements Correlate with Later Response to Treatment Phase 3 HONOR Study Designed to Confirm Phase 2 Results and Address Needs and
Read more →TNXPPhase 2 Trial of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX - 102 SL*) for the Treatment of Military - Related PTSD: Mediators and Moderators of Treatment Response Gregory M. Sullivan
Phase 2 Trial of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX - 102 SL*) for the Treatment of Military - Related PTSD: Mediators and Moderators of Treatment Response Gregory M. Sullivan 1 , Helen Stillwell 1 , Florence Porterfield 1 , Judy Gendr
Read more →TNXPTonix Pharmaceuticals to Present Additional Phase 2 Clinical Results and Design of Ongoing Phase 3 Trial in Military-Related PTSD at the 2017 Military Health System Research Symposium
NEW YORK, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company in Phase 3 development of Tonmya*, or TNX-102 SL, a U.S. Food and Drug Administration-designated Breakthrough Therapy for the treatment of posttraumatic stress disorde
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update
NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company in Phase 3 development of Tonmya*, a U.S. Food and Drug Administration-designated Breakthrough Therapy for the treatment of posttraumatic stress disorder (PTSD), and i
Read more →TNXPInterim Analysis of Phase 3 HONOR study of
Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update Interim Analysis of Phase 3 HONOR study of Tonmya (Cyclobenzaprine HCI Sublingual Tablets) in Military-Related PTSD Expected 1H18 and Topline Results Expected 2H18 2017 (GLOBE NEWS
Read more →TNXPTonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of
Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD 6, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix) a company that is dev
Read more →TNXPTonix Pharmaceuticals Holding Corp. July 2017 Version P0072 7 - 6 - 17 Investor Presentation 2017 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentat
2017 Tonix Pharmaceuticals Holding Corp. July 2017 Version P0072 7 - 6 - 17 Investor Presentation 2017 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and object
Read more →TNXPTonix Pharmaceuticals to Present at the 2017 BIO International Convention
NEW YORK, June 16, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today that it will present at the 2017 BIO International Conventio
Read more →TNXPTonix Pharmaceuticals Participated in the "Pathophysiology of Posttraumatic Stress Disorder: Rethinking Drug Targets” Summit Sponsored by U.S. Department of Defense
NEW YORK, June 15, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today its participation and a poster presentation at the "Pathophy
Read more →TNXPSeth Lederman 1 ,Gregory Sullivan 1 , Judy Gendreau 1 , R Michael Gendreau 2 , Ashild Peters 1 , Perry Peters 1 , Florence Porterfield 1 1 Tonix Pharmaceuticals Inc., 2 Gendreau Co
Seth Lederman 1 ,Gregory Sullivan 1 , Judy Gendreau 1 , R Michael Gendreau 2 , Ashild Peters 1 , Perry Peters 1 , Florence Porterfield 1 1 Tonix Pharmaceuticals Inc., 2 Gendreau Consulting Phase 2 Multicenter Double - Blind Placebo - Controlled Trial of TNX - 102 SL (cyclobenzapr
Read more →TNXPTonix Pharmaceuticals to Present an Update of FDA Designated Breakthrough Therapy-TNX-102 SL for PTSD at the 2017 Marcum MicroCap Conference
NEW YORK, June 12, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today that it will present at the 2017 Marcum MicroCap Conference
Read more →TNXP2017 Tonix Pharmaceuticals Holding Corp.
2017 Tonix Pharmaceuticals Holding Corp. Presented by Gregory Sullivan, MD at American Society of Clinical Psychopharmacology Annual Meeting, Miami, FL May 30, 2017 Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX - 102 SL) for the Treatment of Military - Related PTSD: Retros
Read more →TNXPTonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study
NEW YORK, May 30, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, presented an oral pipeline presentation on May 30, 2017 entitled “Low-Dose Be
Read more →TNXPTonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting
NEW YORK, May 24, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced upcoming presentations of additional analyses of data from its Phas
Read more →TNXPTonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
NEW YORK, May 22, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, presented a poster on May 20, 2017, entitled “Phase 2 Multisite Double-Blind
Read more →TNXPTonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update
NEW YORK, May 15, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, recently announced financial results for the first quarter ended March 31, 20
Read more →TNXPTonix Pharmaceuticals Reports First Quarter
Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update Phase 3 HONOR Study of U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, Fully Funded and Currently Enrolling NEW YORK, May 15, 2017 - Tonix Pharmaceuticals Holding C
Read more →TNXPTonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention
NEW YORK, May 11, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced it will present additional analyses of data from its Phase 2 study
Read more →TNXPTonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use
NEW YORK, May 02, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today the issuance of U.S. Patent No. 9,636,408 (‘408 patent) by th
Read more →TNXPTonix Pharmaceuticals Holding Corp. May 2017 Version P0061 5 - 1 - 17 Investor Presentation 2017 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentati
2017 Tonix Pharmaceuticals Holding Corp. May 2017 Version P0061 5 - 1 - 17 Investor Presentation 2017 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objecti
Read more →TNXPTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update
First Participant Enrolled in Phase 3 HONOR Study of TNX-102 SL in Military-Related PTSD in 1Q2017 TNX-102 SL Designated a Breakthrough Therapy for PTSD by the U.S. FDA in 4Q2016 NEW YORK, April 17, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Ton
Read more →TNXPTonix Pharmaceuticals Reports Fourth
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update First Participant Enrolled in Phase 3 HONOR Study of TNX-102 SL in Military-Related PTSD in 1Q2017 TNX-102 SL Designated a Breakthrough Therapy for PTSD by the U.S.
Read more →TNXPTonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
NEW YORK, April 13, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP) (“Tonix”), a company that is developing innovative pharmaceutical products to address public health challenges, today announced that the underwriters of Tonix’s previously announced public off
Read more →TNXPTONIX PHARMACEUTICALS ANNOUNCES FULL
TONIX PHARMACEUTICALS ANNOUNCES FULL EXERCISE AND CLOSING OF UNDERWRITERS' OVER-ALLOTMENT OPTION NEW YORK, April 13, 2017 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (TNXP) ("Tonix"), a company that is developing innovative pharmaceutical products to address public
Read more →TNXPTonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder
NEW YORK, April 11, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today the receipt of official minutes from its Initial Cross-Disc
Read more →TNXPTonix Pharmaceuticals Reports Results from
Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder Registration of TNX-102 SL Could be Solely Supported by the Phase 3 HONOR Study if Topline Data are Statistically Persuasive NEW
Read more →TNXPTonix Pharmaceuticals Completes $8 Million Public Offering of Common Stock
NEW YORK, April 04, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (“Tonix”), a company that is developing innovative pharmaceutical products to address public health challenges, today announced the closing of its previously announced underwritten publ
Read more →TNXPTONIX PHARMACEUTICALS COMPLETES $8
TONIX PHARMACEUTICALS COMPLETES $8 MILLION PUBLIC OFFERING OF COMMON STOCK NEW YORK, April 4, 2017 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (TNXP) ("Tonix"), a company that is developing innovative pharmaceutical products to address public health challenges, tod
Read more →TNXPTONIX PHARMACEUTICALS ANNOUNCES PROPOSED
TONIX PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK NEW YORK, March 29, 2017 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (TNXP) ("Tonix"), a company that is developing innovative pharmaceutical products to address public health challenges, toda
Read more →TNXPTonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock
NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (“Tonix”) (Nasdaq:TNXP), a company that is developing innovative pharmaceutical products to address public health challenges, announced today the pricing of an underwritten public offering of 1,800,0
Read more →TNXPTonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
NEW YORK, March 29, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP) (“Tonix”), a company that is developing innovative pharmaceutical products to address public health challenges, today announced that it intends to offer shares of its common stock for sale in
Read more →TNXPTonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference
NEW YORK, March 29, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today that it will present at The MicroCap Conference on April 4,
Read more →TNXPTonix Pharmaceuticals Enrolls First Participant
Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL HONOR Study to Enroll 550 Participants in Approximately 35 U.S. Sites with One Unblinded Interim Analysis at Approximately 275 Participants
Read more →TNXPTonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL
NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today that it has enrolled the first participant in the Phase 3 H
Read more →TNXPTonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer’s 27th Annual Healthcare Conference
TNX-102 SL, a Drug in Phase 3 Development, Recently Granted Breakthrough Therapy Designation by the FDA Pivotal Study in Military-Related PTSD to Begin this Month NEW YORK, March 15, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company t
Read more →TNXPTonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL
NEW YORK, March 14, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today that the U.S. Patent and Trademark Office has issued a Noti
Read more →TNXPTonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 29th Annual ROTH Conference
TNX-102 SL, a Phase 3 drug candidate, Recently Granted Breakthrough Therapy Designation by the FDA Pivotal Study in Military-related PTSD to Begin this Quarter NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that
Read more →TNXPTonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus
NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, working with researchers from the University of Alberta, a leading Canadian
Read more →TNXPTonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the Cowen and Company 37th Annual Health Care Conference
TNX-102 SL, a Phase 3 Drug Candidate, Recently Granted Breakthrough Therapy Designation by the US FDA Pivotal Study in Military-Related PTSD to Begin This Quarter NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company th
Read more →TNXPTonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 2017 BIO CEO & Investor Conference
TNX-102 SL, a Phase 3 drug candidate, Recently Granted Breakthrough Therapy Designation by the FDA Pivotal Study in military-related PTSD to Begin this Quarter NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that
Read more →TNXPTonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at NobleCon13
NEW YORK, Jan. 24, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address current and emerging public health challenges, announced today that it will present at NobleCon13, Nob
Read more →TNXPTonix Pharmaceuticals Presented Details of Newly Expanded Product Development Pipeline at 9th Annual Biotech Showcase Conference
Development Programs Include Phase 3-Ready Breakthrough Therapy TNX-102 SL, Designed for Bedtime Dosing for PTSD, IND Drug Candidate TNX-601 Designed for Daytime Dosing for PTSD, and Smallpox Preventing Vaccine TNX-801 with Priority Review Voucher Potential Pivotal Study of TNX-
Read more →TNXPTonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at 9th Annual Biotech Showcase Conference
TNX-102 SL, a Phase 3 Drug candidate, recently granted Breakthrough Therapy designation by the FDA Pivotal study in military-related PTSD to begin this quarter NEW YORK, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is develo
Read more →TNXPTonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA
Responding to AtEase study results in military-related PTSD population, FDA agrees to work closely with Tonix to develop and review TNX-102 SL for PTSD as efficiently as possible NEW YORK, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix
Read more →TNXPTonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder (PTSD)
Sub-Group Analysis of the Phase 2 AtEase Clinical Study Confirms TNX-102 SL’s Potential Efficacy in Combat-Related PTSD Patients Who are the Most Difficult to Treat New Results Presented in Poster Session at the American College of Neuropsychopharmacology (ACNP) Annual Meeting
Read more →TNXPTonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
NEW YORK, Dec. 02, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present efficacy and safety results from the Phase 2 AtEas
Read more →TNXPTonix Pharmaceuticals to Present at 9th Annual LD Micro Main Event Investor Conference
NEW YORK, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the 9th Annual LD Micro Main Event being held D
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2016 Financial Results
NEW YORK, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for PTSD, announced financial results for the third quarter ended September 30, 2016. “Tonix undertook significant changes in th
Read more →TNXPTonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD
NEW YORK, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), will announce new results today from a retrospective analysis of the data from the AtEa
Read more →TNXPTonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting
NEW YORK, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present efficacy and safety results from the Phase 2 AtEas
Read more →TNXPTonix Pharmaceuticals to Present at 22nd Annual BIO-Europe International Partnering Conference
NEW YORK, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the 22nd Annual BIO-Europe International Partne
Read more →TNXPTonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress
NEW YORK, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present efficacy and safety results of TNX-102 SL* for the
Read more →TNXPTonix Pharmaceuticals Completes $5.2 Million Underwritten Public Offering
NEW YORK, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the closing of its previously announced underwritten public offering of 9,500,000 units, consisting of 9,500,000 shares of common, and warrants to purchase an ag
Read more →TNXPTonix Pharmaceuticals to Present Clinical Data at CNS Summit 2016
NEW YORK, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present efficacy results of a retrospective analysis of TN
Read more →TNXPTonix Pharmaceuticals Prices $5.2 Million Underwritten Public Offering
NEW YORK, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the pricing of an underwritten public offering of 9,500,000 units, consisting of 9,500,000 shares of common, and warrants to purchase an aggregate of 4,750,000 s
Read more →TNXPTonix Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Warrants
NEW YORK, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), today announced that it intends to offer shares of its common stock and warrants to purchase common stock in an underwritten public offering. The offering is subject to market a
Read more →TNXPTonix Pharmaceuticals to Host Posttraumatic Stress Disorder (PTSD) Awareness Day
NEW YORK, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for PTSD, announced today that it will host an educational event featuring prominent academic physicians to review issues related
Read more →TNXPTonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference
NEW YORK, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the Second Annual Dawson James Securities Small
Read more →TNXPTonix Pharmaceuticals to Present at 16th Annual Sachs Biotech in Europe Forum
NEW YORK, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the 16th Annual Biotech in Europe Forum being
Read more →TNXPTonix Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investment Conference
NEW YORK, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the Rodman & Renshaw 18th Annual Global Invest
Read more →TNXPTonix Pharmaceuticals Reports Topline Results from Phase 3 AFFIRM Study of TNX-102 SL in Fibromyalgia and Provides Corporate Update
Following Completion of AFFIRM, Tonix to Prioritize Resources for Advancing Posttraumatic Stress Disorder (PTSD) Program into Phase 3 TNX-102 SL Generally Well Tolerated; No New Safety Signals Observed NEW YORK, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding C
Read more →TNXPTonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for TNX-102 SL in Post-Traumatic Stress Disorder
Regulatory Acceptance of Phase 3 Program and Product Registration Plan Dosing in First Phase 3 Trial Expected to Commence in the First Quarter of 2017 NEW YORK, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next
Read more →TNXPTonix Pharmaceuticals Presents Poster on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2016 Military Health System Research Symposium
NEW YORK, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that it will present efficacy and safety results of TNX
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Programs Update
First Phase 3 Study of TNX-102 SL in Fibromyalgia to Report Topline Results in September NEW YORK, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stres
Read more →TNXPTonix Pharmaceuticals Initiates Second Pivotal Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia
NEW YORK, July 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that the first patient has been randomized in RE-AFFIRM
Read more →TNXPTonix Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
NEW YORK, July 07, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that it will present at Cantor Fitzgerald’s 2nd Annual
Read more →TNXPTonix Pharmaceuticals Completes $10 Million Public Offering of Common Stock
NEW YORK, June 21, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock. The shares were sold at the public offering price o
Read more →TNXPTonix Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
NEW YORK, June 17, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive
Read more →TNXPTonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
NEW YORK, June 16, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price of $2.00 per share. Tonix has also granted to the underwriters
Read more →TNXPTonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia
NEW YORK, June 09, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia (FM) and post-traumatic stress disorder (PTSD), announced that today the company presented results from a retrospe
Read more →TNXPTonix Pharmaceuticals to Present at the 2016 BIO International Convention
NEW YORK, June 03, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive
Read more →TNXPTonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) at the American Society of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting
Study Successfully Identified Effective and Well-tolerated Dose for Registration Studies Phase 3 Clinical Program Planned NEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibr
Read more →TNXPTonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting
NEW YORK, May 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced that it will present positive data from the Phase 2 dose-findi
Read more →TNXPTonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
Conference Call and Webcast Today at 8:00 a.m. ET Successfully-executed Dose-finding Study Identified 5.6 mg as the Efficacious and Well-tolerated Dose for Registration Studies Plan to Meet with the U.S. Food and Drug Administration (FDA) to Finalize Phase 3 Clinical Program T
Read more →TNXPTonix Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Programs Update
NEW YORK, May 09, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for common disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder (PTSD), announced fina
Read more →TNXPTonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia
- Top-line Results on Track to be Reported 3Q 2016 for Pivotal Study in Flagship Program - NEW YORK, May 02, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for common disorders of the central nerv
Read more →TNXPTonix Pharmaceuticals to Present at the 10th Annual BIO Europe Spring Conference
NEW YORK, March 29, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Ronald Notvest, Ph.D., MBA, Executive Vice Presid
Read more →TNXPTonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting
- TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for bedtime administration currently under development for the long-term management of fibromyalgia and treatment of post-traumatic stress disorder- - TNX-102 SL pharmacokinetic data demonstrated increased plas
Read more →TNXPTonix Pharmaceuticals to Present at the 28th Annual ROTH Conference
NEW YORK, March 08, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executiv
Read more →TNXPTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Programs Update
NEW YORK, March 04, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced financial results for the fourth quarter and full year ended
Read more →TNXPTonix Pharmaceuticals to Present at Two Investor Conferences in March 2016
NEW YORK, March 03, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executiv
Read more →TNXPTonix Pharmaceuticals Appoints Chief Financial Officer
NEW YORK, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), has appointed Bradley Saenger, CPA, as Chief Financial Officer (CFO). T
Read more →TNXPTonix Pharmaceuticals Reports Top Line Results From Phase 2 Proof-of-Concept Clinical Study of TNX-201 in Episodic Tension-Type Headache
NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), today announced topline results of the Phase 2 proof-of-concept (POC) c
Read more →TNXPTonix Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
NEW YORK, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, will present at the 18th annual BIO CE
Read more →TNXPTonix Pharmaceuticals Announces Management Change
NEW YORK, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (“Tonix”), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, today announced that Jessica Edgar M
Read more →TNXPTonix Pharmaceuticals to Present at Biotech Showcase 2016
NEW YORK, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (“Tonix”), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, will present at the eighth annual Bi
Read more →TNXPTonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
NEW YORK, Dec. 23, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (“Tonix”), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, announced today that it has complete
Read more →TNXPTonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache
NEW YORK, Dec. 8, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix"), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, today announced it has completed pati
Read more →TNXPTonix Pharmaceuticals and U.S. Department of Defense Military Developer in Partnership to Expand Efforts to Examine TNX-102 SL for Post-Traumatic Stress Disorder
NEW YORK, Dec. 7, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix"), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, announced today the signing of a Coop
Read more →TNXPTonix Pharmaceuticals to Participate in Fireside Chat at the Oppenheimer 26th Annual Healthcare Conference
NEW YORK, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix"), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, will participate in a fireside chat a
Read more →TNXPTonix Pharmaceuticals Presents Additional Data on Tonmya(TM) Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia at 2015 ACR/ARHP Annual Meeting
NEW YORK, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix"), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, today presents additional results fr
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Programs Update
NEW YORK, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix"), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, announced financial results for the t
Read more →TNXPTonix Pharmaceuticals Announces Acceptance of Three Abstracts to be Presented at the 2015 ACR/ARHP Annual Meeting
NEW YORK, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix"), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache, announced today that three of its scientific
Read more →TNXPTonix Pharmaceuticals to Present at the 15th Annual Biotech in Europe Forum for Global Partnering and Investment
NEW YORK, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache, will present at the 15th Annual Biotech in Europe Fo
Read more →TNXPTonix Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
NEW YORK, Sept. 8, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix"), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache, will present at the Rodman & Renshaw 17th A
Read more →TNXPTonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium
NEW YORK, Aug. 18, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix") today presented an overview of its development of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for PTSD, including a review of the design of the AtEase Clinical Study, a
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Program Update
NEW YORK, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix"), a clinical-stage pharmaceutical company developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, annou
Read more →TNXPTonix Pharmaceuticals Appoints Mark T. Edgar, PhD as Senior Vice President of Product Development
NEW YORK, July 21, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix"), a clinical-stage company developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, has appointed Mark T
Read more →TNXPTonix Pharmaceuticals Closes $20.1 Million Public Offering of Common Stock
NEW YORK, July 17, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix") today announced the closing of its previously announced underwritten public offering of 2,325,000 shares of its common stock, as well as the sale of 348,750 additional shares p
Read more →TNXPTonix Pharmaceuticals Presents Non-clinical Data on TNX-201 at the 57th Annual Scientific Meeting of the American Headache Society
- TNX-201 demonstrates significant analgesic effects in animal models of migraine and chronic pain - - TNX-201 targets the imidazoline-1 receptor and may represent a novel approach to the treatment of pain - NEW YORK, June 22, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Hold
Read more →TNXPTonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg
NEW YORK, June 17, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix") today reported that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proposed trade name Tonmya (ton-MY-ah) for TNX-102 SL (cyclobenzaprine HCl sublin
Read more →TNXPTonix Pharmaceuticals Initiates Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache
- Frequent episodic tension-type headache estimated to afflict 75 million Americans - - Top-line results expected 4Q 2015 - NEW YORK, June 16, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix"), a clinical-stage company developing next-generati
Read more →TNXPTonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study at EULAR
- Results Further Illustrate Efficacy and Tolerability Profile of TNX-102 SL in Fibromyalgia - - TNX-102 SL Currently Being Evaluated in a Phase 3 Study in Fibromyalgia - NEW YORK, June 11, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix"), a
Read more →TNXPTonix Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference
NEW YORK, May 28, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage company developing next-generation medicines for fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache, will present at the Jefferies 2015 Glo
Read more →TNXPTonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR
NEW YORK, May 26, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix"), a clinical-stage company developing next-generation medicines for fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache, announced today that two abs
Read more →TNXPTonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry
NEW YORK, May 15, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix") today presented results from non-clinical studies at the 2015 Annual Meeting of the Society of Biological Psychiatry in Toronto, Canada. The studies were designed to better und
Read more →TNXPTonix Pharmaceuticals Launches Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia
NEW YORK, May 13, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix") announced today that it has begun a Phase 3 clinical study of TNX-102 SL (cyclobenzaprine HCl sublingual tablet, 2.8 mg) in fibromyalgia, having recently randomized the first pa
Read more →TNXPTonix Pharmaceuticals Reports First Quarter 2015 Financial Results and Clinical Update
On Track to Commence Two Clinical Studies This Quarter; Phase 2 Proof-of-Concept Headache Study Results Due by Year-End NEW YORK, May 11, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix") announced financial results for the first quarter ended
Read more →TNXPTonix Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference
NEW YORK, March 20, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a pharmaceutical company with clinical-stage development programs in fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, will present at the 12th A
Read more →TNXPTonix Pharmaceuticals to Present at the 27th Annual ROTH Conference
NEW YORK, March 4, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, will present at the 27th Annual ROTH Conference to be held at the Ritz-Carlton in Dana Point, California. Seth Lederman, M.D., president and CEO
Read more →TNXPTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
NEW YORK, March 3, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced financial results for the fourth quarter and full year ended December 31, 2014. Tonix filed its Annual Report on Form 10-K for fiscal year 2014 on Friday, February 27, 2015. "
Read more →TNXPTonix Pharmaceuticals to Present at the 8th Annual European Life Sciences CEO Forum
NEW YORK, March 2, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the 8th Annual European Life Sciences CEO Forum & Exhibition in Zurich, Switzerland. Seth Lederman, M.D., Tonix's president and chief executive officer, will deliver a co
Read more →TNXPTonix Pharmaceuticals Announces Closing of $28.7 Million Public Offering of Common Stock
NEW YORK, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the closing of its previously announced underwritten public offering of 4,900,000 shares of its common stock. The shares were sold at the public offering price of $5.85 pe
Read more →TNXPTonix Pharmaceuticals to Present at the BIO CEO & Investor Conference
NEW YORK, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the 17th Annual BIO CEO and Investor Conference in New York City. Seth Lederman, M.D., Tonix's president and chief executive officer, will deliver a corporate overview on
Read more →TNXPTonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder
NEW YORK, Jan. 15, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced today that the first participant in the AtEase study, sponsored by Tonix to evaluate TNX-102 SL for post-traumatic stress disorder (PTSD), has received study medication. The A
Read more →TNXPTonix Pharmaceuticals to Present at the Noble Financial Annual Investor Conference
NEW YORK, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the Eleventh Annual Noble Financial Capital Markets Investor Conference in Sandpiper Bay, FL. Seth Lederman, M.D., Tonix's president and chief executive officer, will del
Read more →TNXPTonix Pharmaceuticals Announces Clinical Progress on Potential Treatment for Headache
NEW YORK, Jan. 9, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) has completed a Phase 1 safety, tolerability, and pharmacokinetic study of TNX-201, which is being developed for episodic tension-type headache. In this single ascending dose, placebo-con
Read more →TNXPTonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia
NEW YORK, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) has received written guidance from the U.S. Food and Drug Administration (FDA) on its Phase 3 clinical study design for TNX-102 SL in fibromyalgia. "Getting this confirmation from the FD
Read more →TNXPTonix Pharmaceuticals to Present at the LD Micro Investor Conference
NEW YORK, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the LD Micro Main Event VII Conference in Los Angeles, CA. Seth Lederman, M.D., Tonix's chief executive officer, will deliver a corporate overview on Tuesday, December 2,
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2014 Financial Results
NEW YORK, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced its financial results for the quarter ended September 30, 2014. "In September, we announced preliminary top line results from the Phase 2b BESTFIT study of TNX-102 SL in fibro
Read more →TNXPTonix Pharmaceuticals Receives IND Clearance for TNX-201 in Episodic Tension-Type Headache
NEW YORK, Oct. 21, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to study TNX-201 for the treatment of episodic tension-type he
Read more →TNXPTonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia
NEW YORK, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced top line results of the Phase 2b BESTFIT (BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy) study of TNX-102 SL as a chronic bedtime treatment for fibr
Read more →TNXPTonix Pharmaceuticals to Present at the BioCentury NewsMakers Conference
NEW YORK, Sept. 19, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the 21st Annual BioCentury NewsMakers in the Biotech Industry conference on Friday, September 26, 2014 at 8:30 am ET in New York City. The presentation will be webcast
Read more →TNXPTonix Pharmaceuticals Announces Transfer to the NASDAQ Global Market
NEW YORK, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company focused on common disorders of the central nervous system, is pleased to announce that, effective today, the transfer of listing of the company's
Read more →TNXPTonix Pharmaceuticals Reports Second Quarter 2014 Financial Results
NEW YORK, Aug. 8, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced its financial results for the quarter ended June 30, 2014. "In the second quarter, we continued to successfully execute against our strategic clinical and corporate devel
Read more →TNXPTonix Pharmaceuticals to Present at Two Investor Conferences in August
NEW YORK, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company focused on common disorders of the central nervous system, announces that Seth Lederman, M.D., Tonix's president and chief executive officer, will
Read more →TNXPTonix Pharmaceuticals Announces Registered Direct Offering of $7.8 Million
NEW YORK, July 11, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company focused on common disorders of the central nervous system, today announced it has agreed to sell 657,000 shares of common stock in a registered d
Read more →TNXPTonix Pharmaceuticals Joins Russell Microcap Index
NEW YORK, June 30, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company focused on common disorders of the central nervous system, was added to the Russell Microcap Index on June 27, 2014. A listing of all members can
Read more →TNXPTonix Pharmaceuticals Appoints Ronald R. Notvest, Ph.D. as Senior Vice President of Commercial Planning and Development
NEW YORK, June 26, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company focused on common disorders of the central nervous system, has appointed Ronald R. Notvest, Ph.D. to its newly created position of Senior Vice Pr
Read more →TNXPTonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder
NEW YORK, June 10, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to develop TNX-102 S
Read more →TNXPTonix Appoints Gregory M. Sullivan, M.D. as Chief Medical Officer
NEW YORK, June 3, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, has appointed Gregory M. Sullivan, M.D. Chief Medical Officer, a newly created position. He will oversee medical aspects of the company's clinica
Read more →TNXPTonix Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
NEW YORK, May 29, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, will present at the Jefferies 2014 Global Healthcare Conference in New York City. Seth Lederman, M.D., Tonix's president and chief executive offi
Read more →TNXPTonix Pharmaceuticals to Present at the LD Micro Invitational Conference
NEW YORK, May 29, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, will present at the 4th Annual LD Micro Invitational Conference in Los Angeles. Leland Gershell, M.D., Ph.D., Tonix's chief financial officer, wi
Read more →TNXPTonix Pharmaceuticals to be Added to the MSCI Global Micro Cap Index
NEW YORK, May 28, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, will be added to the Morgan Stanley Capital International (MSCI) Global Micro Cap Index, effective May 30, 2014. Tonix develops first-in-class me
Read more →TNXPTonix Pharmaceuticals to Present at the MIXiii Biomed Conference in Israel
NEW YORK, May 20, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced that its CEO, Seth Lederman, MD, will be speaking at MIXiii Biomed, an Israel Innovation Conference, to be held in Tel Aviv, Israel on Thursday, May 22nd. Dr. Lederman's t
Read more →TNXPTonix Pharmaceuticals Reports First Quarter 2014 Financial Results
- Three Programs to be in Clinical Development in 2014 - - Cash of $49.5 Million as of March 31, 2014 - NEW YORK, May 13, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced its financial results for the first quarter ended March 31, 2014.
Read more →TNXPTonix Pharmaceuticals Completes Enrollment in BESTFIT Trial of TNX-102 SL for Fibromyalgia
NEW YORK, May 12, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company, today announced that it has completed enrollment in the BESTFIT trial of TNX-102 SL for fibromyalgia, after having achieved the randomization goa
Read more →TNXPTonix Pharmaceuticals Spotlighted in April 7 Issue of BioCentury
NEW YORK, April 9, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage pharmaceutical company, was spotlighted in the April 7, 2014 issue of BioCentury: The Bernstein Report on BioBusiness. An article titled "Confirming Endpoints" focu
Read more →TNXPTonix Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Regulatory Affairs
NEW YORK, April 1, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the appointment of Donald J. Kellerman, Pharm.D. to the position of Senior Vice President, Clinical Development and Regulatory Affairs. Dr. Kellerman will be responsible
Read more →TNXPTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
NEW YORK, March 31, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced financial results for the fourth quarter and full year ended December 31, 2013. "In the fourth quarter, Tonix continued to make steady progress in the BESTFIT trial of
Read more →TNXPTonix Pharmaceuticals to Present at the ROTH Conference
NEW YORK, March 5, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, will be presenting at the 26th Annual ROTH Conference in Laguna Niguel, California. Seth Lederman, M.D., president and CEO of Tonix
Read more →TNXPTonix Pharmaceuticals Completes Pre-IND Meeting With FDA on TNX-201 for Episodic Tension-Type Headache: Clinical Development to Begin in 4Q 2014
NEW YORK, March 3, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, today announced that it recently held a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (
Read more →TNXPTonix Pharmaceuticals Spotlighted in Three Media Outlets in February
NEW YORK, Feb. 21, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, has been featured in TheStreet.com, Genetic Engineering & Biotechnology News and Drug Discovery News during the month of February.
Read more →TNXPTonix Pharmaceuticals to Present at the BIO CEO Conference
NEW YORK, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, will be presenting at the 16th Annual BIO CEO & Investor Conference in New York City. Seth Lederman, M.D., president and CEO of Toni
Read more →TNXPTonix Pharmaceuticals Announces Closing of $43.5 Million Public Offering of Common Stock
NEW YORK, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the closing of its previously announced underwritten public offering of 2,898,550 shares of its common stock. The shares were sold at the public offering price of $15.00
Read more →TNXPTonix Pharmaceuticals Prices Underwritten Public Offering Raising $43.5 Million
NEW YORK, Jan. 24, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the pricing of an underwritten public offering of 2,898,550 shares of its common stock at a price of $15.00 per share. The company has also granted to the underwriters a
Read more →TNXPTonix Pharmaceuticals Announces the Enrollment of Completers From the BESTFIT Trial Into a 12-Month Open-Label Extension Study
NEW YORK, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, announced today that it is enrolling subjects into an open-label extension (OLE) study to the BESTFIT trial of TNX-102 2.8 mg subli
Read more →TNXPTonix Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
NEW YORK, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, will be presenting at the 24th Annual Oppenheimer Healthcare Conference in New York City. Seth Lederman, M.D., president and CEO of
Read more →TNXPTonix Pharmaceuticals to Present at the LD Micro Conference
NEW YORK, Nov. 21, 2013 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a development stage specialty pharmaceutical company, will be presenting at the 6th Annual LD Micro Conference in Los Angeles. Seth Lederman, M.D., president and CEO of Tonix, will deli
Read more →TNXPTonix Pharmaceuticals Reports Third Quarter 2013 Financial Results
NEW YORK, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced its financial results for the quarter ended September 30, 2013. "The third quarter was eventful for Tonix, as we began the first anticipated pivotal trial of our lead th
Read more →TNXPTonix Pharmaceuticals Completes Private Placement
NEW YORK, Dec. 5, 2012 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (OTCQB:TNXP) ("TONIX" or the "Company"), a specialty pharmaceutical company developing novel treatments for challenging disorders of the central nervous system including fibromyalgia ("FM") and post-tr
Read more →TNXPTonix Pharmaceuticals to Present at Fifth Annual LD Micro Conference
NEW YORK, Dec. 5, 2012 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (OTCQB:TNXP) ("TONIX" or the "Company"), a specialty pharmaceutical company developing novel treatments for challenging disorders of the central nervous system, including fibromyalgia ("FM") and post-t
Read more →Competitive Position
How TNXP ranks across every disease it competes inCompetitive Position is a premium feature
See how TNXP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial